var title_f20_55_21360="Simple cyst";
var content_f20_55_21360=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F73503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F73503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Simple cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound image with color of palpable breast mass: simple cyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_55_21360=[""].join("\n");
var outline_f20_55_21360=null;
var title_f20_55_21361="Salter-Harris classification system";
var content_f20_55_21361=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Salter-Harris classification of physeal fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The growth plate is shown in green. The mnemonic refers to the fracture line and its relationship to the growth plate. The metaphysis is the bone above the growth plate, and the epiphysis is the bone below. Type I fractures disrupt the physis. Type II fractures involve a break from the growth plate up into the metaphysis, with the periosteum usually remaining intact. Type III fractures are intraarticular fractures through the epiphysis that extend across the physis. Type IV fractures cross the epiphysis, physis, and metaphysis. Type V fractures are compression injuries to the physis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_55_21361=[""].join("\n");
var outline_f20_55_21361=null;
var title_f20_55_21362="Membranous VSD subcostal coronal 2D still frame";
var content_f20_55_21362=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Membranous VSD subcostal coronal 2D still frame",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subcostal coronal still frame showing a membranous ventricular septal defect (VSD) just apical to the aortic valve.",
"    <div class=\"footnotes\">",
"     AO: aorta; LV: left ventricle; RV: right ventricle; LA: left atrium; RA: right atrium; IVS: intact trabecular portion of the intraventricular septum; arrow: VSD.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_55_21362=[""].join("\n");
var outline_f20_55_21362=null;
var title_f20_55_21363="Ofloxacin (ophthalmic): Pediatric drug information";
var content_f20_55_21363=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ofloxacin (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31780?source=see_link\">",
"    see \"Ofloxacin (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/20/30020?source=see_link\">",
"    see \"Ofloxacin (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9496344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ocuflox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9496345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ocuflox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10512881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Quinolone",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10512928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31780?source=see_link\">",
"      see \"Ofloxacin (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;1 year and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conjunctivitis: Instill 1-2 drops in affected eye(s) every 2-4 hours while awake for the first 2 days, then 4 times/day for an additional 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corneal ulcer: Instill 1-2 drops in affected eye(s) every 30 minutes while awake and every 4-6 hours at night for the first 2 days; then starting day 3, instill 1-2 drops every hour while awake for 4-6 additional days; thereafter, 1-2 drops 4 times/day until clinical cure is achieved",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9497993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]: 0.3% (5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocuflox&reg;: 0.3% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9496351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10512929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for subconjunctival or direct injection into the anterior chamber of the eye. Apply gentle pressure to lacrimal sac during and immediately following instillation (1 minute) or instruct patient to gently close eyelid after administration, to decrease systemic absorption of ophthalmic drops; avoid contact of bottle tip with skin or eye. Remove contact lenses prior to administration (ophthalmic solution contains benzalkonium chloride which may adsorb to soft contact lenses); lenses may be inserted 15 minutes after administration.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10512925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10512885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bacterial keratitis due to susceptible organisms including",
"     <i>",
"      P. aeruginosa",
"     </i>",
"     ,",
"     <i>",
"      Propionibacterium acnes",
"     </i>",
"     ,",
"     <i>",
"      S. marcescens",
"     </i>",
"     ,",
"     <i>",
"      S. aureus",
"     </i>",
"     ,",
"     <i>",
"      S. epidermidis",
"     </i>",
"     , and",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ; treatment of severe bacterial conjunctivitis due to susceptible organisms, including",
"     <i>",
"      Enterobacter cloacae",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      P. mirabilis",
"     </i>",
"     ,",
"     <i>",
"      P. aeruginosa",
"     </i>",
"     ,",
"     <i>",
"      S. aureus",
"     </i>",
"     ,",
"     <i>",
"      S. epidermidis",
"     </i>",
"     , or",
"     <i>",
"      S. pneumoniae",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9496302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ocuflox&reg; may be confused with Occlusal&trade;-HP, Ocufen&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9497571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, burning, chemical conjunctivitis/keratitis, discomfort, dryness, edema, eye pain, foreign body sensation, itching, photophobia, redness, stinging, tearing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10512886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ofloxacin, any component, or other quinolones",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10512888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy (primarily with systemic use). Prolonged use may result in fungal or bacterial superinfection.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10512887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There have been reports of tendon inflammation and/or rupture with systemic quinolone antibiotics. Exposure following ophthalmic administration is substantially lower than with systemic therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9497684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9496364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9775998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal studies; therefore, the manufacturer classifies ofloxacin ophthalmic as pregnancy category C. When administered orally, ofloxacin crosses the placenta. Refer to the Ofloxacin (Systemic) monograph for details. The amount of ofloxacin available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral doses.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10512930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Slit-lamp biomicroscopy and fluorescein staining may be necessary",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10512926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ofloxacin inhibits DNA gyrase (bacterial topoisomerase II) thereby inhibiting relaxation of supercoiled DNA and promoting breakage of DNA strands. DNA gyrase maintains the superhelical structure of DNA and is required for DNA replication, transcription, repair, recombination, and transposition.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10512927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Ocular: Minimal absorption unless inflammation or epithelial defect is present",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10512931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/20/30020?source=see_link\">",
"      see \"Ofloxacin (ophthalmic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contaminating ophthalmic solution containers. Drink plenty of fluids; may cause dizziness or lightheadedness and impair ability to perform activities requiring mental alertness or physical coordination; notify physician if tendon pain or swelling, burning, tingling, numbness, or weakness develops",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16031 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_55_21363=[""].join("\n");
var outline_f20_55_21363=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496344\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496345\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512881\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512928\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497993\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496351\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512929\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512925\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512885\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496302\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497571\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512886\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512888\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512887\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299782\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497684\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496364\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9775998\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512930\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512926\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512927\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512931\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16031\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16031|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31780?source=related_link\">",
"      Ofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/20/30020?source=related_link\">",
"      Ofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/30/484?source=related_link\">",
"      Ofloxacin (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/6/16484?source=related_link\">",
"      Ofloxacin (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/42/20131?source=related_link\">",
"      Ofloxacin (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/41/1688?source=related_link\">",
"      Ofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30165?source=related_link\">",
"      Ofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/28/34246?source=related_link\">",
"      Ofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_55_21364="Minoxidil (systemic): Pediatric drug information";
var content_f20_55_21364=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Minoxidil (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?11/38/11877?source=see_link\">",
"    see \"Minoxidil (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/26/24996?source=see_link\">",
"    see \"Minoxidil (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8774839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8774868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Loniten&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10530290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/38/11877?source=see_link\">",
"      see \"Minoxidil (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &lt;12 years: Initial: 0.1-0.2 mg/kg once daily; maximum dose: 5 mg/day; increase gradually every 3 days; usual dosage: 0.25-1 mg/kg/day in 1-2 divided doses; maximum dose: 50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &gt;12 years and Adults: Initial: 5 mg once daily, increase gradually every 3 days; usual dose: 10-40 mg/day in 1-2 divided doses; maximum dose: 100 mg/day;",
"     <b>",
"      Note:",
"     </b>",
"     Usual dosage range for Adolescents &ge;18 years and Adults (JNC 7): 2.5-80 mg/day in 1-2 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8774977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2.5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8774869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10530305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to food",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10530286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10530252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of severe hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8774841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Loniten&reg; may be confused with Lipitor&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Minoxidil may be confused with metolazone, midodrine, Minipress&reg;, Minocin&reg;, Monopril&reg;, Noxafil&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Noxidil [Thailand] may be confused with Noxafil brand name for posaconazole [U.S. and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8774912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina pectoris, ECG changes (T-wave changes), heart failure, peripheral edema, pericardial effusion with/without tamponade, pericarditis, rebound hypertension (in children after a gradual withdrawal), sodium and water retention, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bullous eruption, hypertrichosis, rash, Stevens-Johnson syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast tenderness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia, thrombocytopenia, transient decreased erythrocyte count (hemodilution), transient decreased hematocrit/hemoglobin (hemodilution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Serum BUN and creatinine increased (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary edema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10530253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to minoxidil or any component; pheochromocytoma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10530257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with coronary artery disease or with recent MI, pulmonary hypertension, significant renal dysfunction, or heart failure; renal failure or dialysis patients may require dosage reduction. Elongations, thickening, and enhanced pigmentation of fine body hair between eyebrows and hairline, sideburns, cheek, and eventually back, arms, legs, and scalp is seen in ~80% of patients within the first 3-6 weeks; may take 1-6 months for hypertrichosis to reverse itself after discontinuation of the drug.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10530254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause pericardial effusion progressing to tamponade",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; pericarditis, angina, and sodium and water retention may also occur; use of minoxidil should be reserved for treatment of hypertension in patients who have not adequately responded to maximum doses of a diuretic and two other antihypertensive agents",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; minoxidil is usually used with a beta-blocker (to treat minoxidil-induced tachycardia) and a diuretic (for treatment of water retention/edema); avoid concomitant use of minoxidil with guanethidine; minoxidil may rapidly control blood pressure; too rapid control of blood pressure may lead to syncope, CVA, MI, or ischemia. Myocardial lesions and other adverse cardiac effects have been shown in experimental animals",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; significance of these findings in humans is unclear.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8774914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Minoxidil (Systemic). Severe hypertrichosis has been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10530285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid natural licorice (causes sodium and water retention and increases potassium loss).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8774882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8774883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10530306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fluids and electrolytes, body weight, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10530287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Produces vasodilation by directly relaxing arteriolar smooth muscle, with little effect on veins; effects may be mediated by cyclic AMP; stimulation of hair growth is secondary to vasodilation, increased cutaneous blood flow, and stimulation of resting hair follicles",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10530288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypotensive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: Within 2-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Up to 2-5 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10530289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: 88% primarily via glucuronidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein-binding: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, adults: 3.5-4.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: 12% excreted unchanged in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis: Dialyzable (50% to 100%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10530307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/26/24996?source=see_link\">",
"      see \"Minoxidil (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dizziness; rise slowly from prolonged lying or sitting position. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen, physical sunscreen (preferred), or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10530308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May take 1-6 months for hypertrichosis to totally reverse after oral minoxidil therapy is discontinued",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, \"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/55/21364/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16020 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-537ACF1ECA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_55_21364=[""].join("\n");
var outline_f20_55_21364=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774839\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774868\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10530290\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774977\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774869\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10530305\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10530286\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10530252\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774841\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774912\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10530253\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10530257\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10530254\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299718\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774914\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10530285\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774882\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774883\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10530306\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10530287\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10530288\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10530289\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10530307\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10530308\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16020\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16020|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/38/11877?source=related_link\">",
"      Minoxidil (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/26/24996?source=related_link\">",
"      Minoxidil (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/47/27379?source=related_link\">",
"      Minoxidil (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/58/33699?source=related_link\">",
"      Minoxidil (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_55_21365="DS features PI";
var content_f20_55_21365=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Problems caused by Down syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 523px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAILAeIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiikLAdTQAtFRmZPWk85aV0OzJaKYJVPengg9DRcQUUUUwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUwCmu4Uc0krhR71Rlm75qXKxUY3JpLg9qrvN71WeQk0wkms2zZQLBmpvnVBRSuVyosiapUnPrVGlBIouJxNeOfPWpwQRkVjJLirkM2DVqRlKBeopFYMMilrQzCiiuWsvH3h2/vZLWyvZZ3WWSASraTCCSRASyJMVEbMAp4DHpQB1NFYvgvxJZ+LvC+n69psdxFZ3qGSNLhQsgAYjkAkdvU1tUAFFZXh7xDpfiKG8l0a6+0x2d1JZTny2TZNHgOvzAZxkcjj0NXr+6Sxsbm7lDGOCJpWC9SFGTj34oAnorH8H+IbTxX4Z0/XNOjnjtL6PzY0nUK4GSOQCRnjsTWxQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFIAooooAKKKKACiiigAooooAKKKKACiiigChrusafoOk3GpaxdxWljbruklkOAOcAepJJAAHJJAHNeP678T9f1d3Tw5axaLYHIW6vovNupBxhlhyFjHX75Jx/CKxfGmvN4w8Uy3O8toulzvBp8WfkklQlZLk+p3ZRD2AJGC1UFRmyVUnHXA6Vy1azvaJ6OHwia5phcXeuXc5lvfFPiGWQ9RFem2T8EiCgVWS1dJvOTUdZSfJPmLqt1uyep/1lWsetLWHM+52qnBdELZ3+v2Dl9P8AFWvRORjFxcC7T/vmZW/mK6zQPipquksE8YW8N7pwADajp8RSSEd2lgycr3LRk4x92uSxTlVgwKZ3DkY61Uako9TOeGpzWx9HWd1BfWkN1ZzRz206CSKWNgyupGQwI4II71NXz34P8XX3gOL7O0K3vhhZXleBFIuLJWO5jHjh4wdzbMBgCcE4xXv1ncwXtpBdWkqTW06LLFKhyrqwyGB7ggg12Qmpq6PKq0pUnZk1FFFWZBRRRQAUjttXNLVa5ftQ3ZDSuyvPJ1zVN2yafK2TUWKxbOiKsJRQxCLudlVR3Y4FZ82tadEcG6R29IwW/lxSbS3LSb2NCisf/hIbUn5IpiPU4H9ali1mCQ4Mbr+INLmRXIzToqKGeKYfu2yfQ8GpaZIVLG+DUYBJ4rlPEXj3RdFv/wCzImuNV1wj5dL0uI3Fx/wILxGOR98j1ppX2JbS3O9tpOevFYHjD4geHfCkqW2pXpl1OUfudNtEM91MT0CxLzz2JwPeuQXT/HHi3I1a/TwhpLDH2PTJFnvnHcPcEbY/+2YJ9TXZ+CvBnh7wpFINC02KCeX/AF1yxMk8x9XkYlj64zj2rSPYwkupP4N1jVtbtLi61jw/PoaGT/RoridJJZI8D5nVeEOc/LkmvOdF+F+uaZ4st9Q0ySx0KxLSyX8On6lcyw3xYNgfZnTbFy2ch2xjgCvZx1rx3w78ZNR8SXEv9ieCdSurNlu/s9x++VTJCpKpKxg8tC5UgbXcg4BAJqyDjtW+B/i688I6RooufDO6x00WyXIQLPHMJmkBEzW7yFMHojREFj15zu6p8HdavdU1fUxc6V/adxq9hqFrdGSQSxJCgWUbtmQW9BweMkYqeL4/Wtx4evNZtPD9xLZ20dpEzCc/8fk+cwEBCcIBy4BPIAXJrQuvi5rNro63t14E1O1VLmeK5nuUuktoIY0DCcsLYy7GyQMxDG05xQBgS/BTV4vDfiPSNMbRLL7ZrP8AaUFxASjXFtuyLSZTCQsa9R/rFz/DjOWJ8F9ZittMjCaXd2dtPeyvpeoX5mt1aeJVWWPZaoqlGDER+VgZ4YZ49z0HUU1fQ9P1GJoWju7eOdWgcvGQyg/KxVSRzwSoPqB0q9QBy3wv8PXfhTwBomh6jJBJd2MHlSPAxZCck/KSAcc9wK6miigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFYXjvVX0PwVruqQnE1pYzTRkjPzhCV/XFbtcB8cZoz8NNctBfWlrczwAILi5SDeA6lhliByARSew46tXPHNLsxYabaWaj/URJGcdyByfxOT+NdZ8PPB+l+KYdT1TXbV7q3W4+yWI86SMKsY/eupRhnMhZc/9M64a/1/TLqV7XSNVjub2WTbt06CW9liQnl1ESFSwH3QWAzjnANenaV4l1y30u003wf8N9XjsbaNYYW1e6hsAqgYBKEs59Txk5J4zXLTpPdo9LEV425YP7jTuPhn4bVR5cur2gJ2jy9VmAz6DcxqMfC7Rw+W1PxEw/unUiB+i5ryH48+APiV43uNFvvsNhOIYmhNhp92SkDlyd5Mu3JZSoJHA2V774F0/UdI8G6Lp+tXP2rUra1jinl3Ftzgc8nrjpnvjNauEUcqqzb3Z5v4r+Gmtw395N4Su5BbPaxQQxXF200hnLtukZpMrGigqSQCxC4UAnNaXhz4TWOn2Ij8S6rqWu3Ug3S+ZcyRQ7iOcKrBj+J/AV6nVe5ILAegqOVGiqSejZ4dqenPoPiK+0kySSQxhLqzeVt7mB8gKxPJKOrLk8kbc16J8B7tz4X1DSnYbNKv5LeBe6wOqyxj6ASFR7KKw/ivZt/anhu+iX5nefT3AHLB08xB7/NEfzrD8HeONA+Hmq+KG8Vamlr9oNq0FsuZZWZYirfu1yV6KMtjoKmn7tQ0rvmoq+6PoOivnHW/2q9CgYrovh7Ub3H8VzKluD+W81yt1+1dq7MfsnhnT4h2Ety8n8gtdR59j64or5Ftv2rdbV/9J8N6bIvpHO6H9c10mkftW6XK6jWPDF7bJ3a1uUnP5ME/nQFj6VPQ1n3DcmvJdX+P3hi+8HajfeF9Tt11q1jE6WGpI0JlCsCyA9CxXcBtYnOODXW/D/x3o/xA0AalosuJEwtzaSEebbOezDuD2YcH6ggTJlwR0Lck1wuv+NSJXttF2kKcNcsMgn/YH9TW543kuY/DV59iSR5X2xnywSwUnDEAc9P51yPhnwbdXW2bVA9pbdRH/wAtH/D+EfXn2rnm5XtE7qUYpc0inajUNZutpNxeTd9xLBf6Cuy0nwiQobUJ8H/nnF/Vv8K6KwtLext1gs4liiX+Fe/ufU+9XIwScAZPoKcaa6kVK7ekdEVbTSrG1x5VrGT/AHnG4/rVuWKPH+rjx/uil3oJAhkjD/3S4z+VfN2iftD63rHxHk0G28P2T2c88lrZoZHjm8wZCGRySoBIG7CjAJ5OOdYxvsczlrqfQcltGW4jUH/ZGK4zVPiJpcN8+l+HILrxPrKfetdL2yJF/wBdZyfLjGeOSSPSqz+CdZ8SAP8AELXGuLZhzoukl7az+kj582YfUqPauz0nTrLSLCOx0qzt7Kzj4SG3jCIPfA7+/U0WSLvJo4s+HPFficZ8X60NI05hzpOgyFWYek1yRub0KoAp9a6vw74f0jw3Y/YtA0210+243LAmC5Hd2+8592JNadFJu41FLUfGcGtC1b5hWavWr1seRRHcmaNHvWNB4W8P2+tHWLfQtKi1YszG9SzjWclgQx8wDdkgkHnnNbI6UVuc5y3hTwJonhzwvcaDFB9vsbmaWe6+3IkhuHkbLFwFCnsMbcYAp58AeDjbxwHwn4fMEbtIkf8AZsO1WYAMwG3AJCrk99o9K6aigBsUaQxJHEipGgCqijAUDoAOwp1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFIAoozVa/v7PToDPqF1b2sI6yTyBFH4k4oAs0V59qPxi8C2c5t4teh1C67Q6bG92zfTyww/Wqv8AwsfXNR48NfDvxJd56Saj5enRn3zIS2P+A59qAPS6K80K/FfVjzJ4V8O27f3Vlvp1/PYlH/CttZ1HnxN8QvEt4T96PT2j06Jh6FY1zj/gVAHfapqun6TB5+qX1rZQ/wDPS5mWJfzYgVxN98ZPA1vcG2tNZGqXX8MGlwSXbMfYxqV/WptM+EHgWwn88+Hra9ue82os927H1Pmlq7WxsbTT4FgsLaC2gXpHDGEUfgOKAPPf+Fg+I9SH/FNfDrXpgf8Alpq0sWnJ9cMWYj/gOaT7P8V9W4lvfCvh2F/+eEMt9On13FUJr0ujFAHmo+Geo6iM+KPHvijUSeGitJksIWHoUiUE/wDfVV9Y+EXg/TfDWsy6R4etJNWNnMYLm6zdSiXyztYNKW+YHBB7V6lXOeOddutD0y1OnQwS397eQ2Nv9oYrEjyHAZ8ckDB4HJOBxnNJuyGtzzH4HzS6pf3+oNLKbeDT7SGKPefLDTAzOQvQHAjFem3d9NE5S0065uiOrKVRB+LEZ/AV598DNGu/Dv8AwlmkagYGltb+EK1uWMZjaBWTbu5GFIGD6d67DXINcuJJBp2pJaRGNwipCodX2/Kxdg2RkYIwODnPGDhFaJHXOV5OVh6eJIo7hINUs7vTmc7VecBoiew3qSB+Nbh615vZ3+vaSp/4Su4+2WLtsk86AM2x5NqtmNdqhQQGD9eSCOlekbdvygY28Y+lOzTsyOaMldKxialrMy3jWWlWb3dymPMYtsjizzhmPf2HNZmsa7ceH7OO71pbV/Nfy4bSyWWW5uH67IkAy7e3AHUkDmmeIdRv2vW03RC0dzGscsziEsWDk4RX2lEbCk7m9h3yIfDOj+JIktZ9Q1h5L1WKyyyxRu3lYGUA2/KGfJ+9wAODngUbrmbKdRJ8kV8zzn4gQ+PfElgl3rc6+EfDpuIoY7G0Kz37NI2xWkcEBfvHIDDAJBU90+EPwd8FarPrT6lpdxfx2M8cMcl1dPlmMSyMSE2r/GBjn3r0H4wPJH4Fu5EhaeZbyzKRKcF2+1RgKD2yTirPwet7vQRqnh7WraBNYD/2pNcW0xkhuBMzKNuVBXZ5QTaR0UHJzwRb5vIU1FQv1Oh074e+DdORVs/C2iRlejfYoy3/AH0Rk/nW3FpGmxKFi0+0RQMYWFQP5VeorayOW5l3Xh3Rbtdt3pGnTr6S2yMP1Fc7qvwp8CaopW78KaQM9WgtxA35x7TXbUUWQ7nyZ8YPgXjUobX4aeEtTJBDT3Ml/GLYAj7qCRt5PqcgDGOc8c54P+EXxa8K63Dqui2tvp95HwS9/CVkU9UdQxDKfQ/zwa+1WGQaz7gHmk9Co6mJok2pT6Tay63aQWWpFcTw283mxq2eqt6Hrg8jOOcZN6hxUN9dRWNjcXdySILeNpZCOu1QSce/FZHR0KOv6xJp8bwadZm/1QwtOlsG2qqL1d252rkYHBLHgdCR4v4k1vUtf8F6lqOp+Ib6C6RwIbKxUxQkHGAVX5iDyNzMcY98V634Y1/SdMtp5tSnkbU7qTzL64itpZIYpMcQ+aqlQIxhMZ4IOcEmsRvC8L3k2reCL+zurOSQ77dZgPLfqQp6Y5+6cYrpoqlKEoydm9mcVeVVTjKK0W6PJvDegve+D/tmq2EaOZWEEskIV5I8D5jxk85Ge9es+B/CvhhfCNt4p1WytrHVTE7zarETBMAGZd+9cclQMn+LPOc1bbw3qmrui61JHZ2o++FkEkjD0XHA+uePSutlihe0hsooI0soAoji2ggbcbevoQCPcVpVqRjSVO92Z0aMpVXUtZHJafceJZQ8lvdxNbSP/o0OqWuZwmODI0ZTBJydpUkDGTnIHXIsghTztnmbRu2ZxnHOM9qdFEsZyAMmpDXCk+p6Ta6EVFHTIopiFXrV22HK1TQZNaFsvIpoiZeHaiiitznCiiigAooooAKKKKACiiigAooooAKKKKACiiigDz742+Jte8F+C7rxFoUulslmY1ktry0klMpeVEBDrKm3G7P3Wz7U2++IqeHPE9n4W121v9V1qW3S7lutJ00pawwvKY/MkDSuyKuMsxJGOe+K2vHa+GdWgsvC3iwebHrchSC1/er5zRYlxvTG3G0HkjOMc9K0z4d0o+J38Qm0B1d7P+z2nLsQYN+/Zszt+9znGffFAHD23xo8Py2pupbDWLa2l0+51OzkmijH26GAEyeUBISDhSQHCZFc78T/AIxLH4J1RvCbX1jrMWm2GrRXE0ETIsNxNEAuCWG/a5BGMDsa7/Tvhl4Q0/zhbaOpjltpbTypbiWWOKGUkyRxo7FYlbJyEC9ap/8ACofBJsrm0k0iaSC5torOQS6hcuTDG4eNAxkJAVlXGCOBjpxQBzniv4nTTaho+n6It7pWoW/iqw0nVLa7ihZmhmV2wCpdcMFHKkMMdq1vCvxn8K+J/FdtoOlvctPdNMttMxiKSmIEt8quZEyASN6LuAOM1paT4K8EXJlTToYb2ey1ZL6eUahLcTJfRDCmWQuXLKG+45I56VqaJ4K0PQ9QN3pEN5ZkyPKbeK/uBbb3zuP2ff5XOSfu9eetAC+Mtb1jR4rUaB4audeuJywKRXMdukQGOXdzxnPYHoa5gS/FbVgSlv4V8OwtwBLJLfTr/wB87E/nXpVFIDzT/hXOv6j/AMjL8RvEVyP+eemLFpyH2OwFsf8AAvxq1p/wc8DWk4uLjQ49Tu/4p9Ule8Zvr5hI/SvQaKAKun6dZabB5OnWdtaQ/wByCJY1/IAVaoooAKKKKACiiigAooooAK5H4s2r3Pw71x4XKXFpB9vhYdRJARMuPxjFddUc8Uc8MkMyB4pFKOrdGBGCDSaurDTs7nAeFpkm8ZeJZoGBgvLfTr2IjurRSKD/AOOCut6V5t4SsNW8LeObPRdXWN7R9Iaysr5JAfta20m+MMmAUkWKVgeobbkHqB6TWKOi99jO8QQRT6PepcTi3t2hZZZcfdXHJrTfrkjAPPNVdQS3ksLhb1N9sYyJFwTlccjA5J+nNctITM001tp+qW32jO7ydQ2mUk/8tASdp56oSw6e1JtIpRctjUgYW/iK9iIdXuIY54ycbWCfI3uCCVzn1GO+N3tXNaBBZxSzJb6YthcqArBfmVlJ/hb6jkYBzyR3PSn+VKI5q2jOT8e7Ws9OiYAiXWbBMfS4Rv8A2WrXgBRe+JPF+rMzMftkemRZHAjt4xnH/bWSWsX4iaibS88LRQ2N1qN3Jqn2iKztQDJL5UMjdyAq7mjyxOADmuy8CaNcaH4at7a/eOTUZXkurt4/umeV2kfHqAWIB9AKuCu7mdV6WOgooorY5wooooAKqXKYJq3TJV3KfWk1dDi7Mx5Fwa57x7tPgvWQ+djW5V8Ej5SwDdPbNdTMlZmrWEWpaZeWE5dYbqJoXKHDAMMZHvWMlpY6Ys8fsvjd4dtfiAng+LT7mK2juRp0d3HtWNJd2wKE6hA3G7PvivZxApUOwODyCc4P4158fg74Nbxn/wAJM9hK1/5vnmMynyWmznzCv97PPXGe1Sn4WaBaMZPDt1rfhyQnP/Eo1KWJSfdGLLj2xiqtEXNM74Rqv8NOGB0rgv7B8f6XzpPjHT9WjH3YNb00KfxlgIY/UrQfE3jbTDjWfAv26MfeuND1GObP0hkCP+p/Cjl7C5+53lBrg4/ix4WimWDW5dR8P3LcCHWbCW2JP+8QU/8AHq67SdX03WYvN0fULPUI8Z3Wk6TAD32k4oaY1JMtn7xpKOpNPRCTUlEkK81pWy4GarW8eelX1GABWkUYzkLRRRWhkFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnfxL8Pa3q/i7wVf6DEmNNlvHluHZdsBe3KRsVJyw3kcAGvOtD8PfFTT9N1OW8/tfUdRexMLWk+oeXbTzecD5sc63pkRtpOAiQqQMHaev0TRQB8723hP4oXWmpp9xfa9Z27+JLebz49TVLiHTzG4mwzTzHCsV+Rnk5GcGr2ueDfiDb3/iJtG1HxBcJbXGkro0sus/66KOMLdM6GQKSSMtvUbjkgHNe9UUAeJT+GfHt34u/0i41ddDk8STzSeVqxixp7QqEA2SBgu/OFGCDzgda4zX5vGfhfwx4eHjfW76BYrLUVaBddjt7qScMfIkZhMrTqqsnyqXPqpzg/UFFAHJ/ChtQf4a+Gn1p7l9RewiedrpmaUsVzly3Oee/NdZRRSAKKKKACiiigAooooAKKKKACiiigAooooA5zx1olzrOkxPpUscGs2Ey3lhLJnZ5q5Gx8HOx1LI3s5PaqXg3xJY+LPDtpq+mkiOYYeJj88Mg+9G3uD37ggjgim+PdfljQ+HdAfzfEuoxFYwnSyiPytcyn+FVz8oPLthRnnGZJoE3hlrW88KW5nigtorS704uFa7iiUJG6seBOqjAJwHHykjCkZT3NYXsWfFthqFzHI1lq81k7gLERDG6IcdwRk5+v0r5o1nQPEVnqt59pm1aC4uJCZ2iuJAtx1544YH1FfTtjrmgeK4ZtPt72KW5CeZLZsxiurfa2NzRnDoytjkjg47EZVdG1JBtXU7dlHQvbNuP1w4GfoB9KxlF3uj18Dj44ZOM4KSfdfqeZ/CHw7r9lpiJe6leWNluPkWZRWfJ5LZcEqM9u/J4HX07V7DX5oIxpOvW9iyoA3n6atwGOOv31xn0qOSGz8O21zrfiDUYRHbRnMzr5cUCnrgEk7jwMkkngAc4Obc65e+KIxbeF1uLTTpR+91qWIx4X0tlYAu57OQEXr8xwKcVy7nLiq31io5pJeisjio5PiPe+IbvUfDsvg3X7rQHl0xjJDNbOrusbyKq+ZtzwgJyMYI9ar6l8afiB4T3Hxp8NpVhT79zZzN5Q/4EA6/+PV2UcVv8O9VTUtPtNnhieCK11FI8k2hjyI7o5PzLhish68K5zhq9QgmiuII5reRJYZFDpIjBlZSMggjggjvW0NUcM1Z6niXhz9pjwPqbImpLqOkSHq1xB5kYP+9GWP5qK9Z8O+JtD8SW/naBq1jqEYALfZ5lcr/vAHK/jiud8X/CfwV4sEjaroNqt0+T9qth5EufUsmNx/3s14Z4s/Zk1XSrk6h4A11pJIjvjgun8mdf92VeCfqF+tXqRofVtFfGmm/GH4nfDO/TTfGtjPfQjgR6mpWRlHUxzj7/ANTvFe8fDv45eD/GbRW32o6Tqj4AtL4hNzeiP91uegyGPpRcLHqdFFFUIhmiDDIqjLHWpUckQbp1qJRLjKxjspBpjVoSwH0qu0VZtGylchzSZqQxmk8s0DuiOTEkTRSgPEww0bDKke4PBrkdY+Gvg3V5fOuvDmnx3IO4T2iG1kB9d0RU5+tdkIialSH2o1E7Hnq/D7UrHB8NeOfElhj7sN88epQqPQJKMgf8CqRR8T9JGfJ8L+I4V7I8un3Dfnvj/lXo8UBParSIF+tWrvcybS2PNU+Jl5pXy+KvAvifSsffnt4FvoEHqXiJOP8AgNbGh/FPwPrbiOx8TacJyceTcyfZ5M+myTac/hXa1k654b0TX4jHrekafqCkYxdW6SfkSOK0MzUjkSWNXjZXRhkMpyCPY1y1t8QfDl3czQWd5NO0TyReYlpN5MkkYJZEmKiN2AU8Bj0q74S8JaF4Rt7qDw5p0VhBcS+bIkbMVLYxkAk4+gwK8y0z4Wa5YeJY73S5LDQrJ/Oa+hsNSuZIL5nVsA2zpti5bOQ7YxwBQB6P4e8Y6drvgm08UWsGoLp9zH5iRC1aacDcV/1cW8k5H8OeOa6NSGUMM4IzyMH8q+b9M+Bniex8IarpEt9ot9cahpMdklxPLIGsnSYv5cREf+pYcngNu9etbmr/AAc1e81fWdTgm0pL641iw1CzuC7iSGKFNsq7gmVLdgMg4GSMUAepeL/Ftp4Zm0q3mtL2+vtUuPs1pa2gTfIwUsTl2VQAB1LCty/uksbG5u5QxjgiaVgvUhRk49+K4b4heA/+Eq8Y+DdWMGmy22j3Msl2t0m55EK/KqjaQcNzgkAdetcToXwg1+w1a2nlvNMWS3/tDz9Tjkc3eqi4DCNbgFMAJkfxP04APNAHok3xD0mL4ZDxy1vfHSTbrc+SETz9pYKBt3bc5P8AerrbSdbq0huIwwSVFkUN1AIzzXzlf/ArxHP4fSwkl0C/m/sSLTYpLueUDT5Uk3M8P7pshhwT8h5PXv8AROmwNa6da28hUvFEkbFemQAOKALNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRSAKKKKACiiigAooooAKKKKACisHxR4r0zw2kKXryTX1xkWthaoZbm5IGSI4xyfdjhR3IrmpLPxL4oJbX7ttB0puml6bNm4kHHE1yPu5wflix1xvNS5JFKLZt69430jSr/wDs2E3Gqaz/ANA3TY/PnAyBlwCFjHP3pCo96xZ4/F3iBD/aV9D4Y09+ttpzCe9YEEYadhsjP+4rEdmrb0TRtO0HThY6JY29hajny4IwoY/3m7s3uST71ZaJyclgazcmzWMEZ2g6Rpug2zwaTaCISv5k0rsZJZ37vJIxLO3uxP4VsKcjNVhE4PT8qsIcDB4pItpGRr3hjSNcliuL+zQ38H+ovoiYrmH/AHJVw6/TOPas4+HtfiAS18Zal5QGALi0tpm/77KAn8a6r6UYoauK9jl7TwjD9uivtYu7rWr2E7oZL9lKQH+9HEihFb/awW966RYhnc5LN71JQSKLD5mRSyAcFQRXKQ+H9R0CVpfAt9BaW7MXfRr4M1mxJyTEV+aAnnhQyZP3K6h0ZjwDSCFvYfjS6jaTVmZdl4+tIbqKy8VWU/hy/lIWM3jK1tO3pFcL8jH/AGW2t/s12VYU9tHc2sttexxXNtKu2SGVA6OPRgeCPY1zcPh7UvDZWTwVeqlkpy2i3zs1qRxkQycvAeuANyf7I61op9zGVPsdrrGlafrVhJY6vZW97ZyfehuIw6H3we/vXz18R/2Y9PvRLeeBbz+z5+v2C7YvC3sr8sv47vwr3Dw54ss9YuXsLiKbTdaiTfLp12AsoXON6EErImf40JHrg8V0VWrPVGeqPiXw98R/iL8GtVj0XxNaXFzp6cLZX7EgoOMwTDPHbgso9M19QfDT4peGviFa50e78rUEXdLYXGEmT1IHRl91yORnB4rpvEfh/SfEulyadr2n29/ZydY5kzg9MqeqnnqMEV8ufEz9nfV/Dl0dd+G91c3McDectoJCt1ARzmJxjfjsOG6Y3GjYNz63or5e+EX7RbxzR6H8SQYpUbyl1TZtKsDjbOgHB7bgPqOrV9OW88V1bxz20qTQSqHSSNgyupGQQRwQR3p3FYlIB61G0SnpxUlFA7kBtxTfs/0qzRSsh8zIBbjuakWNV7U+iiyFdhiiiimIDSUppKYCivHNJ+NT3V7pf27w95Gn6hPf26TQXpmlVrRSzZjMajDAcYY8/r7GKyrfw5odtJayW2jabC9rJJNA0dqimF3++yED5WbuRye9AHlui/G6TUNKudUu/Dcmm6R9j+1W2o3clwtq7eaEEUkn2bAcggjy/NB6Zzmom+ON19gPk+EpZdWGuxaH9i+1tDveVGZHDTRIwztxtdE65JFelr4H8JrJdOvhfQle6UpcMNPiBmUkMQ52/MCQDz3AqW08IeGrNI0tPD2jwJFOlyixWUShJkGEkGF4dQSA3UdqAOI+LfivxRoXgvwzqOm28Gmane6jZwXlvLOknleZ96Hf5bKRnKlwARjIz0rlJfiHrXhT4g/EC51K2bUNNtrrR7eS1/tF9tkZocMYFZMMCxJP+rzgHvx7nqumWGr2T2WrWVrfWcmC8FzEssbYORlWBB55qifCvh4xzxnQdJMc/leav2OPEnlDEW4Y52AYXP3e2KAOE8N/Fq48QeL20yx8K6m+lLqE2nSagiTN5Lxj78g8ry1Unj/Wlh1KjivVKxm8K+Hm1kau2g6SdWDbxemzj88N6+Zjdn3zWzQAUUUUAFFFFABRRXnHxZ8Uax4c13wRFownmj1DUzBc2sCRF7hNhOxTKQFOe+5frQB6PRXgOk/GPVtNfxAdZsLu9uX8TNpGn2Toqm2UrkI7W6SFiOfuiRiema19Z+Ndzpegw3lz4Ye31IW8tzcaTdS3MV0kaOV81VFs37ogZ3yeWO1AHs9FeNX3xZ1nUrnWrHw14YLpZ6RFqL6jJfxoLYTWpmQtGyEsQ2FwN2eScdD0XgHxXq8/wXt/FPiCKC5vo9Ne9PlS4+0BYy2WxGojYkEEAMB6npQB6HRXh8/x2mtNHury98NRCRdDg16CKDUTIHilmSLZIxiHluC4PRgQO1XNR+MWr6f9ujvfBy2l3p2nHVryC41VAVtzJsTyykbCRyPmxlQOm7NAHslFfPcPxQvtD8Z+O9YeG51Hw+JtGEdrPeNHJaJcQZ/cxFWUsS2WXK9Op7S6N8ULzw1Nr1pcW99rd/feMNSsbKOSWZ1hiiWM7BsjlcAbvlRUPU9ACaAPf6K8Vv8A42ahaRSGTwbPaz2+hnW7m21C7a2miUXBgaMKYSSeAwJ25B7VePxc1Fm1u3tfB91e6hp4spEgsrhp98NyhdZG2xb12jG4Kj8njI5pAeuUVzvgPxPD4s8MW+swvZ+XKzqfss0kiKVYgjMkcbA8cgoMe/WrugeItG8RW32jQdUstRhHVraZZNvscHg+xoA1aKKKACiiigArj/FniS9XU08PeFo4ZtckjWaeedS0GnwEkCWTBG5jghIwcsQScKCa2PF+uxeGvDWo6vPG0q2sRZIl6yueEjHuzFVH1rD8H6LLo2lN9vcTazeyG71KcHPmXDD5gP8AYUYRR2VR71EpW0LhG4vhzw3Z6I9xch5b3Vrvm71K6Ia4uD6EgYVBxiNQFUDgdzt0lLWZsFKKKWgAooooAK5/U/DIv76WcazrNrbzlWntbe4CxyEY6MVLx5AAIRlz7EknoKKLBcKKKKACiiigApDS0lAGbr2i2Ou2iQahG26NvMgnicxzW8nZ45Byje469DkcVS0rX77Q9Tg0jxXMs8Ny4i0/WAoRZ3PSGdRxHMexHyP22t8tb1VdXsLTVtLurDUreO5s7iMxyxSDh1Pb29iOQQCORTTsJxvodFRXF/DjUbxV1Lw7q9xLdX+juix3UvL3NrICYJGOOXwrIx7tGT3rtK1TurmDVnY8u+Lvwa0H4hQSXQVdO18L+7v4k+/joJV/jHv1HGDjg+AeFfGHjT4BeJBoPim0lu9AdiRAG3Iy55ltnPHfJU468hScj7QrC8Z+FNH8ZaHNpOv2iXNrJyp6PE3Z0bqrD1/A5BIosFyTwn4l0rxZocGraBdpdWU3AZeCjd1YdVYdwa2a+MdQ0/xd+zj40W+0931LwxeuEJORHcKOfLkA+5KBnDd+cZG5a9/0T4x6B4g8R+FtN0eVZV1u1uJjuIElvJGAVjdexOJP++QRkEGi4WPT6KoNdH1pv2o+tLmRXIzRoqkt161Mk6t1oUkxOLRPRSAgjilqiQNJS0YoABXgnhb4I39n4imm8R3aalaz/bIp7yO8WOW5inRhiWL7LukYZGN05CkZX+6fexRTA+Z/B/wq8S+IPhtqj6hfXFjrVw0FhZi9iaEtYWpISKRWBKrIcsQVbovBBxXr3wi8H3PgzRb+zuQsYuLx7pYY7xbiNNwGdgW3gWMZB+RUwO3XFd1RQAUUUUAFFFFABRRRQAUUUUAFVbzTbG+ntZr2ytria0fzbeSWJXaF8Y3ISPlOO4q1XnPxl8Ear4utNIu/DF5a2WvaZPIYJ7lmVBFLG0cgyoJzypH+7QBpeP8A/hFPCvg3W9X1vw/Z3WmeYt1ewRWUTtcSMwXeythXbLDljmrsfgjwfc2Vqv8Awimgm3RCYY206HEYflgBtwM98da8bm+Aus/2N4nsE1LT5kezGm6AJpH/ANHtzdG4fzTs4booK7uPStPWvgxrM0fi630W/wBP07T9UvNPu7eziZljk8mNlnSVTGVUO5DZ2uDtG4HpQB7RZaJpVhLNLY6ZY20s0aQyPDboheNBtRGIHKqOADwBwK5zxlbeHPCHw18Q/wDEsWx0T7NL9ph0m3jiciRdjMq8LvwRyfQV5tp3wTvlu9BF7Hp0mm2UupyT2lzd/al/0mBEQRhbaJFUOpbYFAXqCc4HVD4f603wAPgie8s5NZ+wm189pXMOd+R8xXdgLgfd7UAb/g3wP4U0/wAG2un2GiWUthc2kImN1aRNJdKACpnwuHboee9buq+GtC1iW3l1bRdMvpbbiB7m1jlMXf5SwO38K8W/4U34hltdWYS6JYLdXGnynR7WaQ2d2tuMSCdvLU/vScnCHoM5qU/BO/v49MttWk04aQmt3Ooz6ZbXEqRW1tKgUQQMqKSMjn7g54HXIB7BP4U8O3GsjV59B0mXVgyv9tezjafcoAU+YRuyAAAc8YFOuvC3h+7tLi1u9C0qe1uLg3c0MtnGySzHrKykYLn+8ea8iuPgxqCa1Pf6e+kwyp4ktdUtJvMk82KzjTa8W/ZnccD5ckHAya91oAwovB/hqKFoYvDujJC1ubQotlEFMJcuYsbfuFyW29MnPWi+8H+Gb/zPt3h3RrnzPL3+dYxPu8tSqZyvO1SQPQEgVu0UgK2nWNpptlFZ6dawWlpCNscEEYjRB6BRwPwrkvEHwu8Ja1d/bW0tbDUxyt/prtaTqfXfGRk/XNdtRQB5kvh74h+Gh/xT/ia18R2S9LTX4tk4A7C4i6n3ZaU/FUaKwj8feG9X8Nnobsx/a7P/AL/RZx/wJRXpmKQqGBBAIPBB70AZ+h65pWvWYutE1Gz1C2P/AC0tplkA9jg8H2NaNcLrvwq8Kapdm+t7B9H1Tkrf6RK1nOpPfKYDH/eBrMXRviR4a/5A+vaf4psV6WusxfZ7kKOyzxjDH3daAND4juLzxD4O0Zlcxy3z6lLg8FLaMsoI7jzXhP4fSujjOUX6V5VqvjxbXxnpt/450jUvC4t7G4tN11GZ7YySSQsCk8QZekZBJC9R+Homj6nZ6jaLdabd297Zt0mtpVlT/vpSRWMr3udELONkalNVg+dvaoZpN8bIhKswIDeme9YPw71WXVvDcb3UUsd1bObOfzWyzSxAJIx/4GG/LPepvqVbQ6aloopiCiiigDz/AFv4jS6RqOsrNoE7aZp5kh+1CcF5J1j3hfLCkqjcAOT/ABKcYNcb4j+LOpX2kz6bpVrLpniCPEvmwOksUiEfIULDIDO8I5HILY6V1upMYvFfiTZxmS2f8WgQH/0EVwfgLTYLvS7bWmxCXR7eEknBgWZigwfQAAH0FdNenGFKM11X4q2p05bCNeq4T6Wfy7fl9x618OL3VdR8Kw3euXMVzPLLJ5UqQiIvEG2qxUcZJViMdivfJrp64L4c62lpHb+GL8hZ4FZbKcfcuIxltvtIqnkfxAbh3A6063pQ1hNJGo2jam4Yi1WQGT5QGbKjpgEHnHFcy1RGIg6dWSkramhRRRQYhSMwVST0pap6vc/Y9MurnZvMMTy7M43bVLYz26UDRb4IBFMlOI2PtWB4Iv5r3w3bXtz5uL15buISn5kikkZ41P0Qrx26VsTS7+F4FK+g+XU5y4JsPib4ZvI0yNRtrrTJjn+6ouIz+Hlzf99GvRK868UZGs+DGUlWGuKMg44NrcgivRa0p7GNZe8FQzShBx1p0z7BWbNJkmqlKxMY3OO+LmmeIfEHhS603w7HoVytxGyXFtqsTnzB2MbhgFYHkFh1wcjFfE09h4i+HHi2wuNU0640/UrGdLmJZlwsmxgcqw4ZTjGQSK/QTNU9Y0vT9b057DWbG2v7J+sNxGHXPqAeh9xg1ClY0cOwtjqNvqml2epWDbrW9hS4hb1R1DD9DViMnvWboOi2Ph3RbTSdJSSOwttwhjkkMhRSxbaGPJALHGScDvWpEvSp6mi21CnLIQeaQjBIpDTEXILjnrV+NwwrDBIPFXLaYjHNUnYzlA0qKRG3KCKWtDEKKKKYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUgCiiigAooooAKKKKAOC8WOlv8AEvw1v5F7puoWhU9DgwSYx9Eb2rG1P4ceG7u8e9sbSbRNTb/l90WZrKX8QnyH8VNbHiry7n4neG4gQXs9Ovrph6b2giX/ANCf8vaulhjCJ05PWsW3zOx0RS5Vc84Wx8faED9h1PS/FNoOkOox/YboD0WWMGNj7uoNU9E+IGn+Hri7t/F9lqXhu4uryS4U38G63zJg7VuIyyNyG5O2vUbhBs3ADIrg9dury28eRnT7QXcC6QX1G1Vdz3MRn2ptB4LJ+8YKfvBmXqRSbXVFJO2jO50+9tdStEutOuoLu1f7s0EiyIfoykg1YIrzRvAXhXVov7X8KmXRrqYfLe6FcNaFvVWQfJn1Vkz1BxT7aL4ieHYgsFzpPiuzXnyrkf2fdgegdcwn6kAmqsnsxWaV2ekVg+NNfbw7oouoIoLi8lmjgt7eWUp5rMwBxgEnauWIAzhTXPQ/FPRrW5jtPFlnqXha8chVGqwFYXP+xOuYyPckVJ8ToJdd8K2N5oUMWqx293HcgWshMsiDIPkSKcZOfm9V3Dg1VOK51z7EOV0+U5m71SfUZvF141o1ndCOMCLzFkIZbYEEMvBGenQ+w6VhahObfwrp62MqxIltBHHIV3LHu2Lvx3wGziuh0Hw/rU3iXWNOtpIpZwttPfXt0D5KSPCv7uNFwW6cLkYUZJJIzyPjy0g8JFPC9xqg1PdZqXaOAI0CmQDaRuP/ACzyRnkbRn7wrfF1KTjBRei7no5NKUZ1IWfNJaWV9kzS1PT7jSvs95d+JIYBbTxzRzT2aKqujZHIcdcEY7gkVc0G0g1L4h6LfWwXUZp7h7+9urVDEVOHCOXGcRqcp5ROTnknkHL13VdG8WR6fpsOs21gLi6G6e5jO2IBHPzbio5OB16kV69oEVgfEN9PcaTa2PiV4V8+WM7/ALTDkBZEfA3KSADkBgQA2flJ2r1aFNuFFJ3W6f8Awf69DhqrETaeJb5l0atp8/O50dFFNZ1GQW/KvOAUEZIyMjrz0rn/ABpdeR4Y1aRclvsskUY/vSONiAfVmUfjVi2tDbyPK8o2KpJPTj1JrlNT1WTWPEXhpbNVbw+dQYGdgcXcqQSyIY/WNGQHd0ZsY4XJUjVwUXo7nY2tv9mtYLZcsIY1iB/3QB/SpCMdRV2BdsQI780TpvjPqORRYnm1OT1phL418EWhj3j7Zc3bcZ2iO1dQfb5plr0ToK861xRD408EXjOUQXlzaNzgHzbZyAfX5oh+OK9ClOEJrSnszCr8RTuZMk1RPJqaY5aovr0qWzSKshKz9X1WLTjHCsb3N7MCYraMgMwHViTwqDux+gyeKln1CCPIjPmN7dPzrMdoIDeXaRobqYb5XJ252jABY9AB+A5PrUOXY1jTb3K8mo65neV0o45+zgSDPt5uevvs/Cp/+EjuTHtg0W5W4/6bzRLED671ZiR9Fz9K8+T4t+DnvDbXGpNBMrFGZoi8QPs6ZBHuOK6Cfxb4ZgtTcyeItJEIG7ct0jE/QA5P5VnzNG7pRZtDVtbhPmSx6deL1aKJXgb6KzMwJ+oH1Fbel6jbapaefaM2FbZJG67XicdUdex//WMjmvLLH4p+FdS1OLT9MvXnuZX2IZF8iMn/AH3x+A6mu7tNlnqD3QiHmugikYcFlByAfpzjPTJ9acZtPUmdFW906I05Dhs1DBcxXA/dvlv7p4IqTFbJ3Odq2jNS0kyMGrVZtmxzxyR6VW1zxb4e0EH+29c0ywI/hubpI2/BScmtIvQ55qzON/aEsby/8B26adZXd7LHqdpM0VrA8zhFkBZtqAkgD0FZ3xO8Ya/PZWJ8C2XimOWVbhTcLpbxRpIqAoJI5bSWQ5JABCopyQX4O3qviX48g8E+GbPWVspNSiurqG3RYS2MSH7+VRu3IGOTgDkipJ/iT4Vt9RWyuNRlhuC0KSCSznVYHmGY0mcptidh/DIVPqKsg858Par8VtZ1IzyS3GnxWuiQXv2O50lVS8uzG26HzGAKEvtJAJI7AVgab45+I7393p1jc3+oa4nhc6jJp9/pkdsYL03KowQeWjMqxltuSwY9z0HscfxI8I3mqHSf7SJnkvJtMIls5lia4jH7yLzGQJkDtnnPGc1heG/Gvww0n7QfDiWWmxyW0148tpo8tvHPDBnzHVxEFkC4P3SfbNAEvwa1PxZqKav/AMJbcSzRL5DWouLKa3mjyp8xWL2tuj8gEbFOM4J6E+lVyH/CyfCQSd31mONILCLVJGkikQLbS48t8lerblAX72TjFafh/wAV6P4ggvpNKuJpWsX8u5hktZYpomxnDROocEjpxz2oA3KK8Rt/jdNqWn+GL6y0l7WLUNabTbuOa2nmYRDf80LBV3udn3VDEE4IzXfj4j+GX8PRa7Bd3lzpMglJuLbTbmYReX9/zQkZMWP9sL0PoaAOvorz7w78T9O1/wCIE3hzT7W4ltvsMN7b6jHHK0cwkXdz+7wi46MzYJ+XrxXoNABRRRQAUUUUAFFFFABRUN7dQ2NncXd04jt4I2lkcgnaqjJPHsK87j+MWiN4UuvEkmm6vFo0MJmS5YQMs2GUBBtlO1zuGEk2E9hQB6VRXM23jzwrNpum3z+IdIt4dRTfbefexIZOcFR82CQ2VIGcEEVbvPFvhyx1FtPvfEGkW9+jqjW0t7GkqswyoKls5I5AxyKANuiufl8a+FYtPjv5fEuiJYySGFLhr+IRtIBkqG3YLDuOtS3/AIt8N6daWt1qHiDSLW1ul3W8097GiTD1Ri2GH0oA26K4XwR8SNL8S6jq+nXMllp2pWWrXOmQWcl6rTXSw4zKqEA4OTwAcYPJruqQBRRRQAUUUUAFFFFAHAuq3HxY1eXqbbSLOAc5x5k07t9PuLXU1yGjj/i6HjM8fc07/wBFS11xYVh1Z0rZCSj9230rk7MbviFqzf3NKs0/Oa5P9BXUzPmNhXLaeMeP9dz/ABadYkfg9yKUi47Fq90G0ubx723e4sL98b7qyk8t5MdN4wVk/wCBqaW0s9YguI/N1iC6tQfmWaxCykf76OFz77PwrVpakoZNHHPA8M8aSwSDDxuoZXHuDwfxri7r4Z6AtxJd+HzfeGr9+TPotwbdWPbdFzGw9tort6BVJtEuKe55zo8/jvw7qGsR2q6V4tiilje5MhGm3j5iXaRy0JAQAfw5Kn61xvhzxhonh+117xB4k/tOHUbuU3kr3FkVaeNmCqkDqWjcAnjD9OeApx6zqp/s7xFBdSMUsdUh/s64fjEcoLGFj9d8if7xQd68esdM8P6r4G1HwX4uvIrKTR7qWETCcRE4kJEqbuDzkEYJwe26s3OPNaSN6FKfJN03rpp5f8PY2p9T8I/EvwDq2oeGdOAvYEbdG9ssdwsijcAduchgCOCQckda5zwx4ostOGgvY317BcWAiS4glzLA0XAkEXzEpujG7bwpKg4DAGut+GfhDRfDHh2S38P3k9zBqI81r4uA8gK7VK8ALjnHGck5rnNXtbXwJ41sGs7OVtHurZIJzKCybiSrHceN2AGI44L9M1jVsp80dj1MHFVqDoVleW8ddu/6bb2t1Pfye4bcOxByD71n6jBqc0if2ff2tpFt+bzLQzOT7HeoA+oNZnw9uWufCVpHI+6WzaSxY+vlOUUn32BDXRV0J3Vzx2nF2Zhnw5DclTrd5d6vggiK5KrAD6+SgVG/4EGqLxYduo+E26Y1hV/O2uFroa5zxpkTeGGH8OuWw646pKv9aBHYRf6tfpTjUMLfu157VKGFWZM4n4j7LfQre/kBxpmqWN4MDOAtwit/467V6Lcf6vivO/iuof4eeJgSB/obsD7ggj+Vei3H+rpw6k1N0zKk+9zWT4g/tF7WKHSktt8j4kluGOyNAOu1eWJPYEe59daUYbmmMoZcHpSaujSLtqcFqNp4lgt3NjqOjTXP8KT2UiIf+BCQkfka8a8a6p4kvZZtL8USSwLjc1nGBFE69iCv319yT+dfROoRPE4yMqejDvXN+NvCqeJ9CVYnSO+t28y2lYZAburd9rDg49j2rG1me3luKo4eqpV4KUXvfW3mj5km0LTXXHkNEfVWIrNj8Lxi8bfcFrcDcu0fMfUf59a7nULF9Puza6qklldqc7ZjtB/3W+6y+4NQ/Z4FYMZ4zGM4zIOPpTVz7WWDy7E2qRivlp99jkb2XwrpGrQ6ZfQzmUojS3AXckJdQy55ywAIyRjHOA2OfU/D3iPXNMd7HS73Udbjt2MRt7XSZr1YyDgqJH8vAGP75FckdE03WdWt7mLS49R1WPYgdWfyW2gBDIAcNgADA645B5r3vwZo76TYD7XK1xqMx8y4nkO53Y9iaqTgktD5DGuvS56c3C19LRV0vVW/G7/XL0vU/H955bW3hS0hJ5E+oXyQKPrFEZHH4tW2ukfEXUlzqXirR9GB6xaTpQnIHoJJ2OPrt/KuysVJj3HpVqri9NEfPTTb1dzho/hfY6iceJfEPinXQfvRXWqPFCfpHEEA/P8AGun0L4aeC9Fw+neGNJjl7StbrI4/4E+T+tbNqPmrWT7orWLbOeaS2MDxv4TsPGGgHSdSkuIIRLHPHLbMFeN0YMpXII7dCCK5m/8AhJouoX1zPe6jq00N7Nb3OoWpeFYr2aEYWSQCMFScZYRlFJ7VqfFe812y8Kq/ha6a11F7mNPMWxmu28vksAsUUpUkDhmjZR0PUV5bpcPibVPiB8PvEeuWviqxja0uLadpbSKd42MvyrL5duuxHUgFmRCFHVSCxsg9A/4VJ4fMgaS41GRf7cm18o0ibWnlXayH5P8AV47df9quH8F/Cv7XrcsF5qtlN4e0ywvNFFja6kL2aAzk+ZG0ggiKbQ3AbewJ64xVbwZqPjWx0HwfZ6rb6z4e0ZrO6e7k0bQEadbkXMmyNrdYHESGPawYRjcT15zUPgx/GehfETWF+w6va+GNQ8QXk8l1HpjSyTt5aeUZFMeVhbH30AJORletAHcx/BHw41peW2o32r6jHc6bDpZ+0yRApDCytEV2Rr8y7VGTnIHOea6rwL4K0/wZBdRaa+8XJUuTZ2luflBA/wCPeGMN1P3sn0xzXH/B/WfGF/rmoWviwarcwxweYl7JafZbR3L8JHFJawzBguOrSDrznFZt7rvxDXx1NBDDqOxddjt4rIacDYPpZX5p2ufLJEnt5nB42mgDpdO+EmjWDaasOo6u1rpuqHVrS2eSIpFKSxZc+XuKEt0LE8DBHOc+8+B3hu70+1spb7VjBbz3M6o7wyozTn58o8TJkc7WChh/e4GOHg1n4l6/aaToeoQ65FLcW+sW+rO2krEjMI3+ygStFsAPygFTg565r0z4DW91ZfC7RbS//tNLu3iEUsGoWht3gYKMxqCiFkHZvmzk/MccAE/hT4Z6V4V1iw1HR9Q1SOS2sI9Nkid4mS5iTOwyZjyGBOcoV6DPfPdUUUAFFFFABRRRQAUUUUAQX8MlxY3EMM3kSyRsiS7A+wkEBtp4OOuDwa8fl+Bdrc3GsTTajY2TX+nSWGzSNM+xxncQfMlTzGV2G0cKEHU4Ga9Z127k0/Q9RvIQrS29tJMgcZBKqSM+3FfP1l8cvEc2gXl9FHoOoSRaB/asn2SCULYz+aEEM371s5GSBlD7HrQB2GrfCC+1KOUyeJLZZ7zR00S+f+zCVeBH3K0QM2YnwADkspPO0dAaj8FYrmTXBBrjxwajPpcqLJbeY0S2UewKW3jeXHU4GPQ1i698UfGegwoutx+GLCd9JfVreQpNJFfNuAS0iJdCJsHJ+91GFxzXK3vj/U/D3xB8Ya5ZwWUGtX1porLod5Gz3Fy0kah4YtrqQ67zk7W6cgUAekXnwk1FpdW/s/xdcWdtqer3Gp3NtHBIiSrKir5TmOZHO3bnIYA55U0vhP4S33hF9FutD8RWzalp+mvpckl7pzTRSxGZpQVRZlMbAtjhyCB0rgV8d6p4K1bxb/ZdlAyah4tuYpr26CmG1AhjIDbpYlyxOAWkUfKepwK1rz4v+LhZQvDa+HYbhfDdxrU+1jexNJDO0ZVJIptu1lXPUlScHOMUAdZafCEW+o293/bQYxeKJ/EmPsmM+YAPIzv7Y+/3/u13/inTdQ1XSWttH1mfRrzerpdwwpKVx2KuCCD3rxy4+L3iWGLVI/J8OC5XT9P1C0e5mFrGouBlo2MsoWRlGcfNHnHbpXpnwt8TyeL/AAjDq8z72klkTcLM2wIVscL5soI/2lcg+1IDBL/FTQRzH4d8WWydCpfTrp/wO6L+VL/wtm10z5fGXhzxD4c28NcXFmbi2B9podw/MCvS8UUAYXhzxf4d8SoG0HW9P1AkZ2QTqzj6rncPxFbtcj4j+G3g7xHIZdV8PWElyTn7RFH5M2fXzE2t+tYX/CttX0k58H+O9e09B0ttQK6jAB6BZPmUfRqAPS6K80/tX4oaH/yEfD+ieJbdePN0q7NpNj1Mc2VJ9g3+FOj+MPh+1kWLxRZ6z4YuGO0Lq1g8aE+0i7kI98igB+kHPxN8auCCFGnIcdmEUhI+uGU/iK6ktXH/AA8uU1a01XWUura5uNVvpLt1tp45/JiAEUKMY2YZEcak89WNdXuzXOdcVoh0hyMVzSExfEiZcfLc6KjA+8Vw4P8A6OFdF1rn9RIj8faA3/PWwvofrhrdx/I0mUdBS0UCgYYpaKKAIrq3gvLWW2u4Y57eVSkkUi7ldT1BFeZ+Lfg/p+p3Bv8AQ7+ex1PzBKxvCbyGVgABuVyT2Azk57g16jRScU9y6dSdN80HZnB3cXiCBdh0FpNoAD2NzE68eisUI+mK4X4iWXiLX9Njs30bXUlhYyxIlplXfGPmZdw6E9xXu3NR3M8NpazXN1KkNvCjSyyOcKiKMlifQCodNM3pYydJqSSujmvhro99o3hSGLWAF1K4le6uEDBtjPj5cjjOAM44yTXUYryfW/GWs6xcqdHuJNH01mCW+5I0nnOMmSRpAwhjABOMbtoJOOFrN0/W/FTQJOfFF2zMAUWW1gdMerDy1Jz16ggHGe9bKk9kWsFXqu9tXqe01zfjYZ/4Rvkj/ie2nT/gdSeB/EEniHR5JbuKOHULSZra6jiJKbwAwdM87WVlYZ5GSOcZpnjJd9z4WXGf+J5A35RzH+lS1Y45RcW4vdHTxthRTw1QDil3U7ktHM/FBTL8PfE4XtYSt+Cjcf0Br0TKywh0IKsMg+ormrq3hvLae2uk8y3njaKVD/EjAhh+IJqr8LtQkbQn0LUJN+q6CwsJyeskYGYZsZ6PHtbPruHaqhvYyqrZm5cLhqhq/dR9aokEGh6Di7orajbPeWE8Ec5t5XXCTBQxjbscHr9O4zXOadeykTW11GIb2Bgs8IOQpPRlPdGHIP4HkEDq6ztX0eHUmjm8yS2vIgVjuYsbgp5KsDwyn+6e/IweaiUb6o1pz5d9jEvre3vYjFdwRTxn+CRAw/WsNvCPh8vv/sm1B/2VxXQSaRrCttGoaaw/vG1kB/ISY/WmnRtWxkanY59DYvj/ANG1jyyOuNdLZlOzsLSyGLO2ii4xlRz+dK7T3N2un6cwW8lXc8uMi2jzgyEdz1Cr3b2DVbTRNWlbbJqVhCv9+G0dn/Dc+AfqDW5pOmW+lW7xW293kbfLNK26SVum5j9OABgAcAAVUYNvUirXutNWXEURxqikkKAAT1P196WinxruYVucZZtE+YVpVXtkwuasVpFWOebuwoooqyQooooAKKKKACiiigAooooAKKKKACiiigAooooAhvLaK8tJ7a5XfBMjRyLkjcpGCMjnoaraBo9j4f0a00rSIPs9haII4Yt7PtX0yxJP4mr9FABRRRQAUUUUAFFFFIAooooAKKKKACuE8f3Uup6vpnhazlkiWf8A07U5InKslojYEeRggyyYTIOdqyV29xNFbQSz3EiRQxKXd3OFVQMkk9gBXnnw+STUor3xLeIy3OuSi7RHHzRWoG22j/74+c/7UjVE3pY0pxu7kep/C/whqc32qXRbezveoudOJs5VPrmIrk/XNVD4M8VaVz4a8dXs0S/dtNet0vlPt5o2yKPxNeg0tTdluKPOG13x1o//ACHPB1tqkI63OgXwJ/78T4c/gxrKm+IXhu68YaE+oXk2hTWsV2stvrdu9k4MixheXGw/dP8AFXrM3+qbNeXXc82v/FCxhz5+h2y3dk9pIu6GcpGDNKynhtsrwRDIPKvSbXVFLmtuehW1xBdWn2u1nhmtCM+fFIrx49dwOP1rkLr4m+GUn8jT7i51aUEgjToDKox1+c7VP4E1znxD8C+GNG0o6no+nto+oz3UFssmlXElmWEkgVgFQhMhdxHykcenFea67c3kdtq9vZ38mpavawlbC21DT4HlkOVy0c6BTKQhc+WyEkgcdMtQT1R006cnF1JrRdrfqe9ab478OXziJ9RXT7o4H2bUR9lk56YD4Df8BJrqNpxnt6+tfJfww1PxZquhaj/bdsb+1jlRYRfIIzICG8xVYr82Pk4OQM44zXWWl5BpLubP+1tAZSHL2sjRRNjuEPyv6EbCfUY5pun2Z008Iq1P2lN29f8APY+iMUYrxKLxdrMfliPxfLtkAaIXVjC7SfQ7FLj6fnT38X68+9D4o/1eTJ9m0uMOnsxKsFHsQD71PIxfUandfeewanqFlpNm15ql3b2dqvBlnkCLn0yep9hzXkninX5vFW2W5gmtfD8QDRWbE+ZdOWG15UHb7u2Ik8nLc4AwJL9by6+3Sm91rUQSEmuZAWUn/nmn3Y191VePWp5oGmWa41V4EtIyG+dSuxF5JOWIUE9SckgYyuSK0hC2u524bBKD5n7z/Ber6kqQveXMvnwwHZOBuDiUnaB+7Ug7cbuWIzlgFzhcmgmty3esWcVpD/xLZjKpuZBzMyg/6sZ+6D/EevQetaGoaTqOreE9Z1BDc6Ro1rp8syTvF5Ut2wTKJGpG5I/V8AnIC9zUF0ot7nTooYo4ocKjR4AMaq6bQnuGKg4/hz2FWpLodlOrF3UHezV33uztPhZx4l8SKBkNbWTkjoDmcYPvjn6V1HibD654Sh9dRkmx/uWs/wDVhXI/DM48aasMsN2mQHC9DiaQZb3549t1XPifqcuieK/AmpMSunw3lwl0x+6EkjVCT9FZ3+iGuep8TPEx2mIl/XQ9Fhj8wnJ+UVZEaAfdFR24K71PUGpqEjhk9SN4UboMH2rjted/D/ivSPEcfFvIyaTqa5wDFI+IZTzj93KwGf7sreldqayPE2kwa5o97pl1xBfQPbuQOV3DAYe4OCPcCh6aoFqrM6iRd64rPnhIrO+HGsT674I0i/vd321ofKusjB8+NjHLx2+dGroZEDj3rVrmVzCL5XZmMRikbOOKuzW5HaqrIwrNo2UkyDZRsqU57ik5pWKuR7PrT+e9OAJ6CnpEW60WE2Rqu48Vetoc06C36EjiriqFGBVqJlKfYAMDApaKK0MgooopgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRSAKKKKACiiigDh/itO11pVh4bgkKza/dCzkKNhltgDJcN/37Vl+rit21VVj+VQq9AoGAAOgHtXL3Mh1X4o30mSbfQrBLVQV4FxcESOQfaOOIf8Drq4f9Uv0rFu8jogrRJBRQKjuZ0toXlldI0RSzO7YVQBkknsAOSaBmB421W5srKCx0fY2uajL9lsFbkLIQS0rD+7GoLn/dA6sKxPh5o9rBq+sSWYJtNPK6Jau4+dlh+edye7PPI+49yla3gC2fXNQn8YXqMsdzGbfSI3yDHZ5BMpB6NMwD+oURjsab8KUf8A4V9o1xMxae8ia9lY9S8ztK36uaVuok9dOhmfGUqdG0OPafMfV4Sj9k2xyM2R3yoZR7kHtXl2nwQ3aamGhiuvOnJeOdAU85crt57ACPn3NehfF+X/AInvhiKWTFuqXdxtzx5iiMByPZHkwe241wWjt5OmyS3KGAry6AEMoVAN2Ou4gbz7tW9M+hyuP7tebb/JHXeFPA2l6p4L0C9tNQ1ayuprKJ5ZY7kyCRivzbkl3qMNuxtAqS48A65bAnTtasrxQ3yx3ts0Tlf9qSMkZHrsGfaur+HkbR+AfDaOEDDToOE5HKAj9Dz75rohFIeiOfoprBSktmeXDFVafwyZ5C/gvxIr7TpWgzGQ5MiXhVQf9oNDuP1Gaii8J+JDIIx4b02LZ0kfUItn4YQt+YFd58QPGmj+AtJi1DxFLLEk0nlQxRxlpJWxk7RxwB1J4HHqKXwx4osvF2jxavoFw8unOMALHiUvnDKQ3TH69QcYzXPNK5qsyrt25l9yORt/Bvim5/10mjaeno0kt0x/BQgH5muh0X4f6VaSQ3OrPLrN/G4kWS64ijYdNkAOxcdQTubPOa6nzTHOsTMHDHaG7g4z/SrFS5yluyKuKrVVactDG8a273vg3xBbpGJZJbC4VVY/eby2xz9cV4tdSrNDo93GWmTCy+Y3DKpVWMv/AHzkEejn0r3q/so9S0+7sZ2ZYrqF4HK9QrqVJHvg18+xMLzwnp890xjCRxyPJGMlQoxuA/AEr6EirpbM68udo1Pk/uO7+GZKfEO6TdsEmk7ipz+9ZZxgj3QMc/8AXQV2XxR0L+3/AAXqEEcIluoU+0wJ/fdMnZ/wJdyfRzXnHha68nxt4Vu5flWaSW2bYc/NNCdv1Xcn8j2r3IHuOnWioveZy5nHlxLfezOI+GGt/wBp+H4oJ5jLdWSRwvIx+aaJo1eCb/gcTKT/ALQcdq7WvJNIh/4RvSItctg32PRr680bU1BLZsRcuYpcf9MdwP8AuNJ7V6vC+9cEgkehzmoRwbkhqK4GYj7c1Kaa4yjD2psEc78NittqXjDTQ5Ig1Y3KKT91LiGOY49t7SfrXcVwPht47X4p61AAA1/pNpc/UxSzRt+jJ+ld9Vw2MaitJgQD1qJ4VNS0VViU7FVrWm/ZfarlFLlQ+dlZbYD0qZIlXtT6KaSQnJsKKKKYgooooAKKKKYBRRRQAUUUUAFFFFABRRRQAUUUUAFeQ/H34qXnw8TSbbRIdNuNTu/NnkS+cqiwRrk4wy/Ox4Xk5IIAJr16uauNJ8Mf8Js99dfZX8S3GntbeXLclpGtA2WCwlsBN3Uhep5PNAGJ8QfF00fwX1HxX4YuvJlbT0vLSbar7d20jIYEZ5wQRWQPjRoelaVOviKHUbTU7JLRJIZUhBuXnTcjRsJPLCkBidzLtA5xW94R0fwX4i+F0Gl+HoWuvBt5HJHFEZJ13L5jbhlyJAN4buPbior/AMA+AtG0W+Oq20FvZXMkDT3d/qEpcPHhYcTySb0K8BdrDGeOtAHGax8W21y58M3Hg+7ltrSe61GzvopY4ZCZILYyKNwLqQCVYMjEEHqRU/hX402Vh4M0h/F41CfWJdIj1IyxwRAXu6URbIlDDMm4j5cLxz0rrfFOieDPD2mWepeJnvWtrK4YQT3l9d3bxyTqISAS7Ngg4x0GSeDk1Bqnwp0e71jwTNb+XbaV4WaR7ey8tpGkJ2lMysxICsobBBye4oAb8XvE+r+HofBcujmWF9Q8QWlnc24SJnlhdXLRZb5QSQBkMOf4gOabYfGDQL260+1Wz1WO5u5L+ExSRR5gks0Dyo5DkZwRjaWBz1FbXja18La9q2h+HvEhlfUJJm1DTo4pZ4XEkK8yLJEV2lQ/GWHXjkVC3ww8IGz0+2TSWjWwkmlgkiu545Q0oxKWkVw77xw24nI4NAHEW3xnvtW8SxR6D4furjRp/DkmsQ+YsS3G9ZWTc2ZwvljbggfPnkcc1qeEfi09/wCEvDF1q+h30mva2kr29lp6xfv1iXc8qb5sKgHGHYMSDgHiuosPht4U0+bTJbLTGgk062aytyl1MP3DMXMT/P8AvELEna+4c1HH8MvCkWl2enxWF1HbWUjyWmzUblZLbeu11ikEm9EI6opCnnigDnJPjl4ba0W6sLDWb+3/ALJOsu9vFEPLtxMYWyHkU7ldSCBn2zXpEWrWL6NFqzXMcOnyQrcCaZhGoRgCCScY4I61zY+GXg8RSRJosccb6YdHZI5pEBtS/mGPAYdWJJb7xJ61sXkGgW2nWXh7Uf7PFpcxi0trG8dWFwqKPkCuSXwAM9fU0gMu5+Jfge2z5vi/w/kHaQuoRMQfoGzWXdfGj4d22fM8V6ecHH7stJ/6CDXS23g/w1a/8evh7R4eNv7uyiXj04WtK102xtGDWtnbQsBgGOJVOPTgUAcB/wALv8CPxa6pd3b9Qtvpl0+4eoPl4I/Gk/4XHosuRY6F4tvj1UW2izHcO+Mgf5Fel4rkPivdzW3gPU4LTH2zUAmm2+WwfMuHWEEe43lvwpN2VxpXdjzrwz4vu7aHUJk8EeOLq61O+nv2k/sxY0Ic4RcvIpAWNI1yR24rfXxt4mcBbP4a68wIwv2i7trfJ98ucD3rtdMs4LO1igto1S3hRYYlA4VFAVR+QFWxWaa7G7T2uefHxT4/cfuvhzFDnjdc+IrcbT6kIjZH45rntQufHfjkajo0eiaDDDZzxR38Z1OUo5wH8l3WHBUgrvVTuxwcBsHvfG2rXVjYR2+khW1m/lFlp6MCQJmBJkYAH5Y1DSNx0THeul8L6HaeHNEttNsd7RxAl5ZG3STSMcvI57szEsT6mnH3nsRL3VucQq/F9wFz4At1HGAt5Lx7fd/KuY8E2/jzUPCWlS6T4k0Gy00QBLeL+yXkYIuUAYvKeRt9TXuZrzX4WL5fw78PhSCDbbgR0IZ2IP60Tdmgpx5rnmXjO28Rwa/c2994xTULu0sQ0ksfh60XYrksIfnZ8lgpY4x2znIxQtrDU5RKyeJdScGRwj2620KyEMVDZEHQ4H4Vv+Mt8njfxUIAFl8m1QA93+z/AHv1Uf8AAaoaTLbm232CstmJX8hH+8qBjgH3rWGtj6PB4OlKEOa7un1fddmdH4R8GR634V0u+Xxn46jingVvs8eriJIWHysgCRrwrBlA6cVp/wDCqtFkbN3qfiW8JHP2jWbhtx9ThhzR8JNXtRpU3h15kS/0+eYRQvlXlty+9ZAD94ZcqSM9OcZrv653KSdjxalFQm4tbM8q8XfA7wvruhixtDeadcLKJhdfaJbhmbGDuErngj0xyB9K6v4f+CrDwR4Wt9F06aeRY3aV55MbpHbqSOgHAAHt+NdVQAT0HWk5N6MlRSd0QRW6o4cs0jgEAtjjPoBU9OZGX7ykfUYptIq9xVO1gR2NeFSWQtZNb0oDyha3tzCigZCozmSPHqNki8fhXuleO66BF478TIvCfaLebHfc9vHuP47R+RrWl8R6OVv98490c/Feta6dZam8JjfTbuG/eKI/cRZBIwT1HlMQPY4r6K8xSu6NgyMMqR0IPQ1842VotxpuqadHIV8zzI2OP9U8gYFR6gfKR7NjtXt/hHUjq/hLRtQMYiNxZxOY16K20Age2Qce1FTox5lDSnLyt9wvw2sopdF8QNcQxvFf6zqDSK3zCRfOaP5gfZAMVneEWl0K+vPCl07NJpirJYSOcmewY4j5zkmMgxMf9lD/ABVpfC07bbxLBsKmHXr0ZPfc4kyPwenfE2xnjsLTxHpsTy6jobtceVGPmuLYjFxCPUlBuA/vxpSavFNHiKVps3kYOoYdDSkZGKp6Xcw3dtFcWkqzW08azRSL0dGAIYfUEGrtSjRqxyNyxsfiZ4XuNhIvLa90129CBHOn/oqT869Crzv4jn7HaaNq4k8sabq9pcSN6Rs/kSf+OzH8q9EFXT7GdXe4UUUVoZBRRRQAUUUUAFFFFABRRRQAUUUUwCiiigAooooAKKKKACiiigAooooAK8s8VeEdRn+Nmg+JrexvrvTEsHtZntr/AMryJd4KsyGRcx46qobOOVPFep0UAfOfgTwR8QPCug+G4LSyvT5ek6jDqOntrOyDz2kdoAu2QhGII+eLBB6spyaztT8A/EnXvCniew1S3v3ScWF1Y2c+qFgs0b/vkVnuZjjGSN77SdpwpAA+naKAPL/i14c1TxD8KINM0LS7571Z7WUWd1eI9wqpIrMGleUhmAB58w59TXNW+h/Ee3ube/hj1n+zYvEa3SaVLq6yXQsNhDK7tKUcbsHYZDivdaKAPnTTvCPxEiOk6nqbSxalYWutAXt9fRy/ZjKg+zktvPy8dshcc1g+FLnxn4hk1uw8H63qcl9B4cto5ZrjWBfQm/MymVo5FlkjRnQOFwQQOy9vqmigD58fwz8RRoM0KXfixpfti3MdqZYVG0IQYmm/tIzeWWweJcjng8Y9A1jTfGNx8GvsOlsth4uNrGGCXjylW3AuqzyMzbiu4BmY4J6/xV6HRQB4O+g/EeGY3mnJriaTB4gsbyDSrjV0lvDZpGwuEaVpirq7FSEaQjjtWYvgTxreS+GtU8QWes38+n67eTSwJrIE6WkijyjG3nKowRjAcNjjpX0XRSAKKKZPLHBDJNPIkcUal3dyAqqBkkk9BQA+uE+IBF34r8F6Y0e5ReT6k3HA8iBgv/j8sZ/Cm/8ACZar4gX/AIorSA9m33dY1UtDbOOMNFGP3sw5POEU44Y0WHg+B9Ri1TxLeTa/rEWfKnukCQ22SCRDAvyp91eTuY4GWrOTurI0hFp3Z06DaoHoKGO0ep7D1NLXI/ES71ARabpGnjyDrc/9nDUBKAbQsCzHb1LGNZNpB+/t+tSa+o/wPH/wkXiO98UyHfYW3madpPQq6Bh59wP9912A/wB2Mf3q9AqrpdhbaXptrYWESw2drEsMMakkIigBRzz0Aq1WsVZWMJPmdyK7mW2tZp2BKxoXIHUgDNcD8Ok8v4feGFAwP7Mtjj0zEp/rXU+Np3tfBuvXETiOSGwuJFc4wpEbEHmsLwrCbfwrocBGDHYW6Ee4iUVnU3NaPU474oaSbOePxPbBzEirBqaKuR5Izsn9cxlsN1+Rif4a4U3I05rVXgxA8aRtNBlkdwAFkx1BZcBgMgkBhnJA+hRbsV5K89Qa4PUPhloskkgsp9S0qCTO+2s5l8g567Y5FYJnPRcD2ojPlWp62FxqpLln02/yt2PONTvARZvpcySawlxG+npGwMhm3AbQvXBG4N22ls19ASYDtjpk4rD8P+F9I0AtLp9ruvXUJJe3DGa5lAAGGlbLEYA4yAPStqlOfM7mWLxP1mSla1hRzXkvjbxBNrOtXNjDey2ui2cv2QiGYxG8uOjgupDbFPyBQRuYMTnAFeieLNSk0bwrrOpQY860s5Zo8jI3hTt/XFeMNpEZ0SPTDI8flooWZT8ySKQwkHvvG7359aqlG7udGW4dVZucldL8ySOG60dWuvDl1dWV5ERIFWZ5Y5sclHjZirAjI7EHGCK9N+HPjBPF+kNLLDHbahAEM8MbFkKuMrIhPO04YYPKsrKc4yfMNEv2vrUicCO/t8R3cOMGOT1x/dbqp6EH61m39lqelanaan4Wu57fUQwgXIDRqnUl89YwF5U5z8uMEA1c6d1eJ243BKrHnpLU+jSVUFpGVEUZZmOAo7knsK8PGov4g1a71+T5UvtqW8agALbIWEWfViGLEn+8AMAUuqS6lr2xfEWom/hU7xaJCsNtu9TGMl8Y43s2PSqDXkdxeRWttA11Cql5RG5SNlHAUuOi567eSFKjqSCEOXVkYPBvDv2tTV9EVo7iJtK1G7hLRJ5EvmzA4LyKZSXX0AUoo/3a9w8JQtb+E9DheIQtHYW6tGBjYREuRj615n8PvDUfia8SW4iW58PafnJHyw3l1uBwAOHjj5JHK7iBztNexMTuOc5zzms6j2XY4sfVjKSpr7N7+r3MvwDKieIvGtoNu8ajDckZ5xJaQc4+qN+tdtXDeFlEHxI8TJg/6Rp9hcdOMg3EZ5+iLXc4qofCeLU+JnnHhmM+G/EWo+F5FK2i7r/Sjjg2zt+8iH/XKRsY/uSJ6V2Xbiuf+Klky6CviG0KLqHh4tqMZY4EkSqfPhJwcB49w/3gp7Vq6PcyXulWtzLbS2jTJ5ghmI3op5UNjgNjBI5weMnFQ1Z2NYy5kZnj3TTq/gnXNPRd0k9lKkY/29hKf+PBa6Hw1qQ1nw5pWpqMC9tYrkD03oG/rVe6hW4t5IXeVFcYLRSFHHuGHINcdo8eufD+yhsLW1m8ReGIBtiEOBqFonJ2lOFnUcY27XA42tTi7Mmauj0uisnw74i0nxHavcaLfRXSRtskVcq8Tf3ZEOGRvZgDWtWpiFFFFABRRRQAUUUUAFFFFABRRRTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiikAV574xuY/FuuQ+E7KRZtNhcT666HKhFwY7QnGN0jYLLnIjVs/eGbPxV8SXGiabY2dtcJpv9qTG1fWbjiDTl25Lsem8jIQHClupAGDz9rqdr5Wm+GfhPLp08sEiy3N0h8+0tYRne00in95K56KG3scsSoBNRJ9EXFdWd3Nf2sWpW2nvKBeXKPJFEqkkomNzcDAUZAycDJAHPFSXtzBYWklzfTxW1sgy00zBEUe5PFeR+CbazkthqXiK013WrzV7mWaHW4YHBEAkMcUZMLB40wgcLjYN/Xqa5bwZ8YPCWs+PRpdh4Su7mZnddPvri8+0SyuoJXAmJ8rdjghjjIzioV3saN2PoSzuYry0hubdmaGZQ6FkZCQehwwBH4iuZ+Iec+FAhUSHxDZ7SRnpvLf+Ohqli1jxZLyPClpED08/WRn8dkLfzrJsDr2tfE/S7bWP7PgtNHt31N7ay3yhZZA0MPmSuBklTOwUKOmecjCWo3oj1IdBRRRW5znLfFOUQ/DTxUzKWB0u5XA75jYf1qezh8vyou0SBfyGKy/jQzD4aa2kblGmWOAEd98qJj8d2PxrejXEkp9XIH51lP4jenpFklIyhhhhkUtFIZWkgK8pyPTvUNX6ZJEH9j60mi1LuYHijTW1nwzq+mRkCW8tJYEJOAHZSFz+OK8e065N7ZQ3DK0cjL+8jYYaOQcOpHYhgw/CvdO5B4ryjUNGuLbxD4pm8iZbdLs3yERkiRXiR22/3juVwQO/1q6UlF6nrZZXVObjJ6MreFPCFt4ql1zUbky20sJjsLC9hJEkbx7mlYDoy7nClWyDtYcdatTeDvFkG4LFot8F6PHdSQFx/uMjBT/wIj3ruPAGnvpfgfQ7SaNo7hbVHmVvvCV/nfPvuY5roI0LtgfjU+0le6MHjqsZynB2TPGrjwP4z1WFoY7fSNOhYYfzb5pXYZ5HyRkAYz7n+fU+HvhfH9oN34wuIdWfAK2aI32cMBjc+45kIAAUEBFHRe9ekIoRcAYpabk3uc9XG1qvxMbDFHBBHDbxpFDGoRI41CqqjoABwB7CorpMgOByOtT0MNykevFJnMnY5SwBi+Ldu2cLdaFIvXqYrlT078Tf5zXf157fSG2+JXhBs7RPDqFqflzn5IZAPb/VE/hXoVVT2MqvxHEfGlyvwz1pQwVZRFC5I/heZEYfkxrpJf8AWN/vH+dU/Hukya74K1zTIADcXVnLHDnHEm07Dz6NtNcd4Y8WeI7/AMP6ZqF34bXUY7u2Sf7Tpl7EAxYZIMUpUowOQQGYAg80p6MdPY7fzojcfZ/Nj8/YZPK3DfsBwWx1xnjPSnngEnGOpzXD63r+i3ap/wAJPomu6T9nO+K9ntHHkMeCVnt2fZ75IB71LZRQ69bz2mleOk1O1aMrNEEs7pvLYYIYhQcEEj5hU3LJvHGnNZMvi3R4D/beljzZfJ+V761HMtu+Pv8AyAsmc7XVcYyc93p95b6jYW17ZSrNa3MazQyL0dGAKsPqCDXjuleLb7wZf6hoGqwT6ho+l3drZ2+rvIu+CKZUMZuuBhQGYCUDBKbWwSCd9S/w4vo5IGU+C7qcRzW7cHSZZGwJIz/z7s7YZD/qywIO3IFRlYiUb7HpdFFFamQUUUUAFFFFABRRRQAUUUUwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooopANdVdCrgMrDBBGQRXL/ES+/sD4fa3caehinW2aK2WFcYmk+SPAH+2611Vec/G3V4tH0PR7i7Z/sUWqQXNyiDc0iQ5lVAO5aVYUA9WHbNKWw1uZnizWn8LeHvD3hfwfNbT67dIlhYb8MkSIoja4cg4CoQD33N8uDzjG8O/Dzwv4O+JOmG20OW51i5t5J49Q+0KI0KKoml8jgISZAAFyPmOMYrmdA0TVb74t6dBq+LPV7y3Os36WoX/QUDMbe2UEEfLIVkbIId2yckA12OiHU7/4za5bpqKyXGjaNb2YuJbYFWaWYTPmNWUA7QikgjpnHas27aI1Svqzs4PFFreeLtT8M2aP/adjax3DyS4EOZPuJkHdnkE8dOhqH4Po9x4autYvWWXU9Uv7mW6mVcK3lytDGEByQgjjQKMn6nJrzjw5qNlH8RvGXibVl0x7Mot1E1xKAyW9vLNCJYwVO5g0A6YxvHOSK9Z+F+nvpnw78O2s8bxXC2MTzI67WWR13uCPXcxz70Q1Yp7HUUUUVqZHHfFdfM8JRwEZE+p6fEfYG8hya24+UB9ea5v4ruBb+F4S7L53iGxUAZ+ba5fB/wC+M/hXRxf6pP8AdFZS+I3p/COooopFC0UlGaBHPQ6lO3i++0i5jjUGBLuzkTOZI87JFbPG5X29P4ZF9DVnSb+HV9OhvNOl3wzg+U7qV5DFeQeeoNZd2wb4kaGAwBi069kkz/dMtsBn8QT+FVvhU6v4H0Zo2DoTKVbOQR9okwQe4qOpr0KVxrdzr/hPw6to7WN34gkWGR4H+aCMK7ztG2Ou2NlU9QXB6iu9tFVIQFGAOBkk8DpyeteV+FmRdD+GN4JI2hUz2jbTkLJLDIAPrujKkepr1S2YeX+NERS2JqKKDVmYUmaKKBnK+Kitv4p8F3LBuNVaH5f+mlpcL+WQPyrv687+Iy4j8NzAkGHXtPbg4PzS+X/KSvRB0qodTKpugrzTw3PJoOreObeTyx4d0u7a5iIJMsJkgS5lQKBgpmR2GDkEkYPBHpdeM+IoRH4k+JnnWEJLaYLlbxioaCNrJ4ywHUgtCVOP7tOewobnanxbpCeFIPEouJTo8sSzCdIHZgjcAlQNw54PHFQXms6fpuoaJt0yaO61yc20TmBYWVgpciUsQwO1WIXBJIxwa85sYbofs6arphijZdP03UbW5LyMJY5Ii7RhVC4OfkPJGPQ1D8W9V1fUvhp4e8WeVaQQWd1Y6tBJDK7yhmQ8uCoCjc4GBn6is/M1R6ILdP8AhaM9rdRQzafreglJopVDLK1vMVKkHqClzgj0FOb4Yaa8H2GXWfEUuh42/wBlSaizW5jxgRk48wp/sl8dunFZ2oC2tfHPhG4j1iW9mF/PbzrLcI7xpcWrvGu1QAqkwIQCOevJ5r0+rik9zObaYUUUVoZhRRRQAUUUUAFFFFABRRRTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiikA2R1jRnkYKigksTgAeprxqOLWPidrP/CU6WbNNE0eYjQYNQjcw3swO2S7cKQQANyxnnBy2PXW8c3Vx468St4C0eaSLTIVWXxFexHBSI8raof78g+96JnrkivSrK1gsbOC0s4khtoEWOKJBhUVRgADsAKAPILvw6/h3xVLqniazu/EC6rYTreSWGnSTIZvMhZIViTcUQRxKqFj1UksCaw9Fi1bQtb8UXWq6NqcnijWTb32mW9rHM0fmESbYnmTCBYi6q+9guFzg8Z+gq5r4heKofCHhmfUXiNzdsRBZWi/furh+I41HXk9fQAntUezRfOz5S+N+p+JfB/i3wz4b0mGB7XRbS3SycWMc5nuCFaR/mVjuL4O0exxzmvsXRZru40awm1GEQX0lvG88Q6JIVBZfwORXOfDLwtN4a0GR9VmW58QalKb3VLkf8tJ26qv+wowqjpgdBmuwq9tiLhRRRQBwHxbjLf8IbJkBYvElmzZPqJFH6sK6eE/uk+lYfxfY2/gee/VGc6dd2l+QoydsVxG7n/vkNW3HhVK5+6SP1rKXxG8PhJKCcUwtTSe5pFDy3pTc00t6UlIdjivGkVvZ65HqOppOdEutNuNKvZokL/ZlkZXWRguSFOHUtjCnaTgcjn9G+KfhjSNEhsNc1W2/tOxjW28u0xKt5tAVHhZflw4A4JXaSQcYzXqT5ABBwRXn/xi1OLRPDOnX7RpmPWrGQnaMkLLvb/x1WqXoWtjN0We21WDSrHT5rW81SbWV13U2sn82Cz+dpCpkX5N2AkYAOWO5umTXqducAg1FJ8pKj7oPAHShDhgaFoDWhbB9KcG9ahz6UufWqIsTUVGD6U4NTEcx8QWVbHSN3fWtNA+v2uKu+rzvx+r3F74StIcFptdtWIxn5YlkmP/AKL/AAr0QdKqHUzqdArB8ReENA8R3Vtca5pNrezW/CPKvO3IO0/3lyAdpyPat6irtcyvY8S8aT2ehXPj7S9V1FdKtdRtptTs0d40jvfMtRFKgLDJdZIw21SCfMBwRWBOIn+EM3hfVNQlTVrOS20d9M3oGfddRvE6Rkb2ZomGDnGFbjINfQl5Y2t6IheW0FwInEsYljD7HHRhkcEetQzaTp0+qQalNYWkmowKUiunhUyxqc5CuRkDk9D3qHC5opnl1rZ67fS+E/D19oV3FeaLfwXF1qbKn2SWGBHRZEk3bmdwU+QrlSWzgDJ9fHSiiqUbEN3CiiiqEFFFFABRRRQAUUUUAFFFFMAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8x074zaBrOk+MrrQ4Lqebw3bS3Lxz7Ylu1QP80TAsdpMZGSMjI4rvfEdjdanoOoWNheiwurmB4Y7ry/M8ksCN4XIyRnI5HNeTxfAay06zt4dB1y4smbRLjRb8yo9wt0sqH51VpMRYkJk2LwSccckgHeeG/iB4e1jwvb6zNrGk2g+zQT3kTX8Z+xNKqkJI2RtOW28gZPbtWiPF3httNm1FfEGjnT4JPJluhex+VHJ/dZ92A3sTmvLb34FTalod9Z6j4mja6m0uy0iCaDTvLSKC2kRwWQysXdvLAzuAGTx2rX1L4Qm48T6hr9priwX0usQaxbJJZ+ZFE8cZTY6+YPMByTkFSD0oA7u58YeGraztLu58RaNDa3au9tNJfRKkyr94oxbDAdyOlMk8aeFo7qW2k8S6IlzEzpJE1/EHRk++CN2QV7+neuA034IadDf+HZ9UvYNVh065v7u6tbqxV4bqS6Cj5UZiI1QqCAd3PcHmrNj8Iha6vbXx1rf5Pia58RbPsmM+coHk539sZ39/QUAdrc+NfCtrBaT3PibRIYbtS9tJJfxKsyg4JQlvmGeMiq2ieLl1Xx1r/h2O0Cppdva3C3SzbhMJlY8LjjG3rk5z2rzib4G6ifCdt4dh8a3CaWkFzFLbC1kWKR5ZWkEm1J1yV3Y2uXU4+6K7jwL4CPhXXb3UjqX2s3OnWNh5fkbNv2aMpvzuOd2c4xx6mkB0+jaLp2irdjS7SK2+13D3dwU6yyucs7HuTWjRRQAE4GT0FeV+E8/EPxy/i6bLeG9HZ7XQ4yPluJfuy3fv02IfQE8GrfxT1C71vULPwBoMzxX2qoZdSuozzZWAOHb2Z/uL9T0xmu+0nTrXSNMtdO06BYLO1iWGGJeiIowB+lAFuiiigAooooAzPE+lprnhzVdJkYKl9ay2xYjO3ehXP4ZrlvAGqvrPgzR7+Yn7RLaoJwRgiVRskH4OrV3leceFV/srxL4q0JtwSG9Go224YHk3QLkD2Eyzj8azmtmbUnujqs0Umabu9Kg1sPzSE0zNITgUrjB27VyXi7Tk8R+IfD/h6VQbeeO+urn1WMW5gBH/ArkflXU96xvCafbviX4kvXjO3TrO102J+2XDTy/wDocP5ChasU3aJH4C1CTVPBWi3Vxv8AtX2ZYrgP94TR/u5M++9GreNc54UAs9Z8XaSJN32TVmuEH91LmNJ8fTe0tdFSLTurk4bIzTs1Ch4xT8mncmw+lzTM0oNMVjm78fbvij4WtFkwLG2vNSdPU7UgT/0bJ+VehVwPgdf7R8d+LdWIjeK1+z6PA46gxqZZh/33MAfdPau+rSGxz1H7wUUUVZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUwCiiigAooooAKKKKACiiigAooooAKKKKACiiigDO8SX8+leHtT1C0s5L65tbaSeO2j+9MyqSEH1Ix/jXjV38VPEJ8NeHbvRtU8H6pq+sanZ2D2UcMqDTzOkh2TETM27cgGdq/df5T292ooA8Hv/iv4w03xqNBv9N0CGa1ks4rhZriO3W78xQZZLd5p0baGyFAjkJ/iKnim23xq1GXx+mkwf2Zc6XIdQj8y4hFi8ElvE0gEhNxIyr8uCzxx9yAQCB71RQB87W/xu8Rf8I9d3L2en3V9Bd2ttcPaW6PZ2SyhyZDcLdtHKAAo5aHBPJHaxqHxm8Q2fhrTL+4XwxEzzXC3T297bXkjomPLaG3W7XcWLYKiVyCOhyM/QNFAFPRbs3+j2N427NxBHKd0RiPzKDyhJK9fukkjpk1coopAFYfjXxJZeEvDN9rWokmG2TKxr96Vzwka/7TMQB9a3K8rsv+Lj/ET7eSJPCfhe4KWoxlL3UAMNKPVIgcKf7xJBOKANv4WeG7zS7C81vxEFbxRrkgur9hz5IxiO3X/ZjXj65ruaKKACiiigAooooAK8/8cRjS/HXhjWVCLFfeZotyxJyS482D/wAiRsv/AG0969ArlPilp8upeAtYS0LLe28X221K9RNCwljx/wACQD8amSuioO0kyyGyKCap6dfQ6np1pqFr/wAe93ClxH/uuoYfoRVnNYHXYdu9KaetGaSgaDqeKz/hcryQeJr1yG+167dlSP7sZWAfpDWnDzMgP94D9azPgy0kvw50u4mUh7p7i65Of9bcSSA/kwq6fxGVbYpyhLb4ra1EoI+26RaXJ68tHLNGf0dK3KyPEUSw/FLSJ8Ya60a7hJ3dfLmt3Ax/wJq16mW7Lp/Cg6U8GmUZpFEmaq6pqEGl6Zeahdki2tIXuJSP7iKWP6Cp8+lcr45jXVJtB8NMQE1q/VJ8g4NvADPKuR3bYqfRj6GgT0VzpPhfplxpfgnTl1EY1K6D315ldp8+dzK4P0L7f+A11dAoroSsrHG3d3CiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUV5efizC/xAv/AAxHZWMMlncx2x+26iLa4nLbcvDEybXUbuP3gZgOAab8NvivZ67BHbeJJ7ew1e4u7yK2RbeWOGWOBjkiRsoWCjLDdn2GRQB6lRXDR/FfwY9tdXH9sMkNvbG8LyWc6CSANsMkW5B5q7uMpurJsfjNoOreNNG0TQo7nUrLUY5SNQgt5yqOjbdu3yuVz1fIVRyeOaAPT6K5nxP458P+GL5LLWbueO6e3e7EcNnPcHyUPzOfLRsAd89Bz0rHuPin4ctJ9QmvNSs10i0s7a9+1RGeVyk7BUJQRYwSQBtdj6haAO+oryzxd8WLKzbRf+EfuLeTf4httG1Rb+3lge1SRWZm2vsKnC5DEFevWt+L4oeD5Ut5P7WaOO4tZr2F5bSeNZYYQTI6lkAYAAnjqORmkBT+K2t6hssPCfhqRo/EOvFo0nUZ+xWy4864PphTheRlmGOldZ4Z0Ox8NaBYaPpUXlWVnEIo16k+pJ7knJJ7kmrGl3lpq1hZ6nZEyW9zCJYJGjZGMbgMOGAYZGDggdquUAFFFFABRRRQAUUUUAFcp8VrhrX4aeKZYx84024Uc4wTGRn9a6uuP+MA3fC7xQo6mwlA/EUpbMcdy3ptlDaWkNrAirBbIsEaDoqoAoH5AVZlQFDgDIHGBWJ4TGybxFAw/ex6xOze4dY5FP8A3ywH4VukbgQGCkjAYjOPfHesEdN3cqINzAepqybdMcZB9aw/Deoy3+nK92gi1G3c295CBjy51xuA/wBk5DKe6sprbabI4oRTv0KV/OLGzurhzgW8Tykj0VS39Kd8LYVt/hr4VjVVXGl2xIXpkxKT+pNYXxGuxa+AvEk5OCNOnReerMhRR/30wrudHsxp2k2VkpBW2gSEEDA+VQOnbpV09zKtsjjvHcbJ478EXIICF761bjk77cuB9Mw/yrYAJYAdzWd8UfMhg8NX6ECOz1y1aUk4ASXfbnP/AH/FaIJVgT1FTP4i6XwltYYwuMZ9zVZkxLsHrUizYrHW/nuvFSWVmw8i0jaW/fAOGdcRRZ7Mclz6Kq5+8Mp2KV1ubqqFGABiuP8AHpVLjw9LbyqLmz1zT5CikblSaRoDkdgVkf64NdjXnHjqfbquqXcQDfYptDQ56bxfeZg/8BkU/jQydz2AdKKKK6DlCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooopgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnOueEfDniLxTHYar4mub26tZxqQ0V7q3ZozuDAgbPPWPO35Q4XpRZ/CDw7bf2UDPqM0enXN5cpHLKm2Q3S7ZFfCAlcHjGCO5Nea6voPia1l+Jl7b2Wo3s1zrdmbaC50qK4juIw8eZVVoTu2LlQw4A5PzfNXQafrXxIHiOCab+1ZLFvFl1pzWkumosI04AGKbeIg4XJIEm7B9+4BvN8EvD0unvZ3Wo61cwrYNplr5s0WbO3Z9xWPEYye2X3nHGa6a88C2E+u+HtYhvdQtL/RYDaxPC0ZE0JxlJA6MCDt6rtPJwRxjxrRvHHxF/t/RdPup75tevLPVJ7jR7zTkt4EliVvsyxyeWrOhIXLB2BJxkU4eJviyPBeu3KNfyastravbwf2PK1xDOZ41lChrSOJ02M/ygyFcZ3EfNQB6J49+Hd94r8e6fqi6q+n6XHpdxp9ybVlFy3mnkLvjddpGQTwR2pmo/BTwxeadfWKzanb2t3Y2mnskMyfJHbuHQqWQncSoyTnPtXdeGLPU9P0WC217Vhq+oqXMl4LZbcSAsSo8tSQMKQvXnGe9alAHnGufB7w3rmpXt5qUl/MLzVINWngZ4zE8kUbRiMgpnyyrHIzk9iKxfGPwZh1jw94T0C0vZptN0i/8ySe+nzOlmwIe3jKIMgjAG48ADk9K9hopANjRY0VI1VUUYVVGAAOwp1FFABRRRQAUUUUAFFFFABXAfHrH/Cp9fz02RZ/7/R139cV8ZXf/hW+s20CCS4vljsIV3YzJPIsSn8C+fwqZfCyo/EjHt9TktvHeqXhiSPRbu4TSnmyc/bIxlXbsqsJPJzz8yLnqK7ToTVIabZSWd5avbRSWt3JI08bLlZS/wB4sPerNtCtvbRQI0jJGgRTI5diAMDLHkn3PJrJG5QvNGgn1WHUopZrW8UKkrwkAXEYJIjkUghgMnB4ZcnBAJBuSxKikgn8anrO1W+hsbK7vrtilraRPPIQMkIilmOPXANJlRuc74pUaxrmgeGY8P8AabhdRvVwCFtbdg/zD0eXyk9/m9K9Mrivhppc5sZvEmrKBrGtrHOyBiRa2+Mw26n/AGQxLHHLs59K7WtYKyMKkuZmL4z0NPEvhXVNHkZUN3A0aSEZ8uTqj/8AAWCt+Fc34S1lte0C2vbiPyb4ZhvYDwYLlDtlQjthgcexB7131edeKLY+GPGNnq9tn+zdeuY7G/h3fcuiNsFwo98CN+mRsPVeVUj1HSlZ2OiktluLWRBLLEzqV8yIgMhI6rkEZHbg0mlaba6VZLa2MXlxBi5JYszuTlndjksxPJYkk06BiJAB0arNZo2kVdUv7bS9Onvb1ylvCu5iBlj2CqO7EkADuSBXl+tm/tNH1m21tYxfXt5p2rEJ1i829ij8gnofL8pVDDr+HPqdzaQXMttJcQxyvbyebCXGfLfBG4e+CRntmuX+KKND4TvNStoUkudO8nUAMYMi20yzlCfTCNx6mhiR6RRUdvNHcQRzQOskUih0deQykZBH4VJXQcoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMjSfDOg6PezXmkaJpdhdzAiWe1tI4nkBOTuZQCeeea16KKACiiigAooopAFFFFABRRRQAUUUUAFFFFABXBfEdku/EfgrS2DHdqMmot6bbeB2Gf8Ato8Vd7XnusySXPxchiK5isNCd1Po09wo/lbmonsXTV5I6WAYiUVJSAYAHpS1mbsK5T4n5i+H3il16/2VdH/yE1dXXM/E6Lzfh34nUDk6XddP+uLf4UmOL1O6tAFtYQBgBAB+VS1W02ZLnTrWeFt0UkSOpxjIIBFWa6DkCuO+LGV8JxyqAWh1PTpfcAXkOSPfGa7GuO+LO4+DvLQZaXUdPj+mbyEZqZbMqHxI0oF/eOf7vAqamx/dJHdiadWSOh7hVe/tory1kt7hQ8EqmKRT3RhtYfkasUjjcjD1FALcx/hBczz/AA30OO7XbcWcTWEg/wBq3doT/wCi812VcL8MF+zXfjCxLlvJ1uWdVP8ACk8UU3/oUj13Vax1SOeatJhRRRVEhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiikAUUUUAFFFFABRRRQAUUUUAFedWUwufil4t+/m2ttOtst05E8nHt84/GvRa810Vl/4Wf45A+8G07P/fh6zqbI1pbnY96KB0oqDQKq6rZx6jpd3Yzf6q6iaBvo6lT+hq1UN5OlrbtPKwWKIGVyewUZJ/IUDW5V+Fl2198N/DM8m7zTp0CuW5JZUCk/mDXU1yPwiga3+GPhdJCCzafDIcDpvUNj/wAerrq2jsjme4Vw/wAUVeZvCVqpws+vW5ceqxJJPj84hXcVw/xT8yJPC16g/d2mvWxlJP3UlDwZ/OYUp/Cxw+JG5D/ql+lPqO3/ANVg9QakrI6HuFJ3paTvQI5zwXE0PxH8ZD/lnNbadP8A8C2TRn9IxXe1wXhsE/FXXmUHaNGsQx7Z8+7x+OK72tIbGVT4goooqzMKKKKACiiigAooooAKKKKACiiigAooooAKKKKYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUgCiiigAooooAKKKKACiiigArzuVktvi3rEHQ3ukWl0DjGTFNNG314kSvRK4Hxuslr4+8H3yKoiuFvNMlbuS8YmQfnbn86ipsaUnaR0tFNU5UH1FOFZmoVyXxSnlXwfeWVoVF5qmzS7cE4/eXDiL9FZm/4DXW1ymso2o/EXwnpwCPFam51aZT6RxiGM/wDfc5P/AAGjfQd7anfWVtDZWcFraoI4II1ijQdFVRgD8hU1FFbnKFc58RdFk8QeCNZ022z9rlt2a2w2MTJ88Rz/AL6rXR0Gk1fQE7HIeFtWj13QrDVYhtS+t47nbn7pZQSv4HI/CtauO+H6f2fJr2h7UQaXqs8cSL/DBNi4i/DEpH/Aa7GsEdT7hSetKaa3KHHUjApiOc8CiWfx941uiP3Ef2GyU/7SQmVvxzOK76uG+EqCXSNa1MPvGp61e3Cn/YWUwp/47CtdzWsPhMZu8mFFFFUQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFMAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4/8A4WX4RCwM2sKom1NtGTfBKp+1rgGMgrxjI+Y4XnrXYV4J4w+CGp674v8AE9/DqdpDpl5HJeaZASweDUXWLMrYXhSYuoJPPTrkA9b0rxho2r3kttpk9zdPDeTafK8VlO0cc8QBdWk2bVxkfMSATwCTRceKrG38cWnhV4rk6hdWT3ySBV8oIrbSCc53Z9se9ebaR8J9ZstN8ERHULJL/S57+61K6iZ90k1yjjfH8oyQWHXbwtc9pHwQ8R2yoqXejaTcLotxpsl/YTSPPczPIHE75jQ5I+U/MSB0J6AA+iqK8v8Agv8AD6+8Dyam98IYzeRwKyWt4kkLPGpUuIltYBGSMZOWLdzkZPmOkeCdai+JmkxW2m/arq21XULy516ewuU8xXQrGJmliRXAPAEcjg5JGByQD6eor5f1X4S+LNE0DxXqEkWmTNe6C1k9hosQHnXHno6skMVvGMBQRzvf/aI6en/B3wTqXhzUdX1a+hsNNg1O3tVj0uxZikbRx4aV8ogEjE8gL9SaQHqNFFFABRRRQAUUUUAFFFFABXDfF5Ug8PadqsjMo0rVrK8JB/h85Y3z7bJXrua5n4m2H9p/DzxJaBPMeTT5/LUDJ3hCUx77gKmSumOLs0yzFwu09VJU1JWZ4dvxqmk2WoL928torkf8DQN/7NWnWSOl7gOtcv4V8u++Knie5ZMvp1hZ2KP6eYZJ3H47o/yFdRnAJ9K574YObi88Z3bKw8zXZYVJzysMMMXH4o3SnHdETfus7qiiitjAKKKKAPO5lFh8XtQjSPbHqekQXRb+9JBM0Z/8dmj/ACFdXXN+OFlg8feC7xRiGX7dYSH3eESqPzt66Q1i92dEX7qA1V1K7SwsJ7uU4jt42nY/7KKWP8qsnpXI/Fi5Nt8PfELLnfJYyW6Af3pcRD9XFSylubXwksRp/wAM/DMPzb2sIppNwwd8i+Y3/jzmuuqGzt4rOzgtrdQsMKLGigYwqjAH5Cpq3SsrHM3dhRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFMAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8B8F/EnUdB1PWINain1OwvfGV/pkM7XjyT2wUKVRISpzEAOzDGfu+vv1Ytp4U8O2ervqtnoOk2+qOzO15FZxpMzNncS4G4k5OTnnNAHi+rfGzXdX8Catqnh/w1e6dF9gkurPVXWR4oykm0q5eAR78ZICs6k8Eg5xu6n8XdT8NW2j2ut+H4rrUtR0mO7szaXxYXlw0qRiEAxLtJDq5IBA5ABxmvR4PB3hiC7uLqDw5osdzcI8c0yWMQeRW+8rMFyQe4PWsXR38JT+Lp/C1l4es4bvw3HHdwMLKFYrfzvmzDjlWJGTgDn1oA4lPj5DdWIvNO8O3FxbXF9babZSiZ2WaaSESSBhHE7DZkDCq7NnhR0qS8+NuoQnT7NPAusf27cWs12+nzR3CttjcqBHtgZ2LYyCyIoyMkV6iPCvh5dIfSl0HSRpbv5rWYs4/JZ/7xTG0n3xVeXwR4Ul0+Cxl8MaG9lAzPFbtp8RjjZvvFV24BPcjrQB5zr/xsudJOsynwrJ9l0iDT7i7FxeGC4RbsL8vlGI/OhYAqWHfkVpfHrU9ZtE8G6fortGmqa5Da3Bjv5bN5FwSIvMjUsqt3ZTkbRgHJx3b+E/Dr288D6BpLQXEcUU0Zs4ysiRY8pWGMEJgbQeFwMYq/fabY6g9s9/ZW109rKJ4GmiVzFIOjpkfKwyeRzSA8ci+K2o6Y09hY6Je67ev4kvdDtoZ9RijYeSisuH8pRtOf4yzDkl2q54h+KusWl5qmkz+H10O9FvP9im1G4lX7TJHAZCYStu8MgBwOZAT6dq67xjceFvB0FhqV/oVu7XOrIsT21nEXW7nO0zEnGGOPmcHcR61Nc23gvQ/GOnRyaXpNp4k1xrj7PNHp6+dcFV3zbpVTjg5O4jOe9AEXwe1rVvEPw40TVNfMD31zbrIZYnz5oIHzsAihGJzlQCB6muzqho2j6Zolq1rounWenWzOZDFaQLChY4y21QBngc+1X6ACiiigAooooAKR1DKVYAg8EHuKWg0AeafCgyp4H0m1uf8AX2Sy2DjPQwSvFj8kFdlXIeCY3tNV8WWErbjb67PKo9EnjjnH6yNXX1zrsdT1sxUGWA9TisH4OP8AaPAsF6UKtfXl5eHIwSJLqVlP/fJWta/n+yWF1c4J8iF5cDvtUt/SqvwqgS2+GfhWNAB/xLLZjjuzRqxP5k1cNzOpsdVRRRWpiFFFFAHD/FaNksfDt+rbRY67ZSMf9mRzA36TVvDoPXFYnxohaX4X+IXRtr29uLpT/tROso/VK3ZOXJHc5rKe5tB+6NrkPiM4kttFsShdb7W7C3ZR/dWYTN+kRrr65LxE4m8f+CLJkDqb26vGzjjyrV1B5/2plqTToz0cdKKKK3OUKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiimAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeEP8KPFU3xGTxFLceH4EW7u3ZrJBbtNBNGVAdUgDM+Tli8rg5OMd/d6KAPnnT/gfr1hpOnwWGpabp14NAudLvbm0kkVp5nkLRscKCygYUk8gdAcCux+Evw81Dwh4n1bUrq00WwtbuwtbVLXTJHcB4gQ7nMafePzZxnJOc9T6rRQB4XqHwj8QXXi3XNRsLvTtMi1MXrPdPKt7dq8sZSMxSG2SSBRnlRK4wSB61m6f8EtetvDOp6fFeWtrcXSWoljS+3Wt75J5SSOO1iKBxnLZkY553dT9DUUAeK+KvhdqWsCwktNC8KWtrBa3VsdDE7/AGKKSUYW6QrbjMo9PLHThgaw9V+BmuXumavFNqOmX9/LpNjZ2V7dM4kiuIHBaTOwlRtyoIJJHB6mvoaikB4P4j+EGvap4ou9RMmjXbTarZX8eoXc0n2mCKEDfbqPLb5SckEOAcDI9Oy+JHgObxJ408H6/a2Wj3g0aScXNtqGVE8bqAuGEb5KNlgCMZPUda9GooA8I0P4PeIbLVraZtVsbOeD+0PO1u0d2vtQ+0BhGZlKAAxkgj526cY61l6L8DtZstG1GyvTBPJeWSWcz22tfZkn2yq4dkWxPzcHJdpSQSDngj6LooA434UeG9T8K+Fm0/WW0o3JuZJVGm20cEao2NqkJHGrMMcsEXPHFdlVPWLa5vdKu7axvXsLqWNkjuo0V2hYjhgrcHHoa86HjLxN4JHlfEPTPt+lpwNf0eFnQAfxXEAy0fqSu5cnigD1GiqOi6vp2uafFfaPfW99Zyfdmt5A6n2yO/t1FXqACg0UUAeb+FAlz4z8dX0LbopNUigB/wBqG0hV/wAmJH4V19cV8MLyE2Oo2EssZ1eHUb+S8jQH7xvJfm+hBXGecYrtawOnyGzQi5hkgf7sqNGfowI/rWZ8I7pbv4Y+F3BJZNPhgfOPvxqI26f7SmtZSQwI6g8VifCkeX4bvYUULbw6vqMcGBwUF3Lj9SR+FVDcipsdnRRRWpiFFFFAHE/Gh5R8MtcitxmW5jS0UYzkyypHj/x+t6X/AFrgdAx/nWJ8UxIdJ0bb/qBrmnGfgY2faU6/8C21tHOeetZT3Nqewlch4m22fj/wPqMzKsH2q5sGJ7NPBlPzaHb/AMCFdfXFfEfUIBceHdHAP9o3mq2UtsSm5f3dyjufcqqsSPQ1JZ6eKKByKK3OYKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiimAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFIAooooAKKKKACkIBGDzS0UAeea38MrVNQl1fwVfzeF9bc7nezUG1uT/ANNrc/I3fkYPOcmqkPxE1LwvNHZ/E/ShpiFgia3YhpdPlJ6bj9+En0cY4JzivTqZNFHPC8U0aSROCrI4yGB6gg9RQAyzure9tYrmyniuLaVQ8csTh0dT0II4I9xUOr6jbaTpd3qN/KIrO0iaeaQj7qKMk/kK4C8+G1xod3LqPw01X/hH7mRi8umyqZdOuD7xZ/dn/ajx9K5bXvHg1ubTvDHja1t/D8i6pENQkeZZ7K6WLMvlJMBtVmdYspJtIVu+eU/IaR2PgDTJobfUdd1O2W21fX7gX1xBjm3TaFihP+0qAbv9tm9q6ql++ocHcG+bI755zTcVidCINRF4dOvBpZiGoGFxbGX7gm2nZu9t2M+1UfhIbM/DjQW0/wA3Y1vul84kyeeWJm3k/wAXm+Zn3zUuo65pemRXsuoX8FpFZIklxJM2xY1fO3JPBJ2nAGT+YqH4WQXEfhiW4uLaa0W/v7y/ht512yRxTTvIgZf4SVYEr2zg85qobmdTY7CiiitTIKKKKAOS+K8tnD8O9efUYnmi+zlY44yQ7TEgRBSOjeYUwexwe1W9NjvItNs49TlSa/SCNbmRBhXlCgOwHoWyar/Eyzu7vwnI2n2r3lxaXVrfC2Q4aZYbiOVkX/aKocDucCq2meKdG1drYabfJO1y0iBFBDxui7mSRT80bgA/KwB4rKe5rT2Nmue8a6Td39ja3+jBP7e0iY3un7wMSPtKvCxPRZELITxglT2roaB+VSaE/hnWrXxFoFhq9gSba7iEqhvvIT1VvRlOVI7EGtOvNdN1e38B65q1rrYe18Paldm9stQILW9vLKR5sErdIsyZdWbCneRkEYr0oGtYu6OeSswoooqhBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiikAUUUUAFFFFABRRRQAUUUUAcB8UfEhtEtvD2n3rWeo6jjzrqInfZ2xYK0igAkyMT5cYAyXOeiGqDXHhvStPufDFnocdxpcJFmLOKNJVubgjcYArf6xwvzPIxwucsc5wvxT8GavqesWviLws6HVbe0ktHia5eB2Qk4aJxlVlCtMql1IHmk5BANcz4Rh1bw9LdJa+E/FN1rUglhsl1Brb7JDCZCyZmRsJkBTJ95nYE/MSDWUua5rG1jxj4s+BfEth8U9Lg8OtDp9q6wjRoY9QVDZ5A3IgLb/wDWFz8oO7PGScV9V/a59H0e/wBR8R3VuYbZHuHNvCUEUSLkjljvbAPPAJOAMV574k8Bto914ZurtNUuUilN5qWo6RZrPdy6iGVkmlGxpGhGZcKoIX5AQR00PFhvPEnha68LaRa+IdTvr7YBe6jpz2MNuolRsyu8cYYDaflRWZunvRJt7jjZao3vA3gu1umh8WeKbCO48UXxW6P2gFxYKcGKGJTwpjXaCwG4tuOea9DoFFaJWMm7hRRRTEFFFFABXG+OvBltrEbatpNvbWviy0AmsdRVAsnmKOI5GHLRsMoytkbWPGcV2VFJq407HDafqEvinwpp+qaJeHTZbhFmAeJZlRhkPDIpwSAwZTtKtleDVbSfGuk3d8dIvry00/xHG5gl0+aQr++7CNiAJAQVYbfmKsOAeKzXTV/C8OrabfaFq9/pVxe3F3bX+hSBpgJ5nlKOm5XRlLY3JkEenIqhoPglPEOravNcaPrWl6Bqdg0F2uq3hkuLuclPLlEZZ/LaJUO12O7LDjC1lZ3sbcytc2rjxUsdz/Z/iDT7e1jx5OoxzSb0RJDtSYZG2S2c5RmOCpIDAc4g+GetrpOvXfgqdbhLeAyyaV9obMkUKlc2zZJJ2B1MbAsGjYDIKMBkeKfDXjHWbG007UNEtNR1CxysGuQ6s1osikgMzRKpZXdBtZfmTLHnHFb3w0+HMvhrVX1jVLmCS++ytY21tbBmjtLcymQRea/zy4+UBmxgDAFEVK4pOLR6TRRRWxiFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows some of the things that can go wrong in children with Down syndrome. Not all children with Down syndrome will have all of these problems.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer Health. Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_55_21365=[""].join("\n");
var outline_f20_55_21365=null;
var title_f20_55_21366="Dissection of myoma";
var content_f20_55_21366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Dissection of myoma during myomectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 452px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_55_21366=[""].join("\n");
var outline_f20_55_21366=null;
var title_f20_55_21367="Treatment of depersonalization disorder";
var content_f20_55_21367=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of depersonalization disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/55/21367/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/55/21367/contributors\">",
"     Daphne Simeon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/55/21367/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/55/21367/contributors\">",
"     David Spiegel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/55/21367/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/55/21367/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/55/21367/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2022276\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depersonalization is a persistent or recurrent feeling of detachment or estrangement from one&rsquo;s self [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/1\">",
"     1",
"    </a>",
"    ]. An individual experiencing depersonalization may report feeling like an automaton, or as if in a dream, or watching himself or herself in a movie. A depersonalized individual may report the sense of being an outside observer of his or her mental processes or body. People experiencing depersonalization often report feeling a loss of control over their thoughts, perceptions, and actions.",
"   </p>",
"   <p>",
"    Depersonalization disorder (DPD) is characterized by the persistence or recurrence of depersonalization, which causes clinically significant distress or impairment, in the presence of intact reality testing. DPD has a prevalence of approximately two percent and is associated with significant morbidity, but often goes undetected or misdiagnosed, leading to delays in treatment.",
"   </p>",
"   <p>",
"    This topic discusses treatment of DPD. The epidemiology, pathogenesis, clinical manifestations, course, and diagnosis of DPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32888?source=see_link\">",
"     \"Depersonalization disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H818987\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of all patients with depersonalization disorder (DPD) should incorporate elements of psychoeducation and supportive psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/2\">",
"     2",
"    </a>",
"    ], including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Information about nature and course of the disorder. Giving the condition a name can be a significant step for the patient.",
"     </li>",
"     <li>",
"      Reassurance about common fears &mdash; The condition will not evolve into a psychotic disorder. There is no evidence linking the disorder to permanent brain damage.",
"     </li>",
"     <li>",
"      Alleviating potential sources of guilt or shame &mdash; In the case of chronic depersonalization triggered by use of an illicit drug, it can be useful to explain to the patient that, while we do not know to a scientific certainty, we assume that the individual had an underlying diathesis to depersonalize, which could have been triggered at any point in his or her life by a variety of chemical or psychosocial stressors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32888?source=see_link&amp;anchor=H10289535#H10289535\">",
"       \"Depersonalization disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients with a drug-induced onset become &ldquo;drug phobic&rdquo; after onset and stop using the drug. The small minority who continue use should be counseled that they must stop or risk an intensification of symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Providing hope for the future &mdash; Although accurate prognostic statistics based on prospective studies are not available, it is clear that at least a portion of sufferers, whether with the assistance of treatment or spontaneously, experience improvement or remissions over time. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32888?source=see_link&amp;anchor=H692245#H692245\">",
"       \"Depersonalization disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis\", section on 'Course'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reassuring women who are considering pregnancy that the heritability, while not well studied, appears to be limited. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32888?source=see_link&amp;anchor=H10289535#H10289535\">",
"       \"Depersonalization disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Challenging the &ldquo;physicality&rdquo; of the experience &mdash; Emphasize that as physical as the symptoms may feel, the disorder is psychological. This understanding can provide the patient with a sense of control over the symptoms that may otherwise be perceived as continuous in intensity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31092064\">",
"    <span class=\"h1\">",
"     PSYCHOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several psychotherapies are used to treat depersonalization disorder, including psychodynamic, cognitive, behavioral, hypnotherapeutic, and supportive therapies. No controlled trials have been performed to assess or compare the efficacy of these interventions.",
"   </p>",
"   <p>",
"    Clinicians working with depersonalized patients may have an excessively pessimistic view of the treatment responsiveness of depersonalization disorder (DPD), because they often have an opportunity to intervene only years after onset [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], at which point the symptoms tend to have become more constant and possibly more treatment resistant. Anecdotal evidence suggests that patients are more likely to respond to treatment if it is begun earlier in the course of the disorder or if the disorder has an episodic or fluctuating course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H818816\">",
"    <span class=\"h2\">",
"     Psychodynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychodynamic psychotherapy for DPD focuses on underlying threats to self-constancy that give rise to affectively intolerable states.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H819758\">",
"    <span class=\"h3\">",
"     Conceptual model",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to psychoanalytic theories, a person in whom the cohesiveness or stability of self-representations is profoundly threatened may resort to depersonalization, ie, a disconnection from the self, as a response to the overwhelming shifts in self-experience. Although such a response may be in some ways ubiquitous, hard-wired, and even adaptive in the short run, its persistence over time becomes maladaptive and pathological. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32888?source=see_link&amp;anchor=H10289556#H10289556\">",
"     \"Depersonalization disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis\", section on 'Psychodynamic model'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Psychodynamic theories similarly suggest that depersonalization can be linked to various levels of character pathology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In psychotic-spectrum character pathology, depersonalization may be triggered by experiences of impaired self and other differentiation.",
"     </li>",
"     <li>",
"      In borderline psychopathology, unstable and switching self representations may be associated with depersonalization experiences.",
"     </li>",
"     <li>",
"      In narcissistic pathology, when self-constancy is threatened by the loss, real or imagined, of self-objects serving purposes of object constancy, depersonalization may arise.",
"     </li>",
"     <li>",
"      In psychopathology related to mood (anxiety, depression) or cognition (obsessions or compulsions) derepressed self-representations associated with overwhelming intrapsychic conflict and associated affect may trigger depersonalization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H819817\">",
"    <span class=\"h3\">",
"     Intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;In psychodynamic psychotherapy, the therapist has the opportunity to observe and analyze, often in a microprocess, moment-to-moment fashion, such dynamics as they occur inside the session or as they are described by the patient. This microanalysis of depersonalization symptoms as they wax and wane during psychotherapy sessions can be most effectively utilized with an affect-phobia psychodynamic model in mind. This model implies that the hypoemotionality, emotional numbness, and alexithymia (inability to describe feelings of individuals with the disorder) stems from a need to &ldquo;dissociate&rdquo; unbearable affects and their accompanied cognitions, relational structures, and historical origins.",
"   </p>",
"   <p>",
"    The goal of an affect-based therapy, such as psychodynamic psychotherapy, is to uncover, experience, label, own, and verbalize intolerable emotions, and to process such emotions in the context of underlying conflicts and disavowed self-representations and self-states (ie, poorly integrated components of identity). Eventually, such emotions can be gradually integrated with the core sense of self, so that the individual can transition from an &ldquo;unreal&rdquo; self to a more &ldquo;real&rdquo; owned self.",
"   </p>",
"   <p>",
"    The affects needing to be dealt with can vary greatly depending on each person&rsquo;s history and sense of self, ranging from the negative to the positive, and can include anger, grief, sorrow, shame, guilt, excitement, and love. In a simple sense, this approach counters the defensive aspect of the depersonalization by mobilizing affect rather than detaching from it. This is consistent with exposure-based and cognitive restructuring treatments for trauma-related conditions such as posttraumatic stress disorder or dissociative identity disorder, as the goal in therapy of DPD is to activate and experience rather than to better temper and regulate intense affects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32888?source=see_link&amp;anchor=H10289563#H10289563\">",
"     \"Depersonalization disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=see_link\">",
"     \"Psychotherapy for posttraumatic stress disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=see_link&amp;anchor=H1118664160#H1118664160\">",
"     \"Psychotherapy for posttraumatic stress disorder\", section on 'Cognitive and behavioral therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At times when patients visibly experience, or report, an acute heightening of their depersonalization outside of or inside the treatment, a microanalysis in undertaken in order to determine what the intolerable affect is that is being defended against (eg, anxiety, shame, rage, guilt, excitement, hope) and the external and internal contexts (cognitions, dynamics, threats to attachment) that acutely activated the peaking of symptoms. Conversely, when a patient reports moments of lessened depersonalization, in or out of session, the circumstances that facilitated the containment and awareness of difficult affects are explored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H819824\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No clinical trials have been conducted on psychodynamic psychotherapy for DPD. In our clinical experience, psychodynamic psychotherapy can be very helpful, especially in patients who have fluctuating symptoms, affect intolerance, and are more psychologically minded. A case report describes such an approach [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/6\">",
"     6",
"    </a>",
"    ]. The continuation and frequency of psychotherapy should be reassessed at the conclusion of each course of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H819831\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our experience, psychodynamic psychotherapy needs to be conducted at a minimum of once weekly, and often more frequently, to facilitate breaking of the dissociation and working with the underlying affects and dynamics. Results may be seen within weeks or months, or may require a more prolonged treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H818879\">",
"    <span class=\"h2\">",
"     Cognitive behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cognitive behavioral therapy has been developed to treat DPD, based on a cognitive-behavioral model of the disorder, which is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32888?source=see_link&amp;anchor=H10289549#H10289549\">",
"     \"Depersonalization disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis\", section on 'Cognitive behavioral model'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H819317\">",
"    <span class=\"h3\">",
"     Intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cognitive behavioral therapy (CBT) for DPD, the focus is on developing techniques to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cognitively re-interpret symptoms as less threatening",
"     </li>",
"     <li>",
"      Reduce symptom monitoring",
"     </li>",
"     <li>",
"      Diminish avoidance and safety behaviors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, consider a patient with DPD who is constantly preoccupied with existential ruminations; has checking rituals to determine whether the symptoms are still present; believes that they have suffered irreversible brain damage; and avoids many activities, such as leaving home, socializing, or being in overstimulating environments out of the fear that these will worsen the symptoms.",
"   </p>",
"   <p>",
"    Using thought-blocking and distraction techniques, the patient can be helped to ruminate less and resist checking rituals using a distracting task. Cognitive corrections can be used to counter catastrophic cognitions, such as the one involving irreversible brain damage. A hierarchical exposure approach can be used to help the patient gradually confront, rather than avoid, situations that worsen the symptoms. If anxiety is exacerbating the symptoms, cognitive and",
"    <span class=\"nowrap\">",
"     relaxation/breathing",
"    </span>",
"    retraining, and grounding techniques involving reorienting the patient to the present time and place, can be used to keep anxiety in better check, while explaining to the patient the vicious cycle of anxiety triggering more depersonalization, and depersonalization then triggering worsened anxiety.",
"   </p>",
"   <p>",
"    Eye movement desensitization and reprocessing (EMDR), a form of CBT that incorporates saccadic eye movements during exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/7\">",
"     7",
"    </a>",
"    ], has also been proposed for use in the treatment of DPD in conjunction with hypnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H819310\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited evidence suggests CBT may be effective for DPD. An uncontrolled, prospective trial tested CBT in 21 patients with chronic DPD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/9\">",
"     9",
"    </a>",
"    ]. Compared to the start of treatment, reductions were seen in depersonalization, derealization, dissociation and other psychiatric symptoms at the end of the 12-week intervention and at a follow-up assessment six months later. At the end of 12 weeks, 29 percent of participants no longer met diagnostic criteria for DPD. Seventeen of the 21 patients received medication concurrently, but only three had medication changes during the intervention period. Further research on the effectiveness of CBT for DPD is needed, including larger, randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H819774\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT is initially undertaken as a 12 to 16 session course with weekly sessions. Progress is assessed at the end of the first round of treatment, and a decision is made about whether patients should continue in once weekly CBT or can taper down to monthly booster sessions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1500170\">",
"    <span class=\"h2\">",
"     Hypnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypnosis, a state of focused concentration, may be useful in helping patients reconceptualize and control their depersonalization symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Patients are shown how to practice cognitive control over the symptoms through self-hypnosis. They learn how to modulate symptoms by making a controlled connection to emotional memories, past self-states,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interactions causing different degrees of depersonalization, including pleasant or less threatening forms of depersonalization.",
"   </p>",
"   <p>",
"    Treatment with hypnosis principally involves teaching the patient self-hypnotic strategies for modulating the symptoms, such as [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inducing physical comfort (imagining floating or other physical sensations)",
"     </li>",
"     <li>",
"      Modulating depersonalization symptoms (feeling more or less detached from one&rsquo;s body)",
"     </li>",
"     <li>",
"      Managing triggering stressors differently",
"     </li>",
"     <li>",
"      Imagining oneself in a physical setting where depersonalization rarely occurs, such as a room at home.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our clinical experience, hypnosis can be helpful, at least temporarily, in alleviating symptoms of depersonalization. There are no data from direct clinical trials on the efficacy of hypnosis in treating DPD.",
"   </p>",
"   <p>",
"    Three to five sessions are usually sufficient to determine whether or not treatment involving hypnosis is likely to help.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H819324\">",
"    <span class=\"h2\">",
"     Supportive psychotherapy for chronic DPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some severely impaired patients with DPD may require long-term supportive psychotherapy. These may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a chronic, continuous course of unrelenting intensity and minimal fluctuations, limiting the therapist&rsquo;s ability to apply psychodynamic or CBT techniques.",
"     </li>",
"     <li>",
"      Patients whose educational, occupational, or social lives have been significantly impaired by the disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In providing supportive psychotherapy for these patients, the clinician should be acutely aware of the patient&rsquo;s interpersonal sensitivity, distress, and sense of hopelessness about the condition.",
"   </p>",
"   <p>",
"    Major goals in the therapy are to maintain or improve occupational and social functioning, and to attenuate to the degree possible the severe distress often associated with the disorder by cultivating an attitude of acceptance within the context of striving for change.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31092071\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a lack of robust evidence from randomized trials on the efficacy of medication for depersonalization disorder (DPD). Benzodiazepines, serotonin reuptake inhibitors, and stimulants have been used to treat symptoms of DPD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2849636\">",
"    <span class=\"h2\">",
"     Serotonin reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective serotonergic reuptake inhibitor (SSRI) and serotonin&ndash;norepinephrine reuptake inhibitor (SNRI) antidepressants are unlikely to be of major benefit for DPD symptoms, but are postulated to reduce comorbid anxiety and depressive symptoms if prominent, which may fuel an intensification of depersonalization symptoms.",
"   </p>",
"   <p>",
"    The only randomized trial comparing an SSRI to placebo in patients with DPD did not find the SSRI to be efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/14\">",
"     14",
"    </a>",
"    ]. The trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    to placebo in 50 patients with DPD. Ratings by clinicians and patients did not find clinically significant differences in depersonalization or dissociation change scores between the fluoxetine and placebo-treated groups. No difference was seen between the two groups on ratings of depression or anxiety.",
"   </p>",
"   <p>",
"    An earlier, uncontrolled trial reported that two of seven patients with DPD showed improvement following enrollment in an eight week course of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective report of patients with DPD found [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of 60 patients with DPD treated with an SSRI, nine patients reported their symptoms had definitely improved, 14 patients reported &ldquo;slightly improved&rdquo;, and 37 reported &ldquo;stayed the same or worsened&rdquo;.",
"     </li>",
"     <li>",
"      Of nine patients with DPD treated with an SNRI, all of the patients reported that their symptoms stayed the same or worsened.",
"     </li>",
"     <li>",
"      Of three patients with DPD treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"       clomipramine",
"      </a>",
"      , all of the patients reported that their symptoms stayed the same or worsened.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our clinical experience, patients with DPD who experience improved anxiety and depression with SSRI treatment often report that although the depersonalization has not changed, they are less distressed by it and better able to ignore it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2849916\">",
"    <span class=\"h2\">",
"     Lamotrigine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     Lamotrigine",
"    </a>",
"    , a mood stabilizing anticonvulsant which promotes glutamate release, has shown mostly positive results in limited study in DPD, meriting further study.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of 80 patients with DPD found that participants treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      were more likely to respond compared to patients receiving placebo (72 versus 16 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/16\">",
"       16",
"      </a>",
"      ]. A concern about this study was the description of enrolled patients as &ldquo;without psychiatric comorbidity&rdquo;, which is unusual given the high rates of comorbidity in this population. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32888?source=see_link&amp;anchor=H2022763#H2022763\">",
"       \"Depersonalization disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis\", section on 'Comorbid conditions'",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      Two small trials from a single research group came to conflicting findings:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Four of four patients with DPD experienced a reduction in depersonalization in an uncontrolled trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      None of nine patients with DPD responded to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      in a placebo-controlled, cross-over trial [",
"      <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2849923\">",
"    <span class=\"h2\">",
"     Naltrexone",
"    </span>",
"    &nbsp;&mdash;&nbsp;An uncontrolled trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    , a non-selective opioid antagonist, in 14 patients with DPD found an average 30 percent reduction in symptoms, with four patients showing marked improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32888?source=see_link&amp;anchor=H409471#H409471\">",
"     \"Depersonalization disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis\", section on 'Neurobiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our clinical experience, patients with pronounced emotional numbing that does not respond to psychotherapy may benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    given orally starting at a dose of 50",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and gradually increased up to 250",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    if tolerated. Naltrexone is a non-selective opioid antagonist. Higher dosing may be required for kappa receptor blockade; however, this has not been studied in treatment for DPD.",
"   </p>",
"   <p>",
"    Randomized trials of opioid antagonists in DPD are warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2849966\">",
"    <span class=\"h2\">",
"     Antipsychotic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no controlled trials on the efficacy of first or second-generation antipsychotic medications in DPD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/13\">",
"     13",
"    </a>",
"    ]. In a retrospective, uncontrolled report that described 13 trials of treatment with an antipsychotic drug in patients with DPD, all 13 patients reported that they had stayed the same or worsened [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/13\">",
"     13",
"    </a>",
"    ]. In our clinical experience, patients often report feeling more dissociated and &ldquo;cloudy&rdquo; with these agents.",
"   </p>",
"   <p>",
"    Antipsychotic medications may be indicated for the treatment of DPD accompanied by psychosis. In our experience, the more sedating antipsychotics often worsen the cloudiness of depersonalization in these patients, while less sedating medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    , can reduce symptoms of anxiety and depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=see_link&amp;anchor=H72104790#H72104790\">",
"     \"Pharmacotherapy for generalized anxiety disorder\", section on 'Antipsychotic medications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31993?source=see_link\">",
"     \"Unipolar depression in adults: Treatment with second-generation antipsychotics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2849930\">",
"    <span class=\"h2\">",
"     Stimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stimulants and related medications (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"     atomoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    ) are used to treat symptoms of DPD; however, there are no randomized trials supporting their use.",
"   </p>",
"   <p>",
"    A retrospective report that described medication trials in patients with DPD found [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of nine cases treated with stimulants, no patients reported that their symptoms had definitely improved; two patients reported their symptoms had slightly improved, and seven patients reported that their symptoms stayed the same or worsened.",
"     </li>",
"     <li>",
"      Of 11 cases treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      , 10 patients reported that their symptoms stayed the same or worsened.",
"     </li>",
"     <li>",
"      Of 15 cases treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"       buspirone",
"      </a>",
"      , all of the patients reported that their symptoms stayed the same or worsened.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H708880\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our clinical experience, benzodiazepines can reduce anxiety in patients with DPD and prominent symptoms of anxiety. There are no controlled trials of benzodiazepines in these patients. In a retrospective report of 35 patients with DPD treated with benzodiazepines, patients reported they had definitely improved in 10 cases, slightly improved in 8 cases, and stayed the same or worsened in 17 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2849519\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;An uncontrolled trial of transcranial magnetic stimulation (TMS) in patients with DPD showed promising results, warranting further study using a randomized design. TMS provided daily for three weeks was associated with decreased DPD symptoms in 6 of 12 patients studied [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/20\">",
"     20",
"    </a>",
"    ]. Five of the six patients received three additional weeks of treatment, experiencing a 68 percent reduction in DPD symptoms from baseline. TMS targeted the right inferior parietal lobule.",
"   </p>",
"   <p>",
"    There are no controlled trials of electroconvulsive therapy (ECT) in DPD patients. In the retrospective report of three patients with DPD treated with ECT, all three reported that they stayed the same or worsened [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21367/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trials have not been conducted of NMDA (N-Methyl-D-aspartate)",
"    <span class=\"nowrap\">",
"     agonists/antagonists",
"    </span>",
"    or cannabinoid antagonists, but would be of interest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32888?source=see_link&amp;anchor=H409471#H409471\">",
"     \"Depersonalization disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis\", section on 'Neurobiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H819610\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest first-line treatment for depersonalization disorder with psychotherapy over other interventions (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The intervention should always include education about the disorder and components of supportive psychotherapy such as reassurance and maintaining hope for the future. Psychotherapy for DPD should be provided weekly for a minimum of three months. (See",
"      <a class=\"local\" href=\"#H818987\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest cognitive-behavioral therapy over other psychotherapies for most patients with DPD (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H818879\">",
"       'Cognitive behavioral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with DPD in whom the fluctuation of symptoms is linked to affect intolerance, we suggest psychodynamic psychotherapy focused on affect processing to treat the disorder rather than CBT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H818816\">",
"       'Psychodynamic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with DPD and significant comorbid depression or anxiety, CBT should target both conditions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the response of depressive symptoms is inadequate, we suggest the addition of an SSRI (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). As an example,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      can be used at an initial therapeutic dose of 20",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link\">",
"       \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the response of anxiety is inadequate, we suggest the addition of a benzodiazepine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). &nbsp;As an example,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      can be used, starting at an initial dose of 0.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      two or three times daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with pronounced emotional numbing that does not respond to psychotherapy, we suggest the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Naltrexone is given orally starting at a dose of",
"      <span class=\"nowrap\">",
"       50mg/day,",
"      </span>",
"      and gradually increased up to",
"      <span class=\"nowrap\">",
"       250mg/day",
"      </span>",
"      if tolerated.",
"     </li>",
"     <li>",
"      In patients with severe, treatment refractory DPD, we recommend supportive psychotherapy that addresses occupational and social functioning, and alleviating to the degree possible the severe distress often associated with the disorder. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) (See",
"      <a class=\"local\" href=\"#H819324\">",
"       'Supportive psychotherapy for chronic DPD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), Fourth edition, Text revision, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     Simeon D, Abugel J. Feeling Unreal: Depersonalization Disorder and the Loss of the Self, Oxford University Press, New York 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21367/abstract/3\">",
"      Phillips ML, Medford N, Senior C, et al. Depersonalization disorder: thinking without feeling. Psychiatry Res 2001; 108:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21367/abstract/4\">",
"      Lanius RA, Vermetten E, Loewenstein RJ, et al. Emotion modulation in PTSD: Clinical and neurobiological evidence for a dissociative subtype. Am J Psychiatry 2010; 167:640.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Treatment of Posttraumatic Stress Disorder:  An assessment of the evidence, The National Academies Press, Washington, DC 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21367/abstract/6\">",
"      Guralnik O, Simeon D. Depersonalization: Standing in the Spaces Between Recognition and Interpellation. Psychoanal Dialogues 2010; 20:400.",
"     </a>",
"    </li>",
"    <li>",
"     Shapiro F. Eye Movement Desensitization and Reprocessing: Basic Protocols, Principles, Guilford, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21367/abstract/8\">",
"      Harriet EH. ECEM (Eye Closure, Eye Movements): application to depersonalization disorder. Am J Clin Hypn 2009; 52:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21367/abstract/9\">",
"      Hunter EC, Baker D, Phillips ML, et al. Cognitive-behaviour therapy for depersonalisation disorder: an open study. Behav Res Ther 2005; 43:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21367/abstract/10\">",
"      Van Dyck R, Spinhoven P. Depersonalization and derealization during panic and hypnosis in low and highly hypnotizable agoraphobics. Int J Clin Exp Hypn 1997; 45:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21367/abstract/11\">",
"      Spiegel D, Carde&ntilde;a E. Disintegrated experience: the dissociative disorders revisited. J Abnorm Psychol 1991; 100:366.",
"     </a>",
"    </li>",
"    <li>",
"     Spiegel H, Spiegel D. Trance and Treatment: Clinical Uses of Hypnosis, American Psychicatric Publishing, Washington, DC 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21367/abstract/13\">",
"      Simeon D, Knutelska M, Nelson D, Guralnik O. Feeling unreal: a depersonalization disorder update of 117 cases. J Clin Psychiatry 2003; 64:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21367/abstract/14\">",
"      Simeon D, Guralnik O, Schmeidler J, Knutelska M. Fluoxetine therapy in depersonalisation disorder: randomised controlled trial. Br J Psychiatry 2004; 185:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21367/abstract/15\">",
"      Simeon D, Stein DJ, Hollander E. Treatment of depersonalization disorder with clomipramine. Biol Psychiatry 1998; 44:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21367/abstract/16\">",
"      Aliyev NA, Aliyev ZN. Lamotrigine in the immediate treatment of outpatients with depersonalization disorder without psychiatric comorbidity: randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2011; 31:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21367/abstract/17\">",
"      Sierra M, Phillips ML, Lambert MV, et al. Lamotrigine in the treatment of depersonalization disorder. J Clin Psychiatry 2001; 62:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21367/abstract/18\">",
"      Sierra M, Phillips ML, Ivin G, et al. A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder. J Psychopharmacol 2003; 17:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21367/abstract/19\">",
"      Simeon D, Knutelska M. An open trial of naltrexone in the treatment of depersonalization disorder. J Clin Psychopharmacol 2005; 25:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21367/abstract/20\">",
"      Mantovani A, Simeon D, Urban N, et al. Temporo-parietal junction stimulation in the treatment of depersonalization disorder. Psychiatry Res 2011; 186:138.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14695 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-C38B34FA94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_55_21367=[""].join("\n");
var outline_f20_55_21367=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H819610\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2022276\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H818987\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31092064\">",
"      PSYCHOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H818816\">",
"      Psychodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H819758\">",
"      - Conceptual model",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H819817\">",
"      - Intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H819824\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H819831\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H818879\">",
"      Cognitive behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H819317\">",
"      - Intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H819310\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H819774\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1500170\">",
"      Hypnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H819324\">",
"      Supportive psychotherapy for chronic DPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31092071\">",
"      PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2849636\">",
"      Serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2849916\">",
"      Lamotrigine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2849923\">",
"      Naltrexone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2849966\">",
"      Antipsychotic medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2849930\">",
"      Stimulants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H708880\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2849519\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H819610\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32888?source=related_link\">",
"      Depersonalization disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=related_link\">",
"      Pharmacotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=related_link\">",
"      Psychotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31993?source=related_link\">",
"      Unipolar depression in adults: Treatment with second-generation antipsychotics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_55_21368="Chapter 2E: Clinical evaluation of the renal circulation";
var content_f20_55_21368=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 2E: Clinical evaluation of the renal circulation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/55/21368/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/55/21368/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/55/21368/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/55/21368/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/55/21368/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/55/21368/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/55/21368/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/55/21368/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2001.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CONCEPT OF CLEARANCE AND MEASUREMENT OF GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimation of the GFR is an essential part of the evaluation of patients with renal disease. Since the total kidney GFR is equal to the sum of the filtration rates in each of the functioning nephrons, the total GFR can be used as an index of functioning renal mass. As an example, the loss of one-half of the functioning nephrons will lead to a significant decline in the GFR (which may be only 20 to 30 percent, not 50 percent, due to compensatory hyperfiltration in the remaining nephrons). At this time, fluid and electrolyte balance may still be maintained and the urinalysis may be normal. Thus, the fall in GFR may be the earliest and only clinical sign of renal disease.",
"   </p>",
"   <p>",
"    Serial monitoring of the GFR can also be used to estimate the severity and to follow the course of kidney disease. A reduction in GFR implies either progression of the underlying disease or the development of a superimposed and potentially reversible problem, such as diminished renal perfusion due to volume depletion. An increase in GFR, on the other hand, indicates improvement or possibly hypertrophy in the remaining nephrons.",
"   </p>",
"   <p>",
"    Measurement of the GFR is also helpful in determining the proper dosage of those drugs that are excreted by the kidney by glomerular filtration. When the GFR falls, drug excretion will be reduced, resulting in an increase in plasma drug levels and potential drug toxicity. To prevent this, drug dosage must be lowered in proportion to the decrease in GFR.",
"   </p>",
"   <p>",
"    How can the GFR be measured? Consider a compound, such as the fructose polysaccharide inulin (not insulin), with the following properties:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Able to achieve a stable plasma concentration",
"     </li>",
"     <li>",
"      Freely filtered at the glomerulus",
"     </li>",
"     <li>",
"      Not reabsorbed, secreted, synthesized, or metabolized by the kidney",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this situation,",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Filtered inulin &nbsp; = &nbsp; excreted inulin",
"   </p>",
"   <p>",
"    The filtered inulin is equal to the GFR times the plasma inulin concentration (Pin), and the excreted inulin is equal to the product of the urine inulin concentration (Uin) and the urine volume (V, in milliliters per minute or liters per day). Therefore,",
"   </p>",
"   <p>",
"    (Eq. 1) &nbsp; &nbsp; &nbsp;GFR &nbsp; x &nbsp; Pin &nbsp; &nbsp;= &nbsp; Uin &nbsp; x &nbsp; V",
"   </p>",
"   <p>",
"    (Eq. 2) &nbsp; &nbsp;GFR &nbsp; = &nbsp; (Uin &nbsp; x &nbsp; V) &nbsp; &divide; &nbsp; Pin",
"   </p>",
"   <p>",
"    The term (Uin &nbsp;x V)",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    Pin is called the clearance of inulin and is an accurate estimate of the GFR. The inulin clearance, in",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    refers to that volume of plasma cleared of inulin by renal excretion. If, for example, 1 mg of inulin is excreted per minute (Uin &nbsp;x V) and the Pin is 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (or to keep the units consistent, 0.01",
"    <span class=\"nowrap\">",
"     mg/mL),",
"    </span>",
"    then the clearance of inulin is 100",
"    <span class=\"nowrap\">",
"     mL/min;",
"    </span>",
"    that is, 100 mL of plasma has been cleared of the 1 mg of inulin that it contained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     USE AND LIMITATIONS OF CREATININE CLEARANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite its accuracy, the inulin clearance is rarely performed clinically because it involves both an intravenous infusion of inulin and an assay for inulin that is not available in most laboratories. The most widely used method to estimate the GFR is the endogenous creatinine clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Creatinine is derived from the metabolism of creatine in skeletal muscle and is released into the plasma at a relatively constant rate. As a result, the plasma creatinine concentration (Pcr) is very stable, varying less than 10 percent per day in serial observations in normal subjects.",
"   </p>",
"   <p>",
"    Like inulin, creatinine is freely filtered across the glomerulus and is neither reabsorbed nor metabolized by the kidney. However, some creatinine enters the urine by tubular secretion via the organic cation secretory pump in the proximal tubule, resulting in creatinine excretion exceeding the amount filtered by 10 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15684?source=see_link\">",
"     \"Chapter 3C: Secretory pathways in proximal tubule\"",
"    </a>",
"    .) Thus, the creatinine clearance (Ccr)",
"   </p>",
"   <p>",
"    (Eq. 3) &nbsp; &nbsp;Ccr &nbsp; = &nbsp; &nbsp; (Ucr &nbsp;x &nbsp;V) &nbsp; &divide; &nbsp; Pcr",
"   </p>",
"   <p>",
"    will tend to exceed the inulin clearance by 10 to 20 percent. Fortuitously, this is balanced by an error of almost equal magnitude in the measurement of the Pcr. One method involves a colorimetric reaction after the addition of alkaline picrate. The plasma, but not the urine, contains noncreatinine chromogens (acetone, proteins, ascorbic acid, pyruvate) which account for approximately 10 to 20 percent of the normal Pcr [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/1\">",
"     1",
"    </a>",
"    ]. Since both the Ucr and Pcr are elevated to roughly the same degree, the errors tend to cancel out and the creatinine clearance is a reasonably accurate estimate of the GFR, particularly in the patient with relatively normal renal function. The normal values for the creatinine clearance are approximately 95 &plusmn; 20",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in women and 120 &plusmn; 25",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in men [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The creatinine clearance is usually determined in the following way. The plasma creatinine concentration is measured in a venous blood sample, and the Ucr &nbsp;x &nbsp;V is concomitantly measured with a 24-h urine collection, since shorter collections tend to give less reliable results. Suppose, for example, that a 30 year-old woman who weighs 60 kg is being evaluated for the possible presence of renal disease and the following results are obtained:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Pcr &nbsp; = &nbsp; 1.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp;Ucr &nbsp; = &nbsp; 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp;V &nbsp; = &nbsp; 1080",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"   </p>",
"   <p>",
"    Since",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;1080",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    &nbsp;&divide; &nbsp;1440",
"    <span class=\"nowrap\">",
"     min/day",
"    </span>",
"    &nbsp; = &nbsp; 0.75",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Ccr &nbsp; = &nbsp; (100 &nbsp;x &nbsp;0.75) &nbsp; &divide; &nbsp; 1.2 &nbsp; = &nbsp; 63",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"   </p>",
"   <p>",
"    This finding suggests that the patient has lost about one-third of her GFR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the creatinine clearance is widely used in clinical medicine, there are two major problems that limit its accuracy as an estimate of the GFR: an incomplete urine collection; and increased tubular secretion of creatinine as renal function declines. The relative constancy of creatinine production and subsequent excretion can be used to assess the completeness of the urine collection. In adults under the age of 50, daily creatinine excretion should be about 20 to 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    lean body weight in men, and 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in women. From the ages of 50 to 90, there is a progressive 50 percent reduction in creatinine excretion (to about 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in men), due primarily to a decrease in skeletal muscle mass. These relationships can be expressed by the following equations, which estimate daily creatinine excretion in",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Creatinine excretion &nbsp; = &nbsp; 28 &nbsp;- &nbsp;[age in",
"    <span class=\"nowrap\">",
"     years/6]",
"    </span>",
"    &nbsp;(in men)",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; = &nbsp; 22 &nbsp;- &nbsp;[age in",
"    <span class=\"nowrap\">",
"     years/9]",
"    </span>",
"    &nbsp;(in women)",
"   </p>",
"   <p>",
"    Creatinine excretion that is much below these expected values suggests an incomplete collection. In the above 30 year-old woman, for example, creatinine excretion is 18",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (1080 mg &nbsp;&divide; &nbsp;60 kg), indicating that a complete collection has probably been obtained (22 -",
"    <span class=\"nowrap\">",
"     [30/9]",
"    </span>",
"    &nbsp;= &nbsp;18.7).",
"   </p>",
"   <p>",
"    The second major error, enhanced creatinine secretion, begins early in the course of progressive renal disease. As the GFR falls, the initial rise in the plasma creatinine concentration enhances creatinine delivery to the proximal secretory pump. This leads to an elevation in creatinine secretion, since the pump is not yet saturated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/3\">",
"     3",
"    </a>",
"    ]. At a GFR of 40 to 80",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    for example, the absolute amount of creatinine secreted may have risen by more than 50 percent, with secretion accounting for as much as 35 percent of urinary creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/3\">",
"     3",
"    </a>",
"    ]. As a result, the Ucr x V &nbsp;is much higher than it would be if creatinine were excreted only by glomerular filtration, resulting in a potentially marked overestimation of the true GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect is that the creatinine clearance may be normal (&gt;90",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    in about one-half of patients with a true GFR (as measured by inulin clearance) of 61 to 70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and one-quarter of those with a GFR of 51 to 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/4\">",
"     4",
"    </a>",
"    ]. This difference may be become proportionately more prominent in patients with more advanced renal disease in whom the creatinine clearance that can, in some cases, exceed the GFR by more than two-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the creatinine clearance is not a predictably accurate measure of the GFR; all that can be concluded is that the creatinine clearance (calculated from a complete urine collection) represents an upper limit of what the true GFR may be. Furthermore, the degree of creatinine secretion appears to vary with time, changing the creatinine clearance independent of alterations in the GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/2,6,7\">",
"     2,6,7",
"    </a>",
"    ]. In some cases, the change in creatinine clearance is discordant from that of the GFR. As an example, the degree of creatinine secretion may fall (via an unknown mechanism) at a time when the GFR is actually increasing in treated patients with lupus nephritis; this improvement, however, may be masked by no change or even a reduction in the creatinine clearance if the decrease in secretion is proportionately greater than the increase in creatinine filtration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only way to determine the GFR accurately is to measure the clearance of inulin or a radiolabeled compound such as iothalamate or DTPA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Unfortunately, determination of the inulin or iothalamate clearance is not routinely available. There are, however, two alternatives that may provide a more accurate estimate of the GFR: averaging the creatinine and urea clearances (see below); and measurement of the creatinine clearance during the administration of the H2-blocker",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    , which is another organic cation that competitively inhibits creatinine secretion.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     Cimetidine",
"    </a>",
"    must be given in relatively high dose to predictably inhibit creatinine secretion in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. As an example, one regimen used a single oral dose of 1200 mg plus a water load with urine collected between three and six hours for both creatinine and inulin clearance. The ratio of the creatinine to inulin clearance at baseline was about 1.5 (range 1.14 to 2.27), indicating substantial creatinine secretion. The ratio fell to 1.02 in eight patients, but remained elevated (1.33) in the remaining patients who had more efficient urinary cimetidine excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to appreciate, however, that exact knowledge of the GFR is not usually required, particularly with the ability to measure plasma levels of many of those potentially toxic drugs that are normally excreted by the kidney (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    or an aminoglycoside antibiotic). What is important to know is whether the GFR is changing (which can usually be determined from the plasma creatinine concentration alone) and whether the GFR is reduced in a patient with kidney disease who has a normal or high-normal plasma creatinine concentration (see below).",
"   </p>",
"   <p>",
"    In addition to the potential errors involved in the use of the creatinine clearance, there is an additional problem in that progressive disease is not always associated with a significant reduction in GFR even if the latter is accurately measured. As noted above, nephron loss is generally associated with compensatory hypertrophy and hyperfiltration in the remaining normal or less affected nephrons. Thus, in a disease such as lupus nephritis, progressive glomerular scarring can occur during the healing phase with little reduction in the total GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. In this setting, the patient must also be monitored for other signs of disease progression, such as an increase in protein excretion or in the systemic blood pressure.",
"   </p>",
"   <p>",
"    The remainder of this chapter is presented separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PLASMA CREATININE AND GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in the GFR (rather than an exact measurement of the GFR) can generally be ascertained from measurement of the Pcr, a routine laboratory test. &nbsp;In a subject in the steady state,",
"   </p>",
"   <p>",
"    &nbsp;(Eq. 4) &nbsp; &nbsp;Creatinine excretion &nbsp; = &nbsp; creatinine production",
"   </p>",
"   <p>",
"    Creatinine excretion is roughly equal to the amount of creatinine filtered (GFR &nbsp;x &nbsp;Pcr) whereas the rate of creatinine production is relatively constant. If these substitutions are made in Eq. (4), then,",
"   </p>",
"   <p>",
"    (Eq. 5) &nbsp; &nbsp; &nbsp;GFR &nbsp;x &nbsp;Pcr &nbsp; = &nbsp; constant",
"   </p>",
"   <p>",
"    Thus, the plasma creatinine concentration varies inversely with the GFR. If, for example, the GFR falls by 50 percent, creatinine excretion also will be reduced. As a result, newly produced creatinine will accumulate in the plasma until the filtered load again equals the rate of production. Excluding changes in tubular secretion, this will occur when the Pcr has doubled,",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     GFR/2",
"    </span>",
"    &nbsp;x &nbsp;2Pcr &nbsp; = &nbsp; &nbsp; GFR &nbsp;x &nbsp;Pcr &nbsp; = &nbsp; constant",
"   </p>",
"   <p>",
"    In adults, the range for the normal Pcr is 0.8 to 1.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in men and 0.6 to 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Creatinine production and the Pcr can be influenced by changes in diet. Creatinine production is determined by the total body creatine content, which itself is determined by the amount of creatine synthesized from amino acids and directly ingested in meat. As an example, creatine production can be enhanced by a high-protein or high-meat diet; this change, however, must persist over a period of weeks to months before creatinine production (and therefore the Pcr) is significantly enhanced, since only 1 to 2 percent of the extra creatine is converted to creatinine per day [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/12\">",
"     12",
"    </a>",
"    ]. Furthermore, the increase in the Pcr may be less than the increment in production because a high-protein diet also tends to raise the GFR and therefore the rate of creatinine excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. On the other hand, switching to a meat-free diet can lower the Pcr by as much as 15 percent without any change in the true GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more acute effect may be seen with the ingestion of cooked meat, since heating promotes the conversion of creatine to creatinine. As an example, eating a 4 oz hamburger can raise creatinine excretion by as much as 350 to 450 mg (a 20 to 30 percent increase) and can acutely elevate the Pcr by as much as 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. Thus, the Pcr should optimally be measured when the patient is fasting.",
"   </p>",
"   <p>",
"    There are three important points to note about the idealized reciprocal relationship between the GFR and the Pcr. First, this curve is valid only in the steady state when the Pcr is stable. If, for example, a patient develops acute renal failure with a sudden drop in the GFR from 120 to 12",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    the Pcr on day 1 will still be normal since there will not have been time for creatinine to accumulate in the plasma. After 7 to 10 days, the Pcr will stabilize roughly at 10",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    a level consistent with the reduced GFR.",
"   </p>",
"   <p>",
"    The steady state can be disturbed by changes in creatinine production as well as urinary excretion. Thus, a malnourished patient with reduced creatinine production may have a stable Pcr despite a fall in GFR.",
"   </p>",
"   <p>",
"    Second, it is important to appreciate the shape of the curve. In a patient with normal renal function, an apparently minor increase in the Pcr from 1.0 to 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    can represent a marked fall in the GFR from 120 to 80",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    In contrast, in a patient with advanced renal failure, a marked increase in the Pcr from 6.0 to 12.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    reflects a relatively small reduction in the GFR from 20 to 10",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Thus, the initial elevation in the Pcr represents the major loss in GFR. Furthermore, progressive reductions in GFR in patients with advanced disease are more easy to detect by measurement of the Pcr (which may show a large increase) than by measurement of the GFR (which may only fall by a few",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    a change that may be less than the sensitivity of the assay) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Third, the relationship between the GFR and the Pcr is dependent upon the rate of creatinine production, which is largely a function of muscle mass and meat and protein intake. As an example, a normal GFR of 120",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    is associated with a Pcr of 1.0",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Although this may be true for a 70-kg man, a similar GFR in a 50-kg woman might be associated with a Pcr of only 0.6",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    In this setting, a Pcr of 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    is not normal and reflects a 40 percent fall in GFR.",
"   </p>",
"   <p>",
"    To account for the effects of body weight, age, and sex on muscle mass, the following formula has been derived to estimate the creatinine clearance (in",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    from the Pcr in the steady state in adult men [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    (Eq. 6) &nbsp; &nbsp;Ccr &nbsp; = &nbsp; [(140 &nbsp;- &nbsp;age) &nbsp;x &nbsp;lean body weight (in kg)] &nbsp; &divide; &nbsp; (Pcr &nbsp; x &nbsp; 72)",
"   </p>",
"   <p>",
"    This value should be multiplied by 0.85 in women, since a lower fraction of the body weight is composed of muscle.",
"   </p>",
"   <p>",
"    The results obtained with this formula appear to correlate fairly well with a simultaneously measured creatinine clearance. Its usefulness can be illustrated by the observation that a Pcr of 1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    represents a creatinine clearance of 101",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in an 85-kg, 20-year-old man,",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Ccr &nbsp; = &nbsp; [(140 &nbsp;- &nbsp;20) &nbsp;x &nbsp;85] &nbsp; &divide; &nbsp; (1.4 &nbsp; x &nbsp; 72)",
"   </p>",
"   <p>",
"    but only a creatinine clearance of 20",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in a 40-kg, 80-year-old woman,",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Ccr &nbsp; = &nbsp; [(140 &nbsp;- &nbsp;80) &nbsp;x &nbsp;40 &nbsp;x &nbsp;0.85] &nbsp; &divide; &nbsp; (1.4 &nbsp; x &nbsp; 72)",
"   </p>",
"   <p>",
"    The latter example calls attention to the danger of overdosing elderly patients who have seriously impaired renal function despite a relatively normal Pcr. The use of this simple formula can help to avoid this problem but should not replace monitoring of plasma drugs levels when potentially toxic agents are given.",
"   </p>",
"   <p>",
"    A similar decline in creatinine production can occur in malnourished patients, such as those with cirrhosis. In addition to the loss of muscle mass, decreased meat intake and perhaps decreased hepatic production of creatine, the precursor of creatinine, can also play a contributory role. The net effect is that some cirrhotic patients with an apparently \"normal\" Pcr of 1 to 1.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    have a GFR (as measured by inulin clearance) that can range from as low as 20 to 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    to a clearly normal value above 100",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The low protein intake and decreased production of urea (due to the hepatic disease) also limit the rise in BUN that should occur as the GFR falls.",
"   </p>",
"   <p>",
"    Thus, the presence of substantial renal dysfunction may be masked in cirrhotic patients if only the BUN and Pcr are measured. Calculation of the creatinine clearance will partially overcome this problem, since the reduction in creatinine production will be accounted for by a decline in creatinine excretion. However, because of increased creatinine secretion, the clearance value obtained may overestimate the true GFR by as much as 40 percent or more in patients with renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, the Pcr tends to vary inversely with the GFR in the steady state. Because of this relationship, serial measurements of the Pcr are typically used to monitor patients with kidney dysfunction. A rise in Pcr indicates disease progression whereas a fall in Pcr suggests recovery of renal function (if muscle mass and meat intake are relatively constant). It is also presumed that a stable Pcr means stable disease, although this may not be an accurate assumption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is now clear that significant disease progression can occur with little or no change in the Pcr in patients with a normal or near-normal GFR (&gt; 60",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    Three factors can contribute to this problem, two of which prevent or minimize any fall in true GFR and one of which (increased creatinine secretion) can limit the rise in Pcr when the GFR does fall:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loss of nephrons leads to compensatory hyperfiltration in the remaining more normal nephrons, thereby maintaining the total GFR despite continued disease activity [",
"      <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/20\">",
"       20",
"      </a>",
"      ]. As described above in lupus nephritis, for example, progressive glomerular scarring may be associated with no detectable change in glomerular filtration due to hypertrophy in normal or less affected glomeruli [",
"      <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Glomerular diseases damage the glomerular basement membrane, tending to lower the GFR by diminishing the effective surface area available for filtration. This effect, however, is counteracted by a rise in glomerular capillary pressure (Pgc) that tends to maintain the GFR despite progressive glomerular injury [",
"      <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/21\">",
"       21",
"      </a>",
"      ]. The mechanism by which this occurs is not well understood; an initial reduction in GFR due to the fall in surface area could lead to diminished macula densa flow and activation of TGF, which could then raise the GFR back to the baseline level.",
"     </li>",
"     <li>",
"      When the GFR does begin to fall, the rise in the Pcr is lessened or prevented by an increase in tubular secretion as described previously [",
"      <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/3\">",
"       3",
"      </a>",
"      ]. The potential result of this adaptation is illustrated in figure 2 (",
"      <a class=\"graphic graphic_figure graphicRef74963 \" href=\"UTD.htm?25/11/25790\">",
"       figure 1",
"      </a>",
"      ). Although a fall in GFR from 120 to 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      should ideally induce a doubling of the Pcr, many patients have only a small increase in the Pcr (of as little as 0.1 to 0.2",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      because of enhanced tubular secretion. With more advanced disease (Pcr &gt;1.5 to 2",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      the Pcr rises as expected, presumably due to saturation of the secretory mechanism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major clinical implication of these findings is that, in a patient with known renal disease, a Pcr that is stable at a level under 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    does not necessarily reflect stable disease. As a result, it is important to look for other signs of disease progression, such as increased proteinuria, a more active urine sediment, or an elevation in the systemic blood pressure. In addition, variations in the degree of creatinine secretion can cause the Pcr to vary independent of the GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Thus, an increase in GFR may not lead to a reduction in the Pcr if it is associated with a proportionate decline in creatinine secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less commonly, an error arises due to an elevation in the measured Pcr without any change in the GFR (or BUN). This is most often due to a large meat meal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/15\">",
"     15",
"    </a>",
"    ], ketoacidosis (in which acetoacetate can raise the Pcr by 0.5 to 2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or more because it is measured as a noncreatinine chromogen) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/22\">",
"     22",
"    </a>",
"    ], or the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    or the antimicrobial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    (which is most often given in combination with sulfamethoxazole), both of which competitively inhibit creatinine secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/10,23,24\">",
"     10,23,24",
"    </a>",
"    ]. In the last setting, the Pcr may increase by as much as 0.4 to 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/24\">",
"     24",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     Ranitidine",
"    </a>",
"    , another commonly used H2-blocker, has a less prominent effect on creatinine handling than cimetidine because it is given in much lower doses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the variability in creatinine secretion and production, other endogenous markers, such as cystatin C, have been evaluated for the estimation of GFR. Cystatin C is a low molecular weight protein that is a member of the cystatin superfamily of cysteine protease inhibitors. It is produced by all nucleated cells and its rate of production is relatively constant, being unaltered by inflammatory conditions or changes in diet. Studies suggest that the plasma cystatin C concentration correlates more closely with the GFR than the plasma creatinine concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. A well-designed report compared the sensitivity of the serum creatinine and cystatin C concentrations to indicate mild degrees of renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/25\">",
"     25",
"    </a>",
"    ]. Using the clearance of radioactive iothalamate as the gold standard, serum cystatin C levels began increasing when the GFR was 88",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, while the serum creatinine concentration only increased when the GFR was 75",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2. Whether measurement of cystatin C levels will become available clinically is at present unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BLOOD UREA NITROGEN AND GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in the GFR also can be detected by changes in the concentration of urea in the blood, measured as the blood urea nitrogen (BUN). Like creatinine, urea is excreted primarily by glomerular filtration and the BUN tends to vary inversely with the GFR.",
"   </p>",
"   <p>",
"    However, two factors can alter the BUN without change in the GFR or Pcr: changes in urea production or tubular urea reabsorption. Urea is formed by the hepatic metabolism of amino acids that are not utilized for protein synthesis. As amino acids are deaminated, ammonia is produced. The development of toxic levels of ammonia in the blood is prevented by the conversion of ammonia (NH3) into urea in a reaction that can be summarized by the following equation:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;2 NH3 &nbsp;+ &nbsp;CO2 &nbsp; &lt;&mdash;&gt; &nbsp;H2N &mdash; CO &mdash; NH2 &nbsp;+ &nbsp;H2O",
"   </p>",
"   <p>",
"    Thus, urea production and the BUN are increased when more amino acids are metabolized in the liver. This may occur with a high-protein diet, enhanced tissue breakdown (due to trauma, gastrointestinal bleeding, or the administration of corticosteroids), or decreased tissue anabolism (due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/27\">",
"     27",
"    </a>",
"    ]. On the other hand, urea production and the BUN are reduced by severe liver disease or a low-protein intake.",
"   </p>",
"   <p>",
"    The second factor is that urea excretion is not determined solely by glomerular filtration. Approximately 40 to 50 percent of the filtered urea is normally reabsorbed by the tubules. This process is passive, being driven by the rise in tubular fluid urea concentration that results from the reabsorption of sodium and water. Thus, urea transport is enhanced in hypovolemic states due to the increase in sodium reabsorption. The net result is reduced urea excretion and an elevation in the BUN that is not due to a fall in GFR and therefore is not associated with a rise in the Pcr [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/27\">",
"     27",
"    </a>",
"    ]. Under most conditions, the ratio of the BUN to the Pcr is 10 to 15:1. When this ratio exceeds 20:1, one of the conditions associated with enhanced urea production or effective circulating volume depletion should be suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, a reduction in the GFR results in elevation in both the BUN and Pcr. Because of the variability in urea production and reabsorption, the Pcr is a more reliable reflection of the GFR. For similar reasons, the urea clearance is not an accurate estimate of the GFR. Since urea is reabsorbed and the degree of reabsorption is variable, the quantity of urea excreted is much less than the amount filtered. As a result, the urea clearance is only 50 to 70 percent that of inulin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overestimation of the GFR with the creatinine clearance and the underestimation with the urea clearance has led to the suggestion that the average of these two values should be used:",
"   </p>",
"   <p>",
"    (Eq. 7) &nbsp; &nbsp;GFR &nbsp; = &nbsp; (Ccr &nbsp;+ &nbsp;Curea) &nbsp; &divide; &nbsp; 2",
"   </p>",
"   <p>",
"    This equation may be most accurate in patients with moderate to advanced renal disease (Pcr &gt; 2.5",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimation of the GFR remains an important method of monitoring patients with renal disease. There is, however, no easily available way to do this accurately. The increase in tubular secretion of creatinine as the GFR begins to fall seriously limits the validity &nbsp;of the creatinine clearance. Since this test can overestimate the GFR by two-fold or more in patients with moderate to advanced renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/5\">",
"     5",
"    </a>",
"    ], it is best used as an upper limit of what the true GFR may be. The Pcr, on the other hand, is helpful in following the course of the disease, since the Pcr tends to vary inversely with the GFR (as long as muscle mass and meat intake are relatively constant). However, enhanced creatinine secretion can minimize any rise in the Pcr as the GFR falls from the normal level of 120",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    down to 60 to 80",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    Thus,",
"    a stable Pcr that is below 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    does not necessarily mean that the renal disease is stable. In this setting, increases in systemic blood pressure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the activity of the urinalysis may be the only clues to progressive disease (unless an inulin or iothalamate clearance can be measured) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/6\">",
"     6",
"    </a>",
"    ]. Once the Pcr is above 1.5 to 2",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    however, tubular secretion is saturated and a stable Pcr makes it unlikely that progressive renal damage is occurring.",
"   </p>",
"   <p>",
"    Variability in the production and tubular reabsorption of urea makes the BUN a less useful reflection of the GFR than the Pcr. The main clinical use of the BUN is in the calculation of the BUN to Pcr ratio, which, if elevated, suggests that diminished renal perfusion contributes to the renal disease (assuming that one of the causes of increased urea production is not present) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CHANGE IN GFR WITH AGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between age and decreasing GFR, via several hypothetical but unproven mechanisms, has been suggested by several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/30\">",
"     30",
"    </a>",
"    ]. In the Baltimore Longitudinal study, for example, the mean rate of decline in creatinine clearance was found to be 0.75",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per year [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/31\">",
"     31",
"    </a>",
"    ]. However, this and others studies may be flawed due to their reliance upon endogenous creatinine clearance measurements and the presence of possible confounding conditions.",
"   </p>",
"   <p>",
"    In an effort to obtain a more reliable correlation between GFR and age, another study which examined the GFR as measured via inulin clearance found that a majority of elderly patients with normal cardiac function had measured clearances within the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/32\">",
"     32",
"    </a>",
"    ]. Thus, although the elderly appear to have lower clearance rates, comorbid conditions may significantly affect measurements of renal function among such patients and increased age is not invariably associated with a decreased GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21368/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF RENAL PLASMA FLOW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of clearance have also been used to measure the RPF in experimental conditions; this test has little clinical utility. Paraaminohippurate (PAH) is an easily measured indicator that enters the urine by glomerular filtration and by the organic anion secretory pathway in the proximal tubule. The combination of filtration and secretion results in the almost complete removal of PAH from the plasma in a single pass through the kidney. Therefore,",
"   </p>",
"   <p>",
"    &nbsp; (Eq. 8) &nbsp; &nbsp;PAH delivery to kidney &nbsp; = &nbsp; PAH excretion",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;RPF &nbsp;x &nbsp;PPAH &nbsp; = &nbsp; UPAH &nbsp;x &nbsp; V",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;RPF &nbsp; = &nbsp; (UPAH &nbsp;x &nbsp;V) &nbsp; &divide; &nbsp; PPAH &nbsp; = &nbsp; CPAH",
"   </p>",
"   <p>",
"    If the hematocrit (Hct) is known, then the renal blood flow (RBF) can be calculated from,",
"   </p>",
"   <p>",
"    &nbsp; (Eq. 9) &nbsp; &nbsp;RBF &nbsp; = &nbsp; CPAH &nbsp; &divide; &nbsp; (1 &nbsp; - &nbsp; Hct)",
"   </p>",
"   <p>",
"    The normal RPF and RBF in humans are roughly 625",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and 1100",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    respectively. Since only 85 to 90 percent of the PAH actually is removed from the circulation in a single pass, the PAH clearance will underestimate both RPF and RBF by 10 to 15 percent.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24617?source=see_link\">",
"     \"Chapter 3A: Cell model for proximal transport\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/1\">",
"      DOOLAN PD, ALPEN EL, THEIL GB. A clinical appraisal of the plasma concentration and endogenous clearance of creatinine. Am J Med 1962; 32:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/2\">",
"      Levey AS. Measurement of renal function in chronic renal disease. Kidney Int 1990; 38:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/3\">",
"      Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/4\">",
"      Kim KE, Onesti G, Ramirez O, et al. Creatinine clearance in renal disease. A reappraisal. Br Med J 1969; 4:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/5\">",
"      Bauer JH, Brooks CS, Burch RN. Clinical appraisal of creatinine clearance as a measurement of glomerular filtration rate. Am J Kidney Dis 1982; 2:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/6\">",
"      Petri M, Bockenstedt L, Colman J, et al. Serial assessment of glomerular filtration rate in lupus nephropathy. Kidney Int 1988; 34:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/7\">",
"      Myers BD, Chagnac A, Golbetz H, et al. Extent of glomerular injury in active and resolving lupus nephritis: a theoretical analysis. Am J Physiol 1991; 260:F717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/8\">",
"      Perrone RD, Steinman TI, Beck GJ, et al. Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis 1990; 16:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/9\">",
"      van Acker BA, Koomen GC, Koopman MG, et al. Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. Lancet 1992; 340:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/10\">",
"      Hilbrands LB, Artz MA, Wetzels JF, Koene RA. Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney Int 1991; 40:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/11\">",
"      Chagnac A, Kiberd BA, Fari&ntilde;as MC, et al. Outcome of the acute glomerular injury in proliferative lupus nephritis. J Clin Invest 1989; 84:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/12\">",
"      Levey AS, Berg RL, Gassman JJ, et al. Creatinine filtration, secretion and excretion during progressive renal disease. Modification of Diet in Renal Disease (MDRD) Study Group. Kidney Int Suppl 1989; 27:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/13\">",
"      Castellino P, Levin R, Shohat J, DeFronzo RA. Effect of specific amino acid groups on renal hemodynamics in humans. Am J Physiol 1990; 258:F992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/14\">",
"      Kontessis P, Jones S, Dodds R, et al. Renal, metabolic and hormonal responses to ingestion of animal and vegetable proteins. Kidney Int 1990; 38:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/15\">",
"      Payne RB. Creatinine clearance: a redundant clinical investigation. Ann Clin Biochem 1986; 23 ( Pt 3):243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/16\">",
"      Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/17\">",
"      Gault MH, Longerich LL, Harnett JD, Wesolowski C. Predicting glomerular function from adjusted serum creatinine. Nephron 1992; 62:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/18\">",
"      Papadakis MA, Arieff AI. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med 1987; 82:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/19\">",
"      Caregaro L, Menon F, Angeli P, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994; 154:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/20\">",
"      Olson JL, Heptinstall RH. Nonimmunologic mechanisms of glomerular injury. Lab Invest 1988; 59:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/21\">",
"      Kaizu K, Marsh D, Zipser R, Glassock RJ. Role of prostaglandins and angiotensin II in experimental glomerulonephritis. Kidney Int 1985; 28:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/22\">",
"      Molitch ME, Rodman E, Hirsch CA, Dubinsky E. Spurious serum creatinine elevations in ketoacidosis. Ann Intern Med 1980; 93:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/23\">",
"      Rocci ML Jr, Vlasses PH, Ferguson RK. Creatinine serum concentrations and H2-receptor antagonists. Clin Nephrol 1984; 22:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/24\">",
"      Berg KJ, Gjellestad A, Nordby G, et al. Renal effects of trimethoprim in ciclosporin- and azathioprine-treated kidney-allografted patients. Nephron 1989; 53:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/25\">",
"      Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/26\">",
"      Newman DJ, Thakkar H, Edwards RG, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/27\">",
"      Dossetor JB. Creatininemia versus uremia. The relative significance of blood urea nitrogen and serum creatinine concentrations in azotemia. Ann Intern Med 1966; 65:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/28\">",
"      Smith HW, Goldring W, Chasis H. THE MEASUREMENT OF THE TUBULAR EXCRETORY MASS, EFFECTIVE BLOOD FLOW AND FILTRATION RATE IN THE NORMAL HUMAN KIDNEY. J Clin Invest 1938; 17:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/29\">",
"      Lubowitz H, Slatopolsky E, Shankel S, et al. Glomerular filtration rate determination in patients with chronic renal disease. J Am Med Assoc 1967; 199:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/30\">",
"      Rodr&iacute;guez-Puyol D. The aging kidney. Kidney Int 1998; 54:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/31\">",
"      Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int 1984; 26:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/32\">",
"      Fliser D, Franek E, Joest M, et al. Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int 1997; 51:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21368/abstract/33\">",
"      Fliser D, Franek E, Ritz E. Renal function in the elderly--is the dogma of an inexorable decline of renal function correct? Nephrol Dial Transplant 1997; 12:1553.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7279 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_55_21368=[""].join("\n");
var outline_f20_55_21368=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CONCEPT OF CLEARANCE AND MEASUREMENT OF GFR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      USE AND LIMITATIONS OF CREATININE CLEARANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PLASMA CREATININE AND GFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BLOOD UREA NITROGEN AND GFR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CHANGE IN GFR WITH AGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MEASUREMENT OF RENAL PLASMA FLOW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7279\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7279|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/11/25790\" title=\"figure 1\">",
"      GFR and plasma creatinine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24617?source=related_link\">",
"      Chapter 3A: Cell model for proximal transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15684?source=related_link\">",
"      Chapter 3C: Secretory pathways in proximal tubule",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_55_21369="Varicella lesion close view";
var content_f20_55_21369=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72210%7EID%2F55533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72210%7EID%2F55533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Varicella",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A vesicle on an erythematous base is present. Varicella lesions are often described as resembling a \"dew drop on a rose petal\".",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary varicella lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vesicular lesions on an erythematous base are characteristic of chickenpox. The lesions occur in crops and are present in a variety of stages from maculopapular to vesicular or even pustular. Central necrosis and early crusting is also visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_55_21369=[""].join("\n");
var outline_f20_55_21369=null;
var title_f20_55_21370="Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy";
var content_f20_55_21370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/55/21370/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/55/21370/contributors\">",
"     Matthew Ellis, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/55/21370/contributors\">",
"     Michael J Naughton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/55/21370/contributors\">",
"     Cynthia X Ma, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/55/21370/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/55/21370/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/55/21370/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/55/21370/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/55/21370/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although metastatic breast cancer is unlikely to be cured, there have been meaningful improvements in survival due to the availability of more effective systemic therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beatson's historic observations on the regression of breast cancer following oophorectomy over 100 years ago provided the first insight into the estrogen-dependent nature of breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/5\">",
"     5",
"    </a>",
"    ]. With the recognition that estrogen has an important role in the promotion and progression of hormone receptor-positive breast cancer, estrogen deprivation therapy is a principle component in the treatment of hormone-sensitive breast cancer in the adjuvant and metastatic setting.",
"   </p>",
"   <p>",
"    The endocrine treatment of breast cancer utilizes strategies that reduce or halt estrogen production, block signaling through the estrogen receptor (ER), or antagonize ER itself. For women with intact ovarian function, this would also include targeting the ovaries directly by inducing temporary (ie, ovarian suppression) or permanent (ovarian ablation) menopause.",
"   </p>",
"   <p>",
"    Endocrine therapy for metastatic breast cancer is presented here. The use of chemotherapy with or without human epidermal growth factor 2 (HER2)-directed therapy for metastatic breast cancer and the approach to breast cancer in men are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: General principles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=see_link\">",
"       \"Breast cancer in men\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15813243\">",
"    <span class=\"h1\">",
"     TREATMENT OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical treatment approach to patients with metastatic breast cancer can be stratified by whether the cancer is hormone receptor-positive (estrogen receptor [ER]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progesterone receptor [PR] positive) and whether or not human epidermal growth factor 2 (HER2) is overexpressed (ie, HER2 positive):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with",
"      <strong>",
"       hormone receptor-positive, HER2-negative",
"      </strong>",
"      breast cancer, we suggest endocrine therapy provided they are appropriate candidates for endocrine treatment. (See",
"      <a class=\"local\" href=\"#H99490814\">",
"       'Patient selection'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H628737497\">",
"       'HER2-negative breast cancer'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients with",
"      <strong>",
"       hormone receptor-positive, HER2-positive",
"      </strong>",
"      breast cancer, we recommend a HER2-directed agent as part of any treatment strategy. We suggest HER2-directed treatment plus endocrine therapy rather than chemotherapy or single-agent HER2 therapy in appropriately selected patients. (See",
"      <a class=\"local\" href=\"#H99490814\">",
"       'Patient selection'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H19266990\">",
"       'HER2-positive breast cancer'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients with",
"      <strong>",
"       hormone receptor-negative, HER2-negative",
"      </strong>",
"      breast cancer, we recommend chemotherapy. These patients are not candidates for endocrine therapy.",
"     </li>",
"     <li>",
"      For patients with",
"      <strong>",
"       hormone receptor-negative, HER2-positive",
"      </strong>",
"      metastatic breast cancer, we recommend HER2-directed therapy in combination with chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is little evidence that concomitant use of endocrine agents plus chemotherapy results in improvements in survival outcomes in women with metastatic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/6\">",
"     6",
"    </a>",
"    ]. Given the objectives of treatment is to maximize quality of life and the relatively worse side effect profiles associated with the use of chemotherapy, we prefer to administer endocrine therapy alone rather than in combination with chemotherapy.",
"   </p>",
"   <p>",
"    The role of adjunctive therapy, such as pain medications and bone modifying agents, in the treatment of patients with metastatic breast cancer is covered separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link\">",
"       \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4488?source=see_link\">",
"       \"Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link\">",
"       \"Cancer pain management with opioids: Optimizing analgesia\"",
"      </a>",
"      .)",
"      <br/>",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8042?source=see_link\">",
"       \"Osteoclast inhibition in the management of bone metastases from breast cancer\"",
"      </a>",
"      .)",
"      <br/>",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19464?source=see_link\">",
"       \"Management of brain metastases in breast cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33924?source=see_link\">",
"       \"Radiation therapy for the management of painful bone metastases\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99490814\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hormone receptor-positive metastatic breast cancer are appropriate candidates for endocrine therapy if they have no or little symptoms related to metastatic breast cancer. In addition, patients who present with any of the following disease characteristics are optimal candidates for endocrine therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No or limited visceral metastases",
"     </li>",
"     <li>",
"      Bone-only metastatic disease",
"     </li>",
"     <li>",
"      Slowly progressive disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with rapidly progressive, imminently life-threatening, visceral, or symptomatic disease should be treated with chemotherapy without endocrine therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056069830\">",
"    <span class=\"h1\">",
"     TREATMENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of treatment depends on whether or not HER2 is overexpressed, prior treatment history, and the menopausal status of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056069850\">",
"    <span class=\"h2\">",
"     HER2 status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 percent of hormone receptor-positive breast cancers are also HER2-positive. These patients should receive HER2-directed therapy in combination with endocrine therapy. (See",
"    <a class=\"local\" href=\"#H19266990\">",
"     'HER2-positive breast cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15462528\">",
"    <span class=\"h2\">",
"     Prior treatment history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of treatment depends on whether prior endocrine therapy was administered, which is consistent with guidelines from the National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who progress &ge;12 months from the end of adjuvant endocrine therapy and patients who present with de novo metastatic breast cancer are eligible for",
"      <strong>",
"       first-line endocrine treatment",
"      </strong>",
"      . (See",
"      <a class=\"local\" href=\"#H1247608049\">",
"       'First-line treatment'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients who progress on or within 12 months of completing adjuvant endocrine therapy are eligible for",
"      <strong>",
"       second-line endocrine treatment",
"      </strong>",
"      . Patients who progress on first-line endocrine therapy for metastatic disease are also eligible for second-line treatment. (See",
"      <a class=\"local\" href=\"#H1248533221\">",
"       'Second-line treatment'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For women who progress after two lines of endocrine therapy, treatment should be based on their prior treatment response, tumor burden, and individual preferences. (See",
"      <a class=\"local\" href=\"#H1248531391\">",
"       'Third- or later line therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15461518\">",
"    <span class=\"h2\">",
"     Menopausal status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment-induced amenorrhea is not a reliable indicator of menopause. Therefore, women who were not menopausal at diagnosis of breast cancer should undergo a formal evaluation to determine their menstrual status. We define menopause in women &lt;60 years using guidelines from the NCCN [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior bilateral oophorectomy",
"     </li>",
"     <li>",
"      No menstrual periods in the preceding 12 or more months occurring:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the absence of chemotherapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30181?source=see_link\">",
"       toremifene",
"      </a>",
"      , or ovarian suppression",
"     </li>",
"     <li>",
"      While undergoing treatment with chemotherapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30181?source=see_link\">",
"       toremifene",
"      </a>",
"      , provided serum estradiol levels are in the postmenopausal range (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=see_link&amp;anchor=H20#H20\">",
"       \"Etiology, diagnosis, and treatment of secondary amenorrhea\", section on 'Step 4: Basic laboratory testing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H628737497\">",
"    <span class=\"h1\">",
"     HER2-NEGATIVE BREAST CANCER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1247608049\">",
"    <span class=\"h2\">",
"     First-line treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248533193\">",
"    <span class=\"h3\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;For premenopausal women who are endocrine therapy naive, progress &gt;12 months from the end of adjuvant therapy, or present with de novo metastatic breast cancer, options include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ovarian suppression or ablation (See",
"      <a class=\"local\" href=\"#H34054295\">",
"       'Ovarian suppression or ablation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Selective estrogen receptor modulator (SERM) (See",
"      <a class=\"local\" href=\"#H34055122\">",
"       'Selective estrogen receptor modulators'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Combination treatment (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      plus ovarian suppression) (See",
"      <a class=\"local\" href=\"#H34054968\">",
"       'Tamoxifen plus ovarian suppression'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A choice between them is based on patient and provider preferences. The authors and some experts at UpToDate prefer combination treatment in the first-line setting, rather than single modality treatment. However, others prefer to treat with a SERM alone. Patients may base their decision on the risks associated with ovarian suppression, including a higher risk of osteoporosis or cardiac disease seen with long-term use of gonadotropin releasing hormones, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    acetate, or as a consequence of oophorectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15706?source=see_link&amp;anchor=H21231420#H21231420\">",
"     \"Elective oophorectomy or ovarian conservation at the time of hysterectomy\", section on 'Long-term health risks'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although ovarian suppression plus endocrine therapy improves disease-free and overall survival compared to ovarian suppression alone, whether it improves outcomes compared to administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    alone is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H34054968\">",
"     'Tamoxifen plus ovarian suppression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In general, aromatase inhibitors (AIs) are contraindicated in premenopausal women with intact ovarian function because AIs may ultimately stimulate an increased production of estrogen in the ovaries through negative feedback to the pituitary gland. (See",
"    <a class=\"local\" href=\"#H34054915\">",
"     'Aromatase inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34054295\">",
"    <span class=\"h4\">",
"     Ovarian suppression or ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic-induced ovarian suppression (ie, use of gonadotropin-releasing hormone [GnRH] agonists) and ovarian ablation (by oophorectomy or ovarian irradiation) appear to be effective, with response rates ranging from 30 to 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In one trial, 136 premenopausal women were randomly assigned treatment with the GnRH agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    or oophorectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/10\">",
"     10",
"    </a>",
"    ]. Although the study did not complete due to poor accrual, goserelin resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similar overall survival (OS) compared to oophorectomy (hazard ratio [HR] for mortality, 0.80, 95% CI 0.53-1.20), though the study was underpowered to show a benefit.",
"     </li>",
"     <li>",
"      Significantly higher rate of mild (grade",
"      <span class=\"nowrap\">",
"       1/2)",
"      </span>",
"      hot flashes (66 versus 43 percent). However, neither arm resulted in serious toxicities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further discussion on ovarian suppression is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link&amp;anchor=H14993426#H14993426\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Cessation of ovarian function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34055122\">",
"    <span class=\"h4\">",
"     Selective estrogen receptor modulators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two SERMs are available for treatment in breast cancer:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30181?source=see_link\">",
"     toremifene",
"    </a>",
"    . Of these, tamoxifen has been more widely studied and is used more commonly in premenopausal women.",
"   </p>",
"   <p>",
"    However, there are little data regarding the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    for premenopausal women with metastatic breast cancer. In a 1991 review that included seven phase II trials of tamoxifen in premenopausal women (n=285), expression of hormone receptors was not required for eligibility [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/9\">",
"     9",
"    </a>",
"    ]. Among these patients, the overall response rate (ORR) was 31 percent, but in 31 patients with confirmed ER-positive disease, the ORR was 45 percent.",
"   </p>",
"   <p>",
"    The administration of SERMs in postmenopausal women is discussed below. (See",
"    <a class=\"local\" href=\"#H444000539\">",
"     'Selective estrogen receptor modulators'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34054511\">",
"    <span class=\"h4\">",
"     Tamoxifen versus ovarian ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The activity of single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    appears to be equivalent to ovarian ablation in premenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In a 1997 meta-analysis of four studies (n=220), there were no statistically significant differences in women who took tamoxifen and those undergoing ovarian ablation in either the risk of disease progression (odds ratio [OR] 0.86) and in the risk of death (OR 0.94) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34054968\">",
"    <span class=\"h4\">",
"     Tamoxifen plus ovarian suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of combined treatment was demonstrated in a 2001 meta-analysis of four randomized trials (n=506) that compared a GnRH agonist plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    to a GnRH agonist alone (64 and 90 percent were chemotherapy and endocrine therapy naive, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/8\">",
"     8",
"    </a>",
"    ]. Compared to ovarian suppression alone, combined therapy significantly improved both progression-free survival (PFS, HR 0.70, p=0.0003) and OS (HR 0.78, p=0.02). Whether combined treatment is superior to single-agent tamoxifen is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34054915\">",
"    <span class=\"h4\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AIs block the enzyme aromatase, which prevents peripheral conversion of androgens to estrogen. Three third-generation AIs in this class are commonly used:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    (2.5 mg daily), anastrazole (1 mg daily), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    (25 mg daily). In general, they are contraindicated in premenopausal women because of concern they may result in reactivation of ovarian function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link&amp;anchor=H5674202#H5674202\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Reactivation of ovarian function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these concerns, AIs have been evaluated in phase II trials in combination with ovarian suppression with promising results [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In one trial, 35 premenopausal women were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    (for ovarian suppression) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/14\">",
"     14",
"    </a>",
"    ]. At a follow-up of 27 months, the time to progression was similar among premenopausal and postmenopausal women (9.5 versus 9 months, respectively), suggesting that the administration of a GnRH agonist plus an AI may be as effective in premenopausal women as it is in postmenopausal women.",
"   </p>",
"   <p>",
"    Whether there is a benefit to combined treatment compared to ovarian suppression alone is not known. Until more data become available, we consider the use of ovarian suppression plus aromatase inhibitors investigational. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248533207\">",
"    <span class=\"h3\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;For postmenopausal women with metastatic breast cancer who are endocrine therapy na&iuml;ve, progress &gt;12 months from the end of adjuvant therapy, or present with de novo metastatic breast cancer, the options include an AI, SERM, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"     fulvestrant",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    For most patients, we suggest an AI as first-line treatment. AIs have demonstrated a survival advantage when compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    in the first-line setting. Although the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"     fulvestrant",
"    </a>",
"    (alone or in combination with an AI) appears promising, we await more data before it is accepted as a treatment option in the first-line setting. (See",
"    <a class=\"local\" href=\"#H34055576\">",
"     'Aromatase inhibitors'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H34055852\">",
"     'Fulvestrant'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    SERMs are a reasonable alternative to AIs in select subsets of women with metastatic breast cancer, including (see",
"    <a class=\"local\" href=\"#H444000539\">",
"     'Selective estrogen receptor modulators'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients unable to tolerate AI treatment due to toxicities (ie, myalgias, arthralgias)",
"     </li>",
"     <li>",
"      Patients with baseline osteoporosis, who may be at an increased risk of fractures",
"     </li>",
"     <li>",
"      Patients with cardiovascular disease, who may be at risk for increased cardiac complications from an AI",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34055576\">",
"    <span class=\"h4\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of AIs as a first line treatment for advanced or metastatic breast cancer in postmenopausal women was shown in a 2006 meta-analysis of 23 randomized trials (n=8504 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/15\">",
"     15",
"    </a>",
"    ]. Treatment with an AI resulted in an improvement in OS compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (HR 0.89, 95% CI 0.80-0.99) and to other endocrine therapies (HR 0.87, 95% CI 0.82-0.93).",
"   </p>",
"   <p>",
"    There are no data to suggest one AI is better than the others. In one trial of 128 women with advanced breast cancer,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    resulted in a similar ORR (15 percent in both groups) and OS (31 and 33 months, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/16\">",
"     16",
"    </a>",
"    ]. Although pharmacokinetic data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    is a more effective aromatase inhibitor, other data suggest that once a certain threshold of aromatase inhibition is reached, differences in estrogen suppression between the AIs are not associated with clinically significant differences in efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444000539\">",
"    <span class=\"h4\">",
"     Selective estrogen receptor modulators",
"    </span>",
"    &nbsp;&mdash;&nbsp;SERMs are effective agents for postmenopausal women with metastatic breast cancer. In a 1998 meta-analysis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    versus other endocrine strategies in postmenopausal women demonstrated that tamoxifen had an equivalent benefit in overall survival (HR 1.02, 95% CI 0.94-1.10) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/19\">",
"     19",
"    </a>",
"    ]. However, the comparator arm consisted of various strategies, including ovarian",
"    <span class=\"nowrap\">",
"     suppression/ablation,",
"    </span>",
"    other antiestrogens, progestins, and androgens.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30181?source=see_link\">",
"     Toremifene",
"    </a>",
"    has equivalent activity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and a similar toxicity profile [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. In addition, toremifene is cross-resistant with tamoxifen and is ineffective as sequential therapy in patients who are refractory to tamoxifen [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Therefore, toremifene is not commonly prescribed as a treatment for breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34055852\">",
"    <span class=\"h4\">",
"     Fulvestrant",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"     Fulvestrant",
"    </a>",
"    is an estrogen receptor antagonist used in the treatment of postmenopausal women. Fulvestrant blocks ER dimerization and DNA binding, increases ER turnover, and inhibits nuclear uptake of the receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Because it blocks ER function before estrogen can bind the receptor, fulvestrant can theoretically overcome resistance that is driven by the agonist properties of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"     Fulvestrant",
"    </a>",
"    is administered as an intramuscular injection (500 mg loading dose on days 1 and 14, then monthly). Although originally approved as a monthly intramuscular injection (250 mg per month), use of the higher dose was proven to be more effective in subsequent trials and is now the preferred schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One trial suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"     fulvestrant",
"    </a>",
"    has equivalent efficacy to anastrazole. In the First-Line Study Comparing Endocrine Treatments (FIRST) trial, 205 patients were randomly assigned treatment with fulvestrant (500 mg dosing schedule) versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    (1 mg orally daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/30,33\">",
"     30,33",
"    </a>",
"    ]. Compared to anastrozole, fulvestrant resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A similar ORR (36 percent in both arms)",
"     </li>",
"     <li>",
"      A longer time to progression (median, 23 versus 13 months, HR 0.66; 95% CI 0.47-0.92)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall survival was not reported for this trial. At this time, more experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"     fulvestrant",
"    </a>",
"    is required before it is accepted as an appropriate alternative to AIs in the first-line setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19267081\">",
"    <span class=\"h4\">",
"     Fulvestrant plus anastrazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to single agent therapy, two separate trials investigating the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"     fulvestrant",
"    </a>",
"    plus anastrazole as first-line therapy have been published but with discrepant results. Of note, in both trials fulvestrant was administered at a dose of 250 mg monthly, which is lower than the usual prescribed dose.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"       Fulvestrant",
"      </a>",
"      <strong>",
"       and Anastrazole Combination Trial (FACT)",
"      </strong>",
"      &mdash; FACT enrolled 514 women (one-third with endocrine-naive disease) and randomly assigned treatment to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"       anastrozole",
"      </a>",
"      alone or in combination with fulvestrant (500 mg loading dose, 250 mg on day 14 and 28, then 250 mg every 28 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/34\">",
"       34",
"      </a>",
"      ]. Fulvestrant plus anastrozole resulted in an equivalent time to progression (median, 11 versus 10 months with anastrozole, HR 0.99, 95% CI 0.81-1.20) and OS (median, 38 months in both arms, HR 1.0, 95% CI 0.76-1.32).",
"     </li>",
"     <li>",
"      <strong>",
"       SWOG S0226",
"      </strong>",
"      &mdash; In the Southwest Oncology Group (SWOG) S0226 trial, 707 women (60 percent endocrine-naive) were randomly assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"       anastrozole",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"       fulvestrant",
"      </a>",
"      (using the same schedule as in the FACT study) or to single agent anastrozole [",
"      <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/35\">",
"       35",
"      </a>",
"      ]. Compared to anastrozole alone, combined treatment resulted in an improvement in PFS (15 versus 14 months, hazard ratio [HR] 0.80, 95% CI 0.68-0.94) and OS (48 versus 41 months, HR 0.81 95% CI 0.65-1.00). On subgroup analysis the benefit of combination therapy appeared to be restricted to previously untreated patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There were significantly more cases of endocrine naive patients in the SWOG S0226 trial than the FACT trial, which might explain the difference in trial outcomes. Further studies are needed to confirm the findings from SWOG S0226 trial and to determine whether this combination is superior to anastrazole alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248533221\">",
"    <span class=\"h2\">",
"     Second-line treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with disease progression following first-line endocrine therapy, second-line treatment is a reasonable option, provided they are not symptomatic and their disease continues to be slowly progressive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who develop symptoms due to disease progression and those with rapidly progressive metastatic disease should be treated with chemotherapy. (See",
"    <a class=\"local\" href=\"#H99490814\">",
"     'Patient selection'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15462792\">",
"    <span class=\"h3\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;For premenopausal women who progress following first-line treatment, we suggest ovarian suppression if this was not previously administered in the first-line setting. However, for women with disease progression despite ovarian suppression, serum estradiol levels should be checked to ensure menopausal status was achieved. If high estradiol levels are noted despite ovarian suppression, we suggest ovarian ablation. (See",
"    <a class=\"local\" href=\"#H34054295\">",
"     'Ovarian suppression or ablation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Once menopause is induced (or confirmed by laboratory testing), the treatment approach for postmenopausal women is used. (See",
"    <a class=\"local\" href=\"#H15462854\">",
"     'Postmenopausal women'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For premenopausal women who refuse ovarian suppression or ablation, we recommend chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15462854\">",
"    <span class=\"h3\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a lack of clinical trials to address the optimal sequence of therapy from the first to the second line setting. The available options include the administration of a non-cross-resistant AI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"     fulvestrant",
"    </a>",
"    , or endocrine therapy plus the mammalian target of rapamycin (mTOR) inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    , in the second-line setting. A choice between them should be individualized based on prior treatment received.",
"   </p>",
"   <p>",
"    The data to support these options are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99491181\">",
"    <span class=\"h4\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no differences in efficacy between the AIs in the second-line setting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/16,36,37\">",
"     16,36,37",
"    </a>",
"    ]. For example, in a phase III trial, 713 women with disease progression on a prior antiestrogen were randomly assigned to treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    or anastrazole [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/37\">",
"     37",
"    </a>",
"    ]. Although the overall response rate was significantly higher with letrozole (19 versus 12 percent), there was no significant difference in time to progression or OS.",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    in the second-line setting after progression on a nonsteroidal AI (anastrazole or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    ) was evaluated in a 2011 systematic review of nine studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/38\">",
"     38",
"    </a>",
"    ]. The overall response rate ranged from 2 to 26 percent with a clinical benefit rate that ranged from 12 to 55 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99491188\">",
"    <span class=\"h4\">",
"     Fulvestrant",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"     Fulvestrant",
"    </a>",
"    results in similar overall response rates and overall survival compared to an AI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/31,39-41\">",
"     31,39-41",
"    </a>",
"    ]. However, these studies utilized a lower dose of fulvestrant (250 mg monthly) than what is used in current in clinical practice. Whether use of a higher dose of fulvestrant results in an improvement in clinical outcomes compared to AI therapy is not known. (See",
"    <a class=\"local\" href=\"#H34055852\">",
"     'Fulvestrant'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8576955\">",
"    <span class=\"h4\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data to inform the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    in the second-line setting. In a combined analysis of two randomized trials evaluating a sequence strategy (ie, tamoxifen followed by anastrazole or vice versa), 137 women crossed over to tamoxifen [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/42\">",
"     42",
"    </a>",
"    ]. Second-line treatment with tamoxifen resulted in a 10 percent objective response rate (ORR) and a clinical benefit rate (ORR plus stable disease for &ge;6 months) of 49 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99491006\">",
"    <span class=\"h4\">",
"     Endocrine plus molecular targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combining endocrine therapy with molecularly targeted treatment appears to be an effective treatment strategy. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    (an mTOR inhibitor) in combination with other endocrine agents can be administered in postmenopausal women. The data on these options are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8576995\">",
"    <span class=\"h5\">",
"     Exemestane plus everolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    plus the steroidal AI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    , was shown in the BOLERO-2 trial, which enrolled 724 women who had progressed on anastrazole. Patients were randomly assigned treatment with exemestane (25 mg daily) plus placebo or exemestane plus everolimus (10 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/43\">",
"     43",
"    </a>",
"    ]. The combination of exemestane and everolimus resulted in the following outcomes when compared to exemestane plus placebo:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An improvement in PFS (median, 7 versus 3 months; HR for mortality 0.43, 95% CI 0.35-0.54)",
"     </li>",
"     <li>",
"      Higher ORR (9.5 versus 0.4 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    was associated with serious side effects (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    including stomatitis (eight percent), dyspnea (four percent), noninfectious pneumonitis (three percent), and elevated liver enzymes (three percent). The impact on overall survival was not reported.",
"   </p>",
"   <p>",
"    For patients who develop shortness of breath or increase in cough,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    should be held and patients assessed for pneumonitis. A brief course of steroids may be necessary. Additional information on the toxicity of everolimus is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=see_link&amp;anchor=H20#H20\">",
"     \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\", section on 'Rapamycin and analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99490987\">",
"    <span class=\"h5\">",
"     Tamoxifen plus everolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    is also an option for patients previously treated with an AI. In a study conducted by the Groupe d&rsquo;Investigateurs Nationaux pour l&rsquo;&Eacute;tude des Cancers Ovariens et du sein (GINECO), 111 postmenopausal women who had progressed on an AI were randomly assigned treatment with tamoxifen with or without everolimus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/44\">",
"     44",
"    </a>",
"    ]. Compared to tamoxifen alone, combination treatment with everolimus resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An improvement in time to progression (median 9 versus 5 months; HR 0.54, 95% CI 0.36-0.81) and in the risk of death (HR 0.45, 95% CI 0.24-0.81)",
"     </li>",
"     <li>",
"      No difference in the ORR (14 versus 13 percent)",
"     </li>",
"     <li>",
"      A lower incidence of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      pain (9 versus 18 percent) and fatigue (6 versus 11 percent)",
"     </li>",
"     <li>",
"      An increase in grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      stomatitis (11 versus 0 percent) and anorexia (7 versus 4 percent)",
"     </li>",
"     <li>",
"      An increase in the incidence of pneumonitis (any grade, 17 versus 4 percent), though grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      toxicity was rare (two versus one patient)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248531391\">",
"    <span class=\"h2\">",
"     Third- or later line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who progress after two lines of endocrine therapy, treatment must be individualized based on their prior treatment response, tumor burden, and preferences for treatment. In general, patients who have progressed after multiple lines of endocrine therapy should receive chemotherapy. However, for patients who are asymptomatic with slowly progressive disease, continuation of endocrine therapy is reasonable. &nbsp;",
"   </p>",
"   <p>",
"    In addition to the previously discussed endocrine therapies above (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , aromatase inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"     fulvestrant",
"    </a>",
"    ), options include the use of hormonal therapies (ie, progestins, estrogens, and androgens). These are discussed above. (See",
"    <a class=\"local\" href=\"#H34055122\">",
"     'Selective estrogen receptor modulators'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H34055576\">",
"     'Aromatase inhibitors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H34055852\">",
"     'Fulvestrant'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34056261\">",
"    <span class=\"h3\">",
"     Progestins",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     Megestrol acetate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    are progestational agents with activity in metastatic breast cancer, with an approximate response rate of 25 percent and median duration of response of 15 months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Activity appears to be maintained in patients who experience disease progression on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . However, the activity of progestins after an aromatase inhibitor has not been studied. Megestrol acetate is typically dosed at 160 mg daily (40 mg four times daily), as higher doses are no more effective but are associated with more weight gain, fluid retention, vaginal bleeding, and a lower quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/45,47\">",
"     45,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of action of progestins in the treatment of advanced breast cancer is unclear. They may inhibit aromatase activity or increase estrogen turnover, since estrogen levels fall during therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/48\">",
"     48",
"    </a>",
"    ]. They may also act through the glucocorticoid receptor, androgen receptor, or progesterone receptor.",
"   </p>",
"   <p>",
"    Progestins are associated with an increased risk of thromboembolic events, and their use should be avoided in patients with thromboembolic disorders or other risk factors for thromboembolic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34056268\">",
"    <span class=\"h3\">",
"     Estrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogenic compounds can be used as a treatment for metastatic breast cancer, though there are no data on the impact on outcomes of treatment compared to placebo. The efficacy was shown in a trial involving 143 women who were randomly assigned to diethylstilbestrol (DES) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/49\">",
"     49",
"    </a>",
"    ]. Compared to tamoxifen, DES resulted in a similar response rate (41 versus 37 percent, p=0.37) and median progression free survival (five versus six months). However, DES was shown to be significantly more toxic and 12 percent on DES discontinued treatment due to congestive heart failure, gastrointestinal intolerance, thrombophlebitis, and the onset of lower extremity edema. None of the patients on tamoxifen discontinued treatment. &nbsp;",
"   </p>",
"   <p>",
"    Patients with prior exposure to endocrine therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    , AIs) may respond to estrogen therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/50\">",
"     50",
"    </a>",
"    ]. If used, estradiol is the preferred estrogen of choice. Although high dose estrogen (estradiol 30 mg daily in divided doses) has typically been used, lower doses (estradiol 6 mg daily in divided doses) may be just as effective with less toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/51\">",
"     51",
"    </a>",
"    ]. In a phase II randomized trial, 66 postmenopausal women who experienced disease progression on an AI were randomly assigned to treatment with low-dose (2 mg three times a day) or high-dose (10 mg three times a day) oral estradiol [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/51\">",
"     51",
"    </a>",
"    ]. Compared to high-dose estradiol therapy, low-dose estradiol therapy resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher ORR (9 versus 3 percent, respectively) that was not statistically significant",
"     </li>",
"     <li>",
"      Similar rate of clinical benefit (ORR plus stable disease, 29 versus 28 percent, respectively)",
"     </li>",
"     <li>",
"      Less serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity including nausea and vomiting (0 versus 16 percent, respectively), hyponatremia (0 versus 16 percent, respectively), pleural effusions (13 versus 0 percent, respectively), hypercalcemia (6 versus 0 percent, respectively), and infections (6 versus 9 percent, respectively)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with progestins, estrogens are contraindicated if the patient has a thromboembolic disorder or other risk factors for thromboembolic disease. For patients who experience vaginal bleeding on estrogens, progestin therapy is effective treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition, patients with bone metastasis should be treated with bisphosphonates before giving estradiol to avoid hypercalcemia.",
"   </p>",
"   <p>",
"    Prior to the introduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , it was observed that 25 to 35 percent of patients treated with high-dose estrogens had a secondary response (termed a &ldquo;withdrawal response&rdquo;) after the estrogen was stopped at disease progression, providing palliation for over 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/52\">",
"     52",
"    </a>",
"    ]. While withdrawal response has been observed upon discontinuation of tamoxifen, progestins, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    , it tends to be infrequent and short-lived [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34056275\">",
"    <span class=\"h3\">",
"     Androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgens, including testosterone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/34/41508?source=see_link\">",
"     fluoxymesterone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    , are inferior to high dose estrogens and rarely used to treat metastatic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/55\">",
"     55",
"    </a>",
"    ]. Although they have response rates of 10 to 20 percent in pretreated patients, side effects include virilization, edema, and jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. We seldom administer androgen therapy for metastatic breast cancer. However, if it is prescribed, the preferred formulation is fluoxymesterone (10 mg by mouth twice daily). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056070066\">",
"    <span class=\"h2\">",
"     Investigational approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of endocrine therapy plus a molecular targeted agent continues to be explored in clinical trials with the aim to overcome endocrine resistance. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/4/7238?source=see_link\">",
"       Exemestane",
"      </a>",
"      <strong>",
"       plus entinostat",
"      </strong>",
"      &mdash; Entinostat is a small molecule inhibitor of class I histone deacetylases, which are proteins required for the control of gene expression. It exerts an antiproliferative effect and promotes apoptosis in breast cancer cell lines and has been evaluated as a second- or later-line treatment in women with ER-positive breast cancers [",
"      <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/59\">",
"       59",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In the ENtinostat Combinations Overcoming REsistance (ENCORE 301) randomized phase II trial, 130 women who had previously progressed on aromatase inhibitor therapy were treated with exemestane (25 mg daily) plus entinostat (5 mg daily) or exemestane plus placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/60\">",
"       60",
"      </a>",
"      ]. The population was heavily pretreated, with 58 percent having progressed after more than one endocrine agent and 62 percent receiving prior chemotherapy. Preliminary results showed that patients receiving combined treatment had the following outcomes, compared to those receiving exemestane plus placebo:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Significantly improved PFS (median, 4 versus 2 months)",
"     </li>",
"     <li>",
"      More episodes of fatigue (46 versus 26 percent) and uncomplicated neutropenia (25 versus 0 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"       Letrozole",
"      </a>",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      <strong>",
"       &mdash;",
"      </strong>",
"      The addition of the vascular endothelial growth factor (VEGF) inhibitor, bevacizumab, to letrozole, showed promising activity in a phase II trial, and further investigation is underway [",
"      <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/61,62\">",
"       61,62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19266990\">",
"    <span class=\"h1\">",
"     HER2-POSITIVE BREAST CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer, should receive HER2-directed therapy as a component of their treatment plan. We suggest first-line combination treatment with endocrine therapy plus HER2-targeted therapy rather than endocrine therapy alone, provided their disease is not imminently life-threatening or symptomatic. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    as a single agent is a reasonable option prior to committing a patient to combination therapy.",
"   </p>",
"   <p>",
"    Patients with symptomatic metastatic breast cancer or rapidly progressive disease should be treated with HER2-directed therapy plus chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056069964\">",
"    <span class=\"h2\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence to inform the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    plus HER2-directed treatment in premenopausal women (with intact ovarian function). However, given the benefit of combination therapy in postmenopausal women, the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    plus tamoxifen is a widely accepted combination in premenopausal women who are otherwise candidates for endocrine therapy. (See",
"    <a class=\"local\" href=\"#H99490814\">",
"     'Patient selection'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1056069971\">",
"     'Postmenopausal women'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056069971\">",
"    <span class=\"h2\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of HER2-directed therapy plus an aromatase inhibitor is an effective treatment strategy for postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer. The available agents include both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    While it is unclear whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    is superior when combined with endocrine therapy, practical considerations should be taken into account with patients when deciding on a treatment approach. Trastuzumab requires intravenous infusion, which may be less convenient for patients on oral endocrine therapy. Lapatinib, as an oral agent, may prevent the need for intravenous infusion, but it has a greater side effect profile (namely skin rash and diarrhea) when compared to trastuzumab.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99491516\">",
"    <span class=\"h3\">",
"     Trastuzumab plus anastrazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    plus anastrazole is an active regimen as a first-line treatment for postmenopausal women with",
"    <span class=\"nowrap\">",
"     ER/PR",
"    </span>",
"    and HER2-positive advanced or metastatic breast cancer. In the TAnDEM study, 207 postmenopausal patients were randomly assigned treatment with the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    plus trastuzumab or anastrozole alone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/63\">",
"     63",
"    </a>",
"    ]. Compared to single agent anastrazole, combination therapy resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant improvement in PFS (median, 5 versus 2 months)",
"     </li>",
"     <li>",
"      An improvement in OS (28.5 versus 23.9 months), but this was not statistically significant. Of note, 70 percent of patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"       anastrozole",
"      </a>",
"      crossed over to a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      -containing regimen upon progression.",
"     </li>",
"     <li>",
"      A higher incidence of toxicities (all grades) including fatigue (21 versus 9 percent), diarrhea (20 versus 8 percent), vomiting (21 versus 4 percent), and pyrexia (18 versus 7 percent). However, serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities were rare in both treatment arms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99491526\">",
"    <span class=\"h3\">",
"     Lapatinib plus letrozole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    is also an option in the first-line setting and is attractive because both agents are orally available. In a randomized trial of 219 postmenopausal women assigned treatment with letrozole (2.5 mg daily) with or without lapatinib (1500 mg daily), combination therapy resulted in [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvement in PFS compared to single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"       letrozole",
"      </a>",
"      (median, 8 versus 3 months; HR 0.71, 95% CI 0.53-0.96)",
"     </li>",
"     <li>",
"      Higher rate of clinical benefit (ORR plus stable disease &gt;6 months, 48 versus 29 percent; HR 0.4, 95% CI 0.2-0.8)",
"     </li>",
"     <li>",
"      Higher rate of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity including diarrhea (10 versus 1 percent) and rash (1 versus 0 percent) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    on OS has not been reported. However, based upon a clinically meaningful increase in PFS, the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved lapatinib in combination with an aromatase inhibitor in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/55/21370/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23941006\">",
"    <span class=\"h2\">",
"     Second-line treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who progress after first-line endocrine therapy plus a HER2-direceted agent, we initiate chemotherapy in combination with a HER2-directed agent. However, patients with slowly progressive disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who are not symptomatic from their cancer are candidates for a second-line endocrine therapy. Patients who develop symptoms due to disease progression and those with rapidly progressive metastatic disease should be treated with chemotherapy plus a HER2-directed agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/11/27827?source=see_link\">",
"       \"Patient information: Treatment of metastatic breast cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264716193\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estrogen has an important role in the promotion and progression of hormone receptor-positive breast cancer. As a result, endocrine therapy has become a principle component in the treatment of hormone-sensitive breast cancer in the adjuvant and metastatic setting. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with hormone receptor-positive, HER2-negative breast cancer, treatment depends on the clinical scenario:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with no or mild symptoms secondary to metastatic breast cancer, we suggest endocrine therapy rather than chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H99490814\">",
"       'Patient selection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: General principles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with symptomatic or rapidly progressive disease or those patients with significant organ involvement (ie, liver or lung metastases), we suggest chemotherapy (with a HER2-directed agent if HER2-positive) rather than endocrine therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: General principles\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are endocrine therapy na&iuml;ve, progress &gt;12 months from the end of adjuvant therapy, or present with de novo metastatic breast cancer are candidates for",
"      <strong>",
"       first-line",
"      </strong>",
"      endocrine therapy. We determine the choice of endocrine treatment based on the menopausal status of the patient (see",
"      <a class=\"local\" href=\"#H1247608049\">",
"       'First-line treatment'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For premenopausal women, the authors and some experts at UpToDate administer a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      plus ovarian suppression. However, other experts at UpToDate prefer treatment with a SERM alone. (See",
"      <a class=\"local\" href=\"#H1248533193\">",
"       'Premenopausal women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For postmenopausal women, we suggest an aromatase inhibitor rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients who are not candidates for an AI and those who cannot tolerate AIs due to treatment-related toxicities, we suggest tamoxifen rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"       fulvestrant",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1248533207\">",
"       'Postmenopausal women'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who progress on or within 12 months of completing adjuvant endocrine therapy and those who progress after first-line endocrine therapy for metastatic disease are eligible for",
"      <strong>",
"       second-line",
"      </strong>",
"      endocrine treatment provided they no or little symptoms related to their disease and their cancer is not rapidly progressive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women who continue to menstruate, we recommend treatment to block ovarian function (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This can be done temporarily using gonadotropin releasing hormones (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      acetate) or permanently (eg, by oophorectomy).",
"     </li>",
"     <li>",
"      For women who progress despite cessation of ovarian function, estradiol levels should be checked to ensure menopausal status is achieved. If high estradiol levels are noted in the context of disease progression, we recommend ovarian ablation (eg, oophorectomy) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For women with disease progression and are confirmed to be amenorrheic, treatment options mirror those for postmenopausal women. (See",
"      <a class=\"local\" href=\"#H15461518\">",
"       'Menopausal status'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15462792\">",
"       'Premenopausal women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For postmenopausal women, who progress following an AI, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"       fulvestrant",
"      </a>",
"      or the combination",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/4/7238?source=see_link\">",
"       exemestane",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The choice of fulvestrant vs exemestane plus everolimus depends on individual patient preferences after consideration of the side effect profiles of each option. (See",
"      <a class=\"local\" href=\"#H15462854\">",
"       'Postmenopausal women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For postmenopausal women who progressed on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , we suggest an AI (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with hormone receptor-positive, HER2-positive breast cancer, we recommend first-line endocrine therapy plus HER2-targeted therapy rather than endocrine therapy alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"       lapatinib",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For premenopausal women, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      rather than in combination with ovarian suppression (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For postmenopausal women, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      plus anastrazole (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/1\">",
"      Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer 2004; 100:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/2\">",
"      Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/3\">",
"      Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/4\">",
"      Dawood S, Broglio K, Gonzalez-Angulo AM, et al. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 2008; 26:4891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/5\">",
"      Stockwell S. Classics in oncology. George Thomas Beatson, M.D. (1848-1933). CA Cancer J Clin 1983; 33:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/6\">",
"      Barrios C, Forbes JF, Jonat W, et al. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol 2012; 23:1378.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network guidelines (Version 2.2011): Invasive breast cancer.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/8\">",
"      Klijn JG, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001; 19:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/9\">",
"      Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 1991; 9:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/10\">",
"      Taylor CW, Green S, Dalton WS, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 1998; 16:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/11\">",
"      Crump M, Sawka CA, DeBoer G, et al. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 1997; 44:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/12\">",
"      Sawka CA, Pritchard KI, Shelley W, et al. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1. Breast Cancer Res Treat 1997; 44:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/13\">",
"      Carlson RW, Theriault R, Schurman CM, et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 2010; 28:3917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/14\">",
"      Park IH, Ro J, Lee KS, et al. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. J Clin Oncol 2010; 28:2705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/15\">",
"      Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 2006; 98:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/16\">",
"      Campos SM, Guastalla JP, Subar M, et al. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer 2009; 9:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/17\">",
"      Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002; 20:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/18\">",
"      Sainsbury R. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy? Br J Cancer 2004; 90:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/19\">",
"      Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16:3439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/20\">",
"      Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995; 13:2556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/21\">",
"      Pyrh&ouml;nen S, Ellm&eacute;n J, Vuorinen J, et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 1999; 56:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/22\">",
"      Milla-Santos A, Milla L, Rallo L, Solano V. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Res Treat 2001; 65:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/23\">",
"      Vogel CL, Shemano I, Schoenfelder J, et al. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol 1993; 11:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/24\">",
"      Buzdar AU, Hortobagyi GN. Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol 1998; 16:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/25\">",
"      DeFriend DJ, Anderson E, Bell J, et al. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer 1994; 70:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/26\">",
"      Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993; 106 ( Pt 4):1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/27\">",
"      DeFriend DJ, Howell A, Nicholson RI, et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994; 54:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/28\">",
"      Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995; 87:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/29\">",
"      Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004; 22:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/30\">",
"      Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009; 27:4530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/31\">",
"      Howell A, Pippen J, Elledge RM, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 2005; 104:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/32\">",
"      Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28:4594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/33\">",
"      Robertson JF, Lindemann JP, Llombart-Cussac A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. Breast Cancer Res Treat 2012; 136:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/34\">",
"      J Bergh, P Jonsson, EK Lidbrink, M Trudeau. FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer. J Clin Oncol 2012; 30:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/35\">",
"      Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012; 367:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/36\">",
"      Dixon JM, Renshaw L, Langridge C, et al. Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability. Breast Cancer Res Treat 2011; 125:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/37\">",
"      Rose C, Vtoraya O, Pluzanska A, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003; 39:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/38\">",
"      Beresford M, Tumur I, Chakrabarti J, et al. A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer. Clin Oncol (R Coll Radiol) 2011; 23:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/39\">",
"      Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003; 98:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/40\">",
"      Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008; 26:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/41\">",
"      Mauriac L, Romieu G, Bines J. Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial. Breast Cancer Res Treat 2009; 117:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/42\">",
"      Th&uuml;rlimann B, Robertson JF, Nabholtz JM, et al. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 2003; 39:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/43\">",
"      Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/44\">",
"      Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012; 30:2718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/45\">",
"      Abrams J, Aisner J, Cirrincione C, et al. Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. J Clin Oncol 1999; 17:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/46\">",
"      Willemse PH, van der Ploeg E, Sleijfer DT, et al. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. Eur J Cancer 1990; 26:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/47\">",
"      Kornblith AB, Hollis DR, Zuckerman E, et al. Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B. J Clin Oncol 1993; 11:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/48\">",
"      Mattsson W. Current status of high dose progestin treatment in advanced breast cancer. Breast Cancer Res Treat 1983; 3:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/49\">",
"      Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981; 304:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/50\">",
"      L&oslash;nning PE, Taylor PD, Anker G, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001; 67:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/51\">",
"      Ellis MJ, Gao F, Dehdashti F, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 2009; 302:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/52\">",
"      Nesto RW, Cady B, Oberfield RA, et al. Rebound response after estrogen therapy for metastatic breast cancer. Cancer 1976; 38:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/53\">",
"      Howell A, Dodwell DJ, Anderson H, Redford J. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 1992; 3:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/54\">",
"      Bhide SA, Rea DW. Metastatic breast cancer response after Exemestane withdrawal: a case report. Breast 2004; 13:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/55\">",
"      GOLDENBERG IS. RESULTS OF STUDIES OF THE COOPERATIVE BREAST CANCER GROUP--1961-63. Cancer Chemother Rep 1964; 41:SUPPL:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/56\">",
"      Coombes RC, Dearnaley D, Humphreys J, et al. Danazol treatment of advanced breast cancer. Cancer Treat Rep 1980; 64:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/57\">",
"      Manni A, Arafah BM, Pearson OH. Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer. Cancer 1981; 48:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/58\">",
"      Schifeling DJ, Jackson DV, Zekan PJ, Muss HB. Fluoxymesterone as third line endocrine therapy for advanced breast cancer. A phase II trial of the Piedmont Oncology Association. Am J Clin Oncol 1992; 15:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/59\">",
"      Huang X, Gao L, Wang S, et al. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res 2009; 69:8403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/60\">",
"      Yardley DA, Ismail-Khan R, Klein P. Results of ENCORE 301, a randomized, phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer progressing on a nonsteroidal aromatase inhibitor (AI). J Clin Oncol 2011; s27:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/61\">",
"      Traina TA, Rugo HS, Caravelli JF, et al. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol 2010; 28:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/62\">",
"      Yardley DA, Burris HA 3rd, Clark BL, et al. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium. Clin Breast Cancer 2011; 11:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/63\">",
"      Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27:5529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/55/21370/abstract/64\">",
"      Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27:5538.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Approval for Lapatinib Ditosylate. Information available online. file://www.cancer.gov/cancertopics/druginfo/fda-lapatinib (Accessed on February 01, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 778 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_55_21370=[""].join("\n");
var outline_f20_55_21370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H264716193\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15813243\">",
"      TREATMENT OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H99490814\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1056069830\">",
"      TREATMENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056069850\">",
"      HER2 status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15462528\">",
"      Prior treatment history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15461518\">",
"      Menopausal status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H628737497\">",
"      HER2-NEGATIVE BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1247608049\">",
"      First-line treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1248533193\">",
"      - Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H34054295\">",
"      Ovarian suppression or ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H34055122\">",
"      Selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H34054511\">",
"      Tamoxifen versus ovarian ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H34054968\">",
"      Tamoxifen plus ovarian suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H34054915\">",
"      Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1248533207\">",
"      - Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H34055576\">",
"      Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H444000539\">",
"      Selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H34055852\">",
"      Fulvestrant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19267081\">",
"      Fulvestrant plus anastrazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1248533221\">",
"      Second-line treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15462792\">",
"      - Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15462854\">",
"      - Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H99491181\">",
"      Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H99491188\">",
"      Fulvestrant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8576955\">",
"      Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H99491006\">",
"      Endocrine plus molecular targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H8576995\">",
"      - Exemestane plus everolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H99490987\">",
"      - Tamoxifen plus everolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1248531391\">",
"      Third- or later line therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34056261\">",
"      - Progestins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34056268\">",
"      - Estrogens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34056275\">",
"      - Androgens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056070066\">",
"      Investigational approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19266990\">",
"      HER2-POSITIVE BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056069964\">",
"      Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056069971\">",
"      Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H99491516\">",
"      - Trastuzumab plus anastrazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H99491526\">",
"      - Lapatinib plus letrozole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23941006\">",
"      Second-line treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H264716193\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=related_link\">",
"      Breast cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4488?source=related_link\">",
"      Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15706?source=related_link\">",
"      Elective oophorectomy or ovarian conservation at the time of hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=related_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19464?source=related_link\">",
"      Management of brain metastases in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8042?source=related_link\">",
"      Osteoclast inhibition in the management of bone metastases from breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/11/27827?source=related_link\">",
"      Patient information: Treatment of metastatic breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=related_link\">",
"      Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33924?source=related_link\">",
"      Radiation therapy for the management of painful bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_55_21371="Prescribing cascades";
var content_f20_55_21371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of prescribing cascades",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Initial drug therapy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse drug event",
"       </td>",
"       <td class=\"subtitle1\">",
"        Subsequent drug therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antipsychotics",
"       </td>",
"       <td>",
"        Extrapyramidal signs and symptoms",
"       </td>",
"       <td>",
"        Antiparkinsonian therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholinesterase inhibitors",
"       </td>",
"       <td>",
"        Urinary incontinence",
"       </td>",
"       <td>",
"        Incontinence treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiazide diuretics",
"       </td>",
"       <td>",
"        Hyperuricemia",
"       </td>",
"       <td>",
"        Gout treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NSAIDs",
"       </td>",
"       <td>",
"        Increased blood pressure",
"       </td>",
"       <td>",
"        Antihypertensive therapy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Medication prescribing cascades occur when patients are prescribed medications to treat the adverse side effects of previously prescribed medications. This leads to polypharmacy and further increases the risk for adverse drug events. Periodic review of medication lists, especially in older adults, can minimize this risk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Rochon PA, Gurwitz JH. Optimizing drug therapy for elderly people: the prescribing cascade. BMJ 1997; 315:1096 and Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005; 165:808.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_55_21371=[""].join("\n");
var outline_f20_55_21371=null;
var title_f20_55_21372="Pneum ILD temsirolimus";
var content_f20_55_21372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested guidelines for evaluating and managing respiratory side effects associated with temsirolimus treatment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Adverse event",
"      </td>",
"      <td class=\"subtitle1\">",
"       Evaluation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Management",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dyspnea",
"      </td>",
"      <td>",
"       <p>",
"        PFTs",
"       </p>",
"       <p>",
"        Chest X-ray",
"       </p>",
"       <p>",
"        Chest CT scan",
"       </p>",
"       <p>",
"        CBC",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        If imaging does not reveal ILD, provide supportive care and treat other factors contributing to dyspnea (eg, anemia)",
"       </p>",
"       <p>",
"        If imaging suggests interstitial lung disease, see below for management",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       ILD in asymptomatic patients",
"      </td>",
"      <td>",
"       <p>",
"        PFTs",
"       </p>",
"       <p>",
"        Chest CT scan",
"       </p>",
"      </td>",
"      <td>",
"       No specific therapy or drug interruption if PFTs are normal and radiographic changes are mild",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       ILD in patients with mild symptoms",
"      </td>",
"      <td>",
"       <p>",
"        PFTs",
"       </p>",
"       <p>",
"        Chest CT scan",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        May require temporary treatment interruption, depending on severity of PFT and CT abnormalities",
"       </p>",
"       <p>",
"        Will need ongoing monitoring of PFTs and chest CT",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       ILD in patients with underlying lung disease or moderate symptoms/PFT/CT abnormalities",
"      </td>",
"      <td>",
"       <p>",
"        PFTs",
"       </p>",
"       <p>",
"        Chest CT scan",
"       </p>",
"       <p>",
"        Diagnostic testing for opportunistic infection",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        May require temsirolimus discontinuation",
"       </p>",
"       <p>",
"        Will need frequent monitoring of PFTs and chest CT",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       ILD in patients with severe or progressive symptoms/PFT abnormalities",
"      </td>",
"      <td>",
"       <p>",
"        PFTs",
"       </p>",
"       <p>",
"        Chest CT scan",
"       </p>",
"       <p>",
"        Diagnostic testing for opportunistic infection",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Discontinue temsirolimus",
"       </p>",
"       <p>",
"        Administer high dose glucocorticoids",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBC: complete blood count; CT: computed tomography; DLCO: diffusing capacity for carbon monoxide; ILD: radiographic evidence of interstitial lung disease; PFTs: pulmonary function tests.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bellmunt, J, Szczylik, C, Feingold, J, et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008; 19:1387.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_55_21372=[""].join("\n");
var outline_f20_55_21372=null;
var title_f20_55_21373="Causes of tinnitus";
var content_f20_55_21373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of tinnitus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Sensorineural hearing loss",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Presbycusis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Late-onset congenital hearing loss",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Noise-induced hearing loss",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ototoxicity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Idiopathic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Vascular insufficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Small vessel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypercoagulable states",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypercholesterolemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diabetic vasculopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypertension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sickle cell anemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Other anemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Bone disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fibrous dysplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paget's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Osteogenesis imperfecta",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Otosclerosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Central nervous system anomalies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pseudotumor cerebri",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vascular malformations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tumor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stroke",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Multiple sclerosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rubella",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neurosyphilis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lyme disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Meningitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic otitis media",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Measles",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytomegalovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Metabolic disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thyroid disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diabetes mellitus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic renal failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hyperparathyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Autoimmune disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Autoimmune inner ear disease (not always associated with systemic autoimmune disease)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rheumatoid arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cochlear injury",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salicylates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antibiotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Loop diuretics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Platinum-based chemotherapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Meniere syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            See Cochlear injury and see separate table",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_55_21373=[""].join("\n");
var outline_f20_55_21373=null;
var title_f20_55_21374="Contents: Pediatrics calculators";
var content_f20_55_21374=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/37/606\">",
"       Calculators",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatrics calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatrics calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical Criteria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/24/13697\">",
"           Calculator: Apgar score",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/63/5109\">",
"           Calculator: Newborn hyperbilirubinemia assessment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9463\">",
"           Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/33/9751\">",
"           Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/14/36070\">",
"           Calculator: Body Mass Index (BMI) percentiles for boys (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/60/35782\">",
"           Calculator: Body Mass Index (BMI) percentiles for girls (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/27/4529\">",
"           Calculator: Body Surface Area (Mosteller, square root method)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/49/43796\">",
"           Calculator: Body mass index for boys (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/19/12596\">",
"           Calculator: Body mass index for girls (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/47/22262\">",
"           Calculator: CDC height for age percentiles for boys (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/7/22646\">",
"           Calculator: CDC height for age percentiles for girls (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/50/35619\">",
"           Calculator: CDC weight for height percentiles for boys (77 to 121 cm tall)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/37/2644\">",
"           Calculator: CDC weight for height percentiles for girls (77 to 121 cm tall)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/25/16788\">",
"           Calculator: CDC/NCHS infant head circumference for age percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/34/34339\">",
"           Calculator: CDC/NCHS infant length for age percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/10/162\">",
"           Calculator: CDC/NCHS infant weight for age percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/53/6997\">",
"           Calculator: CDC/NCHS infant weight for length percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/40/24193\">",
"           Calculator: Glomerular filtration rate estimate by Schwartz formula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/60/8129\">",
"           Calculator: Maintenance fluid calculation for children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/3/30769\">",
"           Calculator: Mid-parental target height prediction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/40/9860\">",
"           Calculator: PELD score for end-stage liver disease (patients less than 12 years old)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/40/36485\">",
"           Calculator: WHO Assessment of Malnutrition in Boys 0 to 2 Years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/32/30213\">",
"           Calculator: WHO Assessment of Malnutrition in Boys 2 to 5 years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/1/36885\">",
"           Calculator: WHO Assessment of Malnutrition in Girls 0 to 2 Years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/48/30469\">",
"           Calculator: WHO Assessment of Malnutrition in Girls 2 to 5 years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/31/35315\">",
"           Calculator: WHO Infant Head Circumference for Age Percentiles (&lt; 24 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/51/10035\">",
"           Calculator: WHO Infant Length for Age Percentiles (&lt; 24 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/46/12003\">",
"           Calculator: WHO Infant Weight for Age Percentiles (&lt; 24 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/54/23398\">",
"           Calculator: WHO Infant Weight for Length Percentiles (&lt; 24 months)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-39CA7A71DD-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f20_55_21374=[""].join("\n");
var outline_f20_55_21374=null;
var title_f20_55_21375="Contents: Disorders of bone";
var content_f20_55_21375=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/41/670\">",
"       Nephrology and Hypertension",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Disorders of bone",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Disorders of bone",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Endocrine disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/26/11687\">",
"           Bone disease in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/11/17593\">",
"           Bone disease with hyperthyroidism and thyroid hormone therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/16/22794\">",
"           Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/51/43829\">",
"           Endocrine dysfunction in the nephrotic syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hereditary disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/42/8872\">",
"           Approach to therapy in multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/33/41495\">",
"           Classification and genetics of multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/45/21209\">",
"           Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/9/38040\">",
"           Osteogenesis imperfecta: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/36/26185\">",
"           Osteogenesis imperfecta: Management and prognosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hyperparathyroidism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/42/8872\">",
"           Approach to therapy in multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/33/41495\">",
"           Classification and genetics of multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/16/22794\">",
"           Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/19/1338\">",
"           Clinical manifestations of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/26/5545\">",
"           Diagnosis and differential diagnosis of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/13/3287\">",
"           Hungry bone syndrome following parathyroidectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/3/9273\">",
"           Indications for parathyroidectomy in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/47/8954\">",
"           Management of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/23/13688\">",
"           Parathyroid carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/28/40387\">",
"           Parathyroid cysts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/58/21416\">",
"           Parathyroid hormone assays and their clinical use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/56/36744\">",
"           Parathyroid hormone secretion and action",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/41/30361\">",
"           Pathogenesis and etiology of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/60/18377\">",
"           Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Multiple endocrine neoplasia syndromes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/14/43240\">",
"           Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/49/17174\">",
"           Multiple endocrine neoplasia type 1: Definition and genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/61/38871\">",
"           Multiple endocrine neoplasia type 1: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Osteomalacia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/9/11416\">",
"           Clinical manifestations, diagnosis, and treatment of osteomalacia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/54/27494\">",
"           Epidemiology and etiology of osteomalacia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Osteoporosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/56/40842\">",
"           Bisphosphonates in the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/10/43173\">",
"           Calcitonin in the prevention and treatment of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/56/12170\">",
"           Calcium and vitamin D supplementation in osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/7/14458\">",
"           Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/23/36213\">",
"           Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/33/22040\">",
"           Denosumab for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/55/11128\">",
"           Diagnosis and evaluation of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/45/32473\">",
"           Epidemiology and etiology of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/25/6553\">",
"           Epidemiology and etiology of premenopausal osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/42/37545\">",
"           Evaluation and management of aromatase inhibitor-induced bone loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/35/42553\">",
"           Evaluation and treatment of premenopausal osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/55/29561\">",
"           Osteoporosis after solid organ or stem cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/19/37178\">",
"           Osteoporosis in patients with chronic kidney disease: Diagnosis, evaluation, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/42/29354\">",
"           Osteoporotic fracture risk assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/37/42583\">",
"           Overview of dual-energy x-ray absorptiometry",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/52/39754\">",
"           Overview of the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/26/15786\">",
"           Parathyroid hormone therapy for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/53/3929\">",
"           Pathogenesis of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/54/42855\">",
"           Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/4/11333\">",
"           Pharmacology of bisphosphonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/36/17994\">",
"           Prevention and treatment of glucocorticoid-induced osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/21/33113\">",
"           Prevention of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/28/40393\">",
"           Screening for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/32/41481\">",
"           Selective estrogen receptor modulators for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/58/31657\">",
"           Treatment of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/21/3417\">",
"           Treatment of vitamin D deficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/28/44487\">",
"           Use of biochemical markers of bone turnover in osteoporosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/6/36969\">",
"           Antiepileptic drugs and bone disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/33/42519\">",
"           Bone physiology and biochemical markers of bone turnover",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/21/9562\">",
"           Drugs that affect bone metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/58/33706\">",
"           Medical consultation for patients with hip fracture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/54/30569\">",
"           Metabolic bone disease in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/8/29830\">",
"           Metabolic bone disease in primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/5/34906\">",
"           Normal skeletal development and regulation of bone formation and resorption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/43/28346\">",
"           Osteonecrosis (avascular necrosis of bone)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Paget disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/50/7978\">",
"           Clinical manifestations and diagnosis of Paget disease of bone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/22/10602\">",
"           Treatment of Paget disease of bone",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal osteodystrophy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/43/28343\">",
"           Bone biopsy and the diagnosis of renal osteodystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/3/9273\">",
"           Indications for parathyroidectomy in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/57/33690\">",
"           Treatment of hyperphosphatemia in chronic kidney disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/56/40842\">",
"           Bisphosphonates in the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/10/43173\">",
"           Calcitonin in the prevention and treatment of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/56/12170\">",
"           Calcium and vitamin D supplementation in osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/45/32473\">",
"           Epidemiology and etiology of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/52/39754\">",
"           Overview of the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/58/31657\">",
"           Treatment of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/21/3417\">",
"           Treatment of vitamin D deficiency in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vitamin D",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/18/38184\">",
"           Causes of vitamin D deficiency and resistance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9462\">",
"           Metabolism of vitamin D",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/3/39990\">",
"           Overview of vitamin D",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/21/3417\">",
"           Treatment of vitamin D deficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/29/31193\">",
"           Vitamin D and extraskeletal health",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-4147D62EFF-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f20_55_21375=[""].join("\n");
var outline_f20_55_21375=null;
